19. Literaturverzeichnis – Kolorektales Karzinom
1. Zentrum für Krebsregisterdaten (ZfKD) im Robert Koch-Institut, Krebsregisterdaten des ZfKD von 1999 bis 2022, 2022.
2. André, T, Elez, E, Lenz, HJ, Jensen, LH, Touchefeu, Y, Van Cutsem, E, et.al. Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial., Lancet, 2025. 405 (10476)(10476): p. 383-395., https://pubmed.ncbi.nlm.nih.gov/39874977/
3. Elez, E, Yoshino, T, Shen, L, Lonardi, S, Van Cutsem, E, Eng, C, et.al. Encorafenib, Cetuximab, and mFOLFOX6 in , N Engl J Med, 2025. 392 (24)(24): p. 2425-2437., https://pubmed.ncbi.nlm.nih.gov/40444708/
4. Courneya, KS, Vardy, JL, O'Callaghan, CJ, Gill, S, Friedenreich, CM, Wong, RKS, et.al. Structured Exercise after Adjuvant Chemotherapy for Colon Cancer., N Engl J Med, 2025. 393 (1)(1): p. 13-25., https://pubmed.ncbi.nlm.nih.gov/40450658/
5. Lee, J, Lee, J, Ahn, J, Lee, DW, Kim, HR, Kang, MY, Association of sedentary work with colon and rectal cancer: systematic review and meta-analysis., Occup Environ Med, 2022. 79 (4)(4): p. 277-286., https://pubmed.ncbi.nlm.nih.gov/33910983/
6. Wang, X, Sun, J, Yin, X, Zou, C, Li, H, Effects of behavioral change techniques on diet and physical activity in colorectal cancer patients: a systematic review and meta-analysis., Support Care Cancer, 2022. 31 (1)(1): p. 29., https://pubmed.ncbi.nlm.nih.gov/36515770/
7. Wang, J, Huang, L, Gao, Y, Wang, Y, Chen, S, Huang, J, et.al. Physically active individuals have a 23% lower risk of any colorectal neoplasia and a 27% lower risk of advanced colorectal neoplasia than their non-active counterparts: systematic review and meta-analysis of observational studies., Br J Sports Med, 2020. 54 (10)(10): p. 582-591., https://pubmed.ncbi.nlm.nih.gov/31296585/
8. Xie, F, You, Y, Huang, J, Guan, C, Chen, Z, Fang, M, et.al. Association between physical activity and digestive-system cancer: An updated systematic review and meta-analysis., J Sport Health Sci, 2021. 10 (1)(1): p. 4-13., https://pubmed.ncbi.nlm.nih.gov/33010525/
9. Jaspan, V, Lin, K, Popov, V, The impact of anthropometric parameters on colorectal cancer prognosis: A systematic review and meta-analysis., Crit Rev Oncol Hematol, 2021. 159 (): p. 103232., https://pubmed.ncbi.nlm.nih.gov/33497759/
10. Li, H, Boakye, D, Chen, X, Hoffmeister, M, Brenner, H, Association of Body Mass Index With Risk of Early-Onset Colorectal Cancer: Systematic Review and Meta-Analysis., Am J Gastroenterol, 2021. 116 (11)(11): p. 2173-2183., https://pubmed.ncbi.nlm.nih.gov/34309586/
11. Lazzeroni, M, Bellerba, F, Calvello, M, Macrae, F, Win, AK, Jenkins, M, et.al. A Meta-Analysis of Obesity and Risk of Colorectal Cancer in Patients with Lynch Syndrome: The Impact of Sex and Genetics., Nutrients, 2021. 13 (5)(5):, https://pubmed.ncbi.nlm.nih.gov/34065344/
12. Papadimitriou, N, Bull, CJ, Jenab, M, Hughes, DJ, Bell, JA, Sanderson, E, et.al. Separating the effects of early and later life adiposity on colorectal cancer risk: a Mendelian randomization study., BMC Med, 2023. 21 (1)(1): p. 5., https://pubmed.ncbi.nlm.nih.gov/36600297/
13. Renehan, A. G., Tyson, M., Egger, M., Heller, R. F., Zwahlen, M., Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies, Lancet, 2008. 371(9612): p. 569-78., http://www.ncbi.nlm.nih.gov/pubmed/18280327
14. Botteri, E, Borroni, E, Sloan, EK, Bagnardi, V, Bosetti, C, Peveri, G, et.al. Smoking and Colorectal Cancer Risk, Overall and by Molecular Subtypes: A Meta-Analysis., Am J Gastroenterol, 2020. 115 (12)(12): p. 1940-1949., https://pubmed.ncbi.nlm.nih.gov/32773458/
15. Ye, X, Chen, Y, Gu, J, Risk factors for advanced colorectal neoplasm in young adults: a meta-analysis., Future Oncol, 2023. 19 (18)(18): p. 1293-1302., https://pubmed.ncbi.nlm.nih.gov/37259811/
16. World Cancer Research Fund/American Institute for Cancer Research, Continuous Update Expert Report 2018. Diet, nutrition, physical activity and colorectal cancer, Available at dietandcancerreport.org, 2018.
17. Papadimitriou, N, Markozannes, G, Kanellopoulou, A, Critselis, E, Alhardan, S, Karafousia, V, et.al. An umbrella review of the evidence associating diet and cancer risk at 11 anatomical sites., Nat Commun, 2021. 12 (1)(1): p. 4579., https://pubmed.ncbi.nlm.nih.gov/34321471/
18. Papadimitriou, N, Bouras, E, van den Brandt, PA, Muller, DC, Papadopoulou, A, Heath, AK, et.al. A Prospective Diet-Wide Association Study for Risk of Colorectal Cancer in EPIC., Clin Gastroenterol Hepatol, 2022. 20 (4)(4): p. 864-873.e13., https://pubmed.ncbi.nlm.nih.gov/33901663/
19. Vieira, AR, Abar, L, Chan, DSM, Vingeliene, S, Polemiti, E, Stevens, C, et.al. Foods and beverages and colorectal cancer risk: a systematic review and meta-analysis of cohort studies, an update of the evidence of the WCRF-AICR Continuous Update Project., Ann Oncol, 2017. 28 (8)(8): p. 1788-1802., https://pubmed.ncbi.nlm.nih.gov/28407090/
20. Jin, S, Je, Y, Nuts and legumes consumption and risk of colorectal cancer: a systematic review and meta-analysis., Eur J Epidemiol, 2022. 37 (6)(6): p. 569-585., https://pubmed.ncbi.nlm.nih.gov/35622305/
21. Deutsche Gesellschaft für Ernährung e. V. (DGE), Gut essen und trinken – DGE stellt neue lebensmittelbezogene Ernährungsempfehlungen für Deutschland vor, DGE Presseinformation, 2024., https://www.dge.de/presse/meldungen/2024/gut-essen-und-trinken-dge-stellt-neue-lebensmittelbezogene-ernaehrungsempfehlungen-fuer-deutschland-vor/
22. Jun, S, Park, H, Kim, UJ, Choi, EJ, Lee, HA, Park, B, et.al. Cancer risk based on alcohol consumption levels: a comprehensive systematic review and meta-analysis., Epidemiol Health, 2023. 45 (): p. e2023092., https://pubmed.ncbi.nlm.nih.gov/37905315/
23. Cho, E., Smith-Warner, S. A., Ritz, J., van den Brandt, P. A., Colditz, G. A., Folsom, A. R., et.al. Alcohol intake and colorectal cancer: a pooled analysis of 8 cohort studies, Ann Intern Med, 2004. 140(8): p. 603-13., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15096331, http://annals.org/article.aspx?articleid=717373
24. Moskal, A., Norat, T., Ferrari, P., Riboli, E., Alcohol intake and colorectal cancer risk: a dose-response meta-analysis of published cohort studies, Int J Cancer, 2007. 120(3): p. 664-71., http://www.ncbi.nlm.nih.gov/pubmed/17096321
25. Wactawski-Wende, J., Kotchen, J. M., Anderson, G. L., Assaf, A. R., Brunner, R. L., O Sullivan, M. J., et.al. Calcium plus vitamin D supplementation and the risk of colorectal cancer, N Engl J Med, 2006. 354(7): p. 684-96.
26. Wallace, K., Baron, J. A., Cole, B. F., Sandler, R. S., Karagas, M. R., Beach, M. A., et.al. Effect of calcium supplementation on the risk of large bowel polyps, J Natl Cancer Inst, 2004. 96(12): p. 921-5.
27. Moazzen, S, Dolatkhah, R, Tabrizi, JS, Shaarbafi, J, Alizadeh, BZ, de Bock, GH, et.al. Folic acid intake and folate status and colorectal cancer risk: A systematic review and meta-analysis., Clin Nutr, 2018. 37 (6 Pt A)(6 Pt A): p. 1926-1934., https://pubmed.ncbi.nlm.nih.gov/29132834/
28. Emmanouilidou, G, Kalopitas, G, Bakaloudi, DR, Karanika, E, Theocharidou, E, Germanidis, G, et.al. Vitamin D as a chemopreventive agent in colorectal neoplasms. A systematic review and meta-analysis of randomized controlled trials., Pharmacol Ther, 2022. 237 (): p. 108252., https://pubmed.ncbi.nlm.nih.gov/35926664/
29. Chapelle, N, Martel, M, Toes-Zoutendijk, E, Barkun, AN, Bardou, M, Recent advances in clinical practice: colorectal cancer chemoprevention in the average-risk population., Gut, 2020. 69 (12)(12): p. 2244-2255., https://pubmed.ncbi.nlm.nih.gov/32989022/
30. Vinceti, M, Filippini, T, Del Giovane, C, Dennert, G, Zwahlen, M, Brinkman, M, et.al. Selenium for preventing cancer., Cochrane Database Syst Rev, 2018. 1 (1)(1): p. CD005195., https://pubmed.ncbi.nlm.nih.gov/29376219/
31. Weingarten, M. A., Zalmanovici, A., Yaphe, J., Dietary calcium supplementation for preventing colorectal cancer and adenomatous polyps, Cochrane Database Syst Rev, 2008. p. CD003548., http://www.ncbi.nlm.nih.gov/pubmed/18254022
32. Grau, M. V., Baron, J. A., Sandler, R. S., Wallace, K., Haile, R. W., Church, T. R., et.al. Prolonged effect of calcium supplementation on risk of colorectal adenomas in a randomized trial, J Natl Cancer Inst, 2007. 99(2): p. 129-36., http://www.ncbi.nlm.nih.gov/pubmed/17227996
33. Wallace, K., Baron, J. A., Cole, B. F., Sandler, R. S., Karagas, M. R., Beach, M. A., et.al. Effect of calcium supplementation on the risk of large bowel polyps, J Natl Cancer Inst, 2004. 96(12): p. 921-5., http://www.ncbi.nlm.nih.gov/pubmed/15199111
34. Wactawski-Wende, J., Kotchen, J. M., Anderson, G. L., Assaf, A. R., Brunner, R. L., O Sullivan, M. J., et.al. Calcium plus vitamin D supplementation and the risk of colorectal cancer, N Engl J Med, 2006. 354(7): p. 684-96., http://www.ncbi.nlm.nih.gov/pubmed/16481636
35. Bjelakovic, G., Nikolova, D., Gluud, L. L., Simonetti, R. G., Gluud, C., Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis, JAMA, 2007. 297(8): p. 842-57., http://www.ncbi.nlm.nih.gov/pubmed/17327526
36. Jacobs, E. T., Jiang, R., Alberts, D. S., Greenberg, E. R., Gunter, E. W., Karagas, M. R., et.al. Selenium and colorectal adenoma: results of a pooled analysis, J Natl Cancer Inst, 2004. 96(22): p. 1669-75., http://www.ncbi.nlm.nih.gov/pubmed/15547179
37. Peters, U., Chatterjee, N., Church, T. R., Mayo, C., Sturup, S., Foster, C. B., et.al. High serum selenium and reduced risk of advanced colorectal adenoma in a colorectal cancer early detection program, Cancer Epidemiol Biomarkers Prev, 2006. 15(2): p. 315-20., http://www.ncbi.nlm.nih.gov/pubmed/16492922
38. Emilsson, L, Holme, Ø, Bretthauer, M, Cook, NR, Buring, JE, Løberg, M, et.al. Systematic review with meta-analysis: the comparative effectiveness of aspirin vs. screening for colorectal cancer prevention., Aliment Pharmacol Ther, 2017. 45 (2)(2): p. 193-204., https://pubmed.ncbi.nlm.nih.gov/27859394/
39. Heer, E, Ruan, Y, Mah, B, Nguyen, T, Lyons, H, Poirier, A, et.al. The efficacy of chemopreventive agents on the incidence of colorectal adenomas: A systematic review and network meta-analysis., Prev Med, 2022. 162 (): p. 107169., https://pubmed.ncbi.nlm.nih.gov/35878711/
40. Guirguis-Blake, JM, Evans, CV, Perdue, LA, Bean, SI, Senger, CA, Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force., JAMA, 2022. 327 (16)(16): p. 1585-1597., https://pubmed.ncbi.nlm.nih.gov/35471507/
41. Ma, Y, You, W, Cao, Y, He, X, Wang, J, Zhang, Y, et.al. Chemoprevention of colorectal cancer in general population and high-risk population: a systematic review and network meta-analysis., Chin Med J (Engl), 2023. 136 (7)(7): p. 788-798., https://pubmed.ncbi.nlm.nih.gov/37027286/
42. Bardou, M., Barkun, A., Martel, M., Effect of statin therapy on colorectal cancer, Gut, 2010. 59(11): p. 1572-85., http://www.ncbi.nlm.nih.gov/pubmed/20660702
43. Dobrzycka, M, Spychalski, P, Łachiński, AJ, Kobiela, P, Jędrusik, P, Kobiela, J, Statins and Colorectal Cancer - A Systematic Review., Exp Clin Endocrinol Diabetes, 2020. 128 (4)(4): p. 255-262., https://pubmed.ncbi.nlm.nih.gov/30149418/
44. Farquhar, C., Marjoribanks, J., Lethaby, A., Suckling, J. A., Lamberts, Q., Long term hormone therapy for perimenopausal and postmenopausal women, Cochrane Database Syst Rev, 2009. p. CD004143., http://www.ncbi.nlm.nih.gov/pubmed/19370593
45. Gartlehner, G, Patel, SV, Reddy, S, Rains, C, Schwimmer, M, Kahwati, L, Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force., JAMA, 2022. 328 (17)(17): p. 1747-1765., https://pubmed.ncbi.nlm.nih.gov/36318128/
46. Grossman, DC, Curry, SJ, Owens, DK, Barry, MJ, Davidson, KW, Doubeni, CA, et.al. Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women: US Preventive Services Task Force Recommendation Statement., JAMA, 2017. 318 (22)(22): p. 2224-2233., https://pubmed.ncbi.nlm.nih.gov/29234814/
47. Nakhostin, L, Stadler, A, Stute, P, Impact of menopausal hormone therapy on colorectal cancer risk-A systematic review., Clin Endocrinol (Oxf), 2021. 95 (3)(3): p. 390-397., https://pubmed.ncbi.nlm.nih.gov/33752259/
48. Guittet, L, Quipourt, V, Aparicio, T, Carola, E, Seitz, JF, Paillaud, E, et.al. Should we screen for colorectal cancer in people aged 75 and over? A systematic review - collaborative work of the French geriatric oncology society (SOFOG) and the French federation of digestive oncology (FFCD)., BMC Cancer, 2023. 23 (1)(1): p. 17., https://pubmed.ncbi.nlm.nih.gov/36604640/
49. O'Sullivan, DE, Sutherland, RL, Town, S, Chow, K, Fan, J, Forbes, N, et.al. Risk Factors for Early-Onset Colorectal Cancer: A Systematic Review and Meta-analysis., Clin Gastroenterol Hepatol, 2022. 20 (6)(6): p. 1229-1240.e5., https://pubmed.ncbi.nlm.nih.gov/33524598/
50. Williams, GJ, Hellerstedt, ST, Scudder, PN, Calderwood, AH, Yield of Surveillance Colonoscopy in Older Adults with a History of Polyps: A Systematic Review and Meta-Analysis., Dig Dis Sci, 2022. 67 (8)(8): p. 4059-4069., https://pubmed.ncbi.nlm.nih.gov/34406584/
51. Knudsen, AB, Rutter, CM, Peterse, EFP, Lietz, AP, Seguin, CL, Meester, RGS, et.al. Colorectal Cancer Screening: An Updated Modeling Study for the US Preventive Services Task Force., JAMA, 2021. 325 (19)(19): p. 1998-2011., https://pubmed.ncbi.nlm.nih.gov/34003219/
52. Winawer, S. J., Zauber, A. G., Ho, M. N., O'Brien, M. J., Gottlieb, L. S., Sternberg, S. S., et.al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup, N Engl J Med, 1993. 329(27): p. 1977-81., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8247072, http://www.nejm.org/doi/pdf/10.1056/NEJM199312303292701
53. Citarda, F., Tomaselli, G., Capocaccia, R., Barcherini, S., Crespi, M., Efficacy in standard clinical practice of colonoscopic polypectomy in reducing colorectal cancer incidence, Gut, 2001. 48(6): p. 812-5., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11358901, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1728339/pdf/v048p00812.pdf
54. Zauber, A. G., Winawer, S. J., O Brien, M. J., Lansdorp-Vogelaar, I., van Ballegooijen, M., Hankey, B. F., et.al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths, N Engl J Med, 2012. 366(8): p. 687-96., http://www.ncbi.nlm.nih.gov/pubmed/22356322
55. Nishihara, R, Wu, K, Lochhead, P, Morikawa, T, Liao, X, Qian, ZR, et.al. Long-term colorectal-cancer incidence and mortality after lower endoscopy., N Engl J Med, 2013. 369 (12)(12): p. 1095-105., https://pubmed.ncbi.nlm.nih.gov/24047059/
56. Bretthauer, M, Løberg, M, Wieszczy, P, Kalager, M, Emilsson, L, Garborg, K, et.al. Effect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death., N Engl J Med, 2022. 387 (17)(17): p. 1547-1556., https://pubmed.ncbi.nlm.nih.gov/36214590/
57. Hol, L., van Leerdam, M. E., van Ballegooijen, M., van Vuuren, A. J., van Dekken, H., Reijerink, J. C., et.al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy, Gut, 2010. 59(1): p. 62-8., http://www.ncbi.nlm.nih.gov/pubmed/19671542
58. Quintero, E., Castells, A., Bujanda, L., Cubiella, J., Salas, D., Lanas, A., et.al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening, N Engl J Med, 2012. 366(8): p. 697-706., http://www.ncbi.nlm.nih.gov/pubmed/22356323
59. Grobbee, EJ, van der Vlugt, M, van Vuuren, AJ, Stroobants, AK, Mallant-Hent, RC, Lansdorp-Vogelaar, I, et.al. Diagnostic Yield of One-Time Colonoscopy vs One-Time Flexible Sigmoidoscopy vs Multiple Rounds of Mailed Fecal Immunohistochemical Tests in Colorectal Cancer Screening., Clin Gastroenterol Hepatol, 2020. 18 (3)(3): p. 667-675.e1., https://pubmed.ncbi.nlm.nih.gov/31419575/
60. Ran, T, Cheng, CY, Misselwitz, B, Brenner, H, Ubels, J, Schlander, M, Cost-Effectiveness of Colorectal Cancer Screening Strategies-A Systematic Review., Clin Gastroenterol Hepatol, 2019. 17 (10)(10): p. 1969-1981.e15., https://pubmed.ncbi.nlm.nih.gov/30659991/
61. Gheysariyeha, F, Rahimi, F, Tabesh, E, Hemami, MR, Adibi, P, Rezayatmand, R, Cost-effectiveness of colorectal cancer screening strategies: A systematic review., Eur J Cancer Care (Engl), 2022. 31 (6)(6): p. e13673., https://pubmed.ncbi.nlm.nih.gov/35974390/
62. Wang, L, Liu, C, Wang, Y, Du, L, Cost-effectiveness of risk-tailored screening strategy for colorectal cancer: A systematic review., J Gastroenterol Hepatol, 2022. 37 (7)(7): p. 1235-1243., https://pubmed.ncbi.nlm.nih.gov/35434850/
63. Ramos, MC, Passone, JAL, Lopes, ACF, Safatle-Ribeiro, AV, Ribeiro Júnior, U, de Soárez, PC, Economic evaluations of colorectal cancer screening: A systematic review and quality assessment., Clinics (Sao Paulo), 2023. 78 (): p. 100203., https://pubmed.ncbi.nlm.nih.gov/37099816/
64. Atkin, WS., Cook, CF., Cuzick, J., Edwards, R., Northover, JM., Wardle, J., Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial, Lancet, 2002. 359(9314): p. 1291-300.
65. Brenner, H., Chang-Claude, J., Seiler, C. M., Hoffmeister, M., Long-term risk of colorectal cancer after negative colonoscopy, J Clin Oncol, 2011. 29(28): p. 3761-7.
66. Brenner, H., Chang-Claude, J., Seiler, C. M., Rickert, A., Hoffmeister, M., Protection from colorectal cancer after colonoscopy: a population-based, case-control study, Ann Intern Med, 2011. 154(1): p. 22-30.
67. Brenner, H., Hoffmeister, M., Arndt, V., Stegmaier, C., Altenhofen, L., Haug, U., Protection from right- and left-sided colorectal neoplasms after colonoscopy: population-based study, J Natl Cancer Inst, 2010. 102(2): p. 89-95.
68. Imperiale, T. F., Wagner, D. R., Lin, C. Y., Larkin, G. N., Rogge, J. D., Ransohoff, D. F., Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings, N Engl J Med, 2000. 343(3): p. 169-74.
69. Kahi, C. J., Imperiale, T. F., Juliar, B. E., Rex, D. K., Effect of screening colonoscopy on colorectal cancer incidence and mortality, Clin Gastroenterol Hepatol, 2009. 7(7): p. 770-5; quiz 711.
70. Lieberman, D. A., Weiss, D. G., Bond, J. H., Ahnen, D. J., Garewal, H., Chejfec, G., Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380, N Engl J Med, 2000. 343(3): p. 162-8.
71. Rex, D.K., Cutler, C.S., Lemmel, G.T., Rahmani, E.Y., Helper, D.J., Lehman, G.A., et.al. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies, Gastroenterology, 1997. 112(1): p. 24-8.
72. Juul, FE, Cross, AJ, Pinsky, P, Senore, C, Løberg, M, 15-Year Benefits of Sigmoidoscopy Screening on Colorectal Cancer Incidence and Mortality., Ann Intern Med, 2023. 176 (6)(6): p. eL230025., https://pubmed.ncbi.nlm.nih.gov/37335997/
73. Brenner, H, Tao, S, Superior diagnostic performance of faecal immunochemical tests for haemoglobin in a head-to-head comparison with guaiac based faecal occult blood test among 2235 participants of screening colonoscopy., Eur J Cancer, 2013. 49 (14)(14): p. 3049-54., https://pubmed.ncbi.nlm.nih.gov/23706981/
74. Gies, A, Cuk, K, Schrotz-King, P, Brenner, H, Direct Comparison of Diagnostic Performance of 9 Quantitative Fecal Immunochemical Tests for Colorectal Cancer Screening., Gastroenterology, 2018. 154 (1)(1): p. 93-104., https://pubmed.ncbi.nlm.nih.gov/28958859/
75. Guo, F, Chen, C, Holleczek, B, Schöttker, B, Hoffmeister, M, Brenner, H, Strong Reduction of Colorectal Cancer Incidence and Mortality After Screening Colonoscopy: Prospective Cohort Study From Germany., Am J Gastroenterol, 2021. 116 (5)(5): p. 967-975., https://pubmed.ncbi.nlm.nih.gov/33929378/
76. Chiu, HM, Chen, SL, Yen, AM, Chiu, SY, Fann, JC, Lee, YC, et.al. Effectiveness of fecal immunochemical testing in reducing colorectal cancer mortality from the One Million Taiwanese Screening Program., Cancer, 2015. 121 (18)(18): p. 3221-9., https://pubmed.ncbi.nlm.nih.gov/25995082/
77. Gemeinsamer Bundesausschuss (G-BA), Richtlinie für organisierte Krebsfrüherkennungsprogramme – oKFE-RL, 2024.
78. Shaukat, A, Mongin, SJ, Geisser, MS, Lederle, FA, Bond, JH, Mandel, JS, et.al. Long-term mortality after screening for colorectal cancer., N Engl J Med, 2013. 369 (12)(12): p. 1106-14., https://pubmed.ncbi.nlm.nih.gov/24047060/
79. Lindholm, E, Brevinge, H, Haglind, E, Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer., Br J Surg, 2008. 95 (8)(8): p. 1029-36., https://pubmed.ncbi.nlm.nih.gov/18563785/
80. Faivre, J, Dancourt, V, Lejeune, C, Tazi, MA, Lamour, J, Gerard, D, et.al. Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study., Gastroenterology, 2004. 126 (7)(7): p. 1674-80., https://pubmed.ncbi.nlm.nih.gov/15188160/
81. Scholefield, JH, Moss, SM, Mangham, CM, Whynes, DK, Hardcastle, JD, Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up., Gut, 2012. 61 (7)(7): p. 1036-40., https://pubmed.ncbi.nlm.nih.gov/22052062/
82. Kronborg, O, Jørgensen, OD, Fenger, C, Rasmussen, M, Randomized study of biennial screening with a faecal occult blood test: results after nine screening rounds., Scand J Gastroenterol, 2004. 39 (9)(9): p. 846-51., https://pubmed.ncbi.nlm.nih.gov/15513382/
83. Holme, Ø, Løberg, M, Kalager, M, Bretthauer, M, Hernán, MA, Aas, E, et.al. Long-Term Effectiveness of Sigmoidoscopy Screening on Colorectal Cancer Incidence and Mortality in Women and Men: A Randomized Trial., Ann Intern Med, 2018. 168 (11)(11): p. 775-782., https://pubmed.ncbi.nlm.nih.gov/29710125/
84. Miller, EA, Pinsky, PF, Schoen, RE, Prorok, PC, Church, TR, Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: long-term follow-up of the randomised US PLCO cancer screening trial., Lancet Gastroenterol Hepatol, 2019. 4 (2)(2): p. 101-110., https://pubmed.ncbi.nlm.nih.gov/30502933/
85. Atkin, W, Wooldrage, K, Parkin, DM, Kralj-Hans, I, MacRae, E, Shah, U, et.al. Long term effects of once-only flexible sigmoidoscopy screening after 17 years of follow-up: the UK Flexible Sigmoidoscopy Screening randomised controlled trial., Lancet, 2017. 389 (10076)(10076): p. 1299-1311., https://pubmed.ncbi.nlm.nih.gov/28236467/
86. Segnan, N, Armaroli, P, Bonelli, L, Risio, M, Sciallero, S, Zappa, M, et.al. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian Randomized Controlled Trial--SCORE., J Natl Cancer Inst, 2011. 103 (17)(17): p. 1310-22., https://pubmed.ncbi.nlm.nih.gov/21852264/
87. Zhang, J, Chen, G, Li, Z, Zhang, P, Li, X, Gan, D, et.al. Colonoscopic screening is associated with reduced Colorectal Cancer incidence and mortality: a systematic review and meta-analysis., J Cancer, 2020. 11 (20)(20): p. 5953-5970., https://pubmed.ncbi.nlm.nih.gov/32922537/
88. Brenner, H, Stock, C, Hoffmeister, M, Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies., BMJ, 2014. 348 (): p. g2467., https://pubmed.ncbi.nlm.nih.gov/24922745/
89. García-Albéniz, X, Hsu, J, Bretthauer, M, Hernán, MA, Effectiveness of Screening Colonoscopy to Prevent Colorectal Cancer Among Medicare Beneficiaries Aged 70 to 79 Years: A Prospective Observational Study., Ann Intern Med, 2017. 166 (1)(1): p. 18-26., https://pubmed.ncbi.nlm.nih.gov/27669524/
90. Shaukat, A, Levin, TR, Current and future colorectal cancer screening strategies., Nat Rev Gastroenterol Hepatol, 2022. 19 (8)(8): p. 521-531., https://pubmed.ncbi.nlm.nih.gov/35505243/
91. Cardoso, R, Guo, F, Heisser, T, Hackl, M, Ihle, P, De Schutter, H, et.al. Colorectal cancer incidence, mortality, and stage distribution in European countries in the colorectal cancer screening era: an international population-based study., Lancet Oncol, 2021. 22 (7)(7): p. 1002-1013., https://pubmed.ncbi.nlm.nih.gov/34048685/
92. Liang, Q, Mukama, T, Sundquist, K, Sundquist, J, Brenner, H, Kharazmi, E, et.al. Longer Interval Between First Colonoscopy With Negative Findings for Colorectal Cancer and Repeat Colonoscopy., JAMA Oncol, 2024. 10 (7)(7): p. 866-873., https://pubmed.ncbi.nlm.nih.gov/38696176/
93. van Roon, AH, Goede, SL, van Ballegooijen, M, van Vuuren, AJ, Looman, CW, Biermann, K, et.al. Random comparison of repeated faecal immunochemical testing at different intervals for population-based colorectal cancer screening., Gut, 2013. 62 (3)(3): p. 409-15., https://pubmed.ncbi.nlm.nih.gov/22387523/
94. Lin, JS, Perdue, LA, Henrikson, NB, Bean, SI, Blasi, PR, Screening for Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force., JAMA, 2021. 325 (19)(19): p. 1978-1998., https://pubmed.ncbi.nlm.nih.gov/34003220/
95. Levin, TR, Conell, C, Shapiro, JA, Chazan, SG, Nadel, MR, Selby, JV, Complications of screening flexible sigmoidoscopy., Gastroenterology, 2002. 123 (6)(6): p. 1786-92., https://pubmed.ncbi.nlm.nih.gov/12454834/
96. de Haan, M. C., van Gelder, R. E., Graser, A., Bipat, S., Stoker, J., Diagnostic value of CT-colonography as compared to colonoscopy in an asymptomatic screening population: a meta-analysis, Eur Radiol, 2011. 21(8): p. 1747-63., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3128257/pdf/330_2011_Article_2104.pdf
97. El-Maraghi, R. H., Kielar, A. Z., CT colonography versus optical colonoscopy for screening asymptomatic patients for colorectal cancer a patient, intervention, comparison, outcome (PICO) analysis, Acad Radiol, 2009. 16(5): p. 564-71., http://www.ncbi.nlm.nih.gov/pubmed/19345897
98. Rex, DK, Adler, SN, Aisenberg, J, Burch, WC, Carretero, C, Chowers, Y, et.al. Accuracy of capsule colonoscopy in detecting colorectal polyps in a screening population., Gastroenterology, 2015. 148 (5)(5): p. 948-957.e2., https://pubmed.ncbi.nlm.nih.gov/25620668/
99. Pecere, S, Senore, C, Hassan, C, Riggi, E, Segnan, N, Pennazio, M, et.al. Accuracy of colon capsule endoscopy for advanced neoplasia., Gastrointest Endosc, 2020. 91 (2)(2): p. 406-414.e1., https://pubmed.ncbi.nlm.nih.gov/31629719/
100. Cash, BD, Fleisher, MR, Fern, S, Rajan, E, Haithcock, R, Kastenberg, DM, et.al. Multicentre, prospective, randomised study comparing the diagnostic yield of colon capsule endoscopy versus CT colonography in a screening population (the TOPAZ study)., Gut, 2021. 70 (11)(11): p. 2115-2122., https://pubmed.ncbi.nlm.nih.gov/33443017/
101. Imperiale, TF, Ransohoff, DF, Itzkowitz, SH, Levin, TR, Lavin, P, Lidgard, GP, et.al. Multitarget stool DNA testing for colorectal-cancer screening., N Engl J Med, 2014. 370 (14)(14): p. 1287-97., https://pubmed.ncbi.nlm.nih.gov/24645800/
102. Brenner, H, Chen, H, Fecal occult blood versus DNA testing: indirect comparison in a colorectal cancer screening population., Clin Epidemiol, 2017. 9 (): p. 377-384., https://pubmed.ncbi.nlm.nih.gov/28761377/
103. Gachabayov, M, Lebovics, E, Rojas, A, Felsenreich, DM, Latifi, R, Bergamaschi, R, Performance evaluation of stool DNA methylation tests in colorectal cancer screening: a systematic review and meta-analysis., Colorectal Dis, 2021. 23 (5)(5): p. 1030-1042., https://pubmed.ncbi.nlm.nih.gov/33410272/
104. Johnson, DA, Barclay, RL, Mergener, K, Weiss, G, König, T, Beck, J, et.al. Plasma Septin9 versus fecal immunochemical testing for colorectal cancer screening: a prospective multicenter study., PLoS One, 2014. 9 (6)(6): p. e98238., https://pubmed.ncbi.nlm.nih.gov/24901436/
105. Nasir Kansestani, A, Zare, ME, Tong, Q, Zhang, J, Comparison of faecal protein biomarkers' diagnostic accuracy for colorectal advanced neoplasms: a systematic review and meta-analysis., Sci Rep, 2022. 12 (1)(1): p. 2623., https://pubmed.ncbi.nlm.nih.gov/35173276/
106. Pox, C. P., Schmiegel, W., Role of CT colonography in colorectal cancer screening: risks and benefits, Gut, 2010. 59(5): p. 692-700.
107. Graser, A, Melzer, A, Lindner, E, Nagel, D, Herrmann, K, Stieber, P, et.al. Magnetic resonance colonography for the detection of colorectal neoplasia in asymptomatic adults., Gastroenterology, 2013. 144 (4)(4): p. 743-750.e2., https://pubmed.ncbi.nlm.nih.gov/23415805/
108. Spada, C, Hassan, C, Barbaro, B, Iafrate, F, Cesaro, P, Petruzziello, L, et.al. Colon capsule versus CT colonography in patients with incomplete colonoscopy: a prospective, comparative trial., Gut, 2015. 64 (2)(2): p. 272-81., https://pubmed.ncbi.nlm.nih.gov/24964317/
109. Traverso, G., Shuber, A., Levin, B., Johnson, C., Olsson, L., Schoetz, D. J., Jr., et.al. Detection of APC mutations in fecal DNA from patients with colorectal tumors, N Engl J Med, 2002. 346(5): p. 311-20., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11821507, http://www.nejm.org/doi/pdf/10.1056/NEJMoa012294
110. Ahlquist, D. A., Skoletsky, J. E., Boynton, K. A., Harrington, J. J., Mahoney, D. W., Pierceall, W. E., et.al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel, Gastroenterology, 2000. 119(5): p. 1219-27.
111. Dong, S. M., Traverso, G., Johnson, C., Geng, L., Favis, R., Boynton, K., et.al. Detecting colorectal cancer in stool with the use of multiple genetic targets, J Natl Cancer Inst, 2001. 93(11): p. 858-65., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11390535, http://jnci.oxfordjournals.org/content/93/11/858.full.pdf
112. Imperiale, T. F., Ransohoff, D. F., Itzkowitz, S. H., Turnbull, B. A., Ross, M. E., Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population, N Engl J Med, 2004. 351(26): p. 2704-14.
113. Ahlquist, D. A., Sargent, D. J., Loprinzi, C. L., Levin, T. R., Rex, D. K., Ahnen, D. J., et.al. Stool DNA and occult blood testing for screen detection of colorectal neoplasia, Ann Intern Med, 2008. 149(7): p. 441-50, W81.
114. Nakama, H., Zhang, B., Fukazawa, K., Abdul Fattah, A. S., Family history of colorectal adenomatous polyps as a risk factor for colorectal cancer, Eur J Cancer, 2000. 36(16): p. 2111-4.
115. Issaka, RB, Chan, AT, Gupta, S, AGA Clinical Practice Update on Risk Stratification for Colorectal Cancer Screening and Post-Polypectomy Surveillance: Expert Review., Gastroenterology, 2023. 165 (5)(5): p. 1280-1291., https://pubmed.ncbi.nlm.nih.gov/37737817/
116. Bibbins-Domingo, K, Grossman, DC, Curry, SJ, Davidson, KW, Epling, JW, García, FAR, et.al. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement., JAMA, 2016. 315 (23)(23): p. 2564-2575., https://pubmed.ncbi.nlm.nih.gov/27304597/
117. Stürzlinger, H, Conrads-Frank, A, Eisenmann, A, Invansits, S, Jahn, B, Janzic, A, et.al. Stool DNA testing for early detection of colorectal cancer: systematic review using the HTA Core Model, Ger Med Sci, 2023. 21 (): p. Doc06., https://pubmed.ncbi.nlm.nih.gov/37426885/
118. Feng, Z, Oberije, CJG, van de Wetering, AJP, Koch, A, Wouters, KAD, Vaes, N, et.al. Lessons From a Systematic Literature Search on Diagnostic DNA Methylation Biomarkers for Colorectal Cancer: How to Increase Research Value and Decrease Research Waste?, Clin Transl Gastroenterol, 2022. 13 (6)(6): p. e00499., https://pubmed.ncbi.nlm.nih.gov/35584320/
119. Raut, JR, Guan, Z, Schrotz-King, P, Brenner, H, Fecal DNA methylation markers for detecting stages of colorectal cancer and its precursors: a systematic review., Clin Epigenetics, 2020. 12 (1)(1): p. 122., https://pubmed.ncbi.nlm.nih.gov/32778176/
120. Jin, P, Kang, Q, Wang, X, Yang, L, Yu, Y, Li, N, et.al. Performance of a second-generation methylated SEPT9 test in detecting colorectal neoplasm., J Gastroenterol Hepatol, 2015. 30 (5)(5): p. 830-3., https://pubmed.ncbi.nlm.nih.gov/25471329/
121. Tóth, K, Sipos, F, Kalmár, A, Patai, AV, Wichmann, B, Stoehr, R, et.al. Detection of methylated SEPT9 in plasma is a reliable screening method for both left- and right-sided colon cancers., PLoS One, 2012. 7 (9)(9): p. e46000., https://pubmed.ncbi.nlm.nih.gov/23049919/
122. Kim, YC, Kim, JH, Cheung, DY, Kim, TH, Jun, EJ, Oh, JW, et.al. The Usefulness of a Novel Screening Kit for Colorectal Cancer Using the Immunochromatographic Fecal Tumor M2 Pyruvate Kinase Test., Gut Liver, 2015. 9 (5)(5): p. 641-8., https://pubmed.ncbi.nlm.nih.gov/25473070/
123. Chandan, S, Facciorusso, A, Yarra, P, Khan, SR, Ramai, D, Mohan, BP, et.al. Colonoscopy-Related Adverse Events in Patients With Abnormal Stool-Based Tests: A Systematic Review of Literature and Meta-analysis of Outcomes., Am J Gastroenterol, 2022. 117 (3)(3): p. 381-393., https://pubmed.ncbi.nlm.nih.gov/35029161/
124. Greegor, D.H., Occult blood testing for detection of asymptomatic colon cancer., Cancer, 1971. 28: p. 131-4., http://onlinelibrary.wiley.com/store/10.1002/1097-0142(197107)28:1<131::AID-CNCR2820280125>3.0.CO;2-I/asset/2820280125_ftp.pdf?v=1&t=ik52llmb&s=924d09ddaeaf06a565a6016d3967619b4be1b1c3
125. Ahlquist, D. A., McGill, D. B., Fleming, J. L., Schwartz, S., Wieand, H. S., Rubin, J., et.al. Patterns of occult bleeding in asymptomatic colorectal cancer, Cancer, 1989. 63(9): p. 1826-30.
126. Macrae, F. A., St John, D. J., Caligiore, P., Taylor, L. S., Legge, J. W., Optimal dietary conditions for hemoccult testing, Gastroenterology, 1982. 82(5 Pt 1): p. 899-903.
127. Hundt, S., Haug, U., Brenner, H., Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection, Ann Intern Med, 2009. 150(3): p. 162-9.
128. Westwood, M, Lang, S, Armstrong, N, van Turenhout, S, Cubiella, J, Stirk, L, et.al. Faecal immunochemical tests (FIT) can help to rule out colorectal cancer in patients presenting in primary care with lower abdominal symptoms: a systematic review conducted to inform new NICE DG30 diagnostic guidance., BMC Med, 2017. 15 (1)(1): p. 189., https://pubmed.ncbi.nlm.nih.gov/29061126/
129. Halloran, SP, Launoy, G, Zappa, M, European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition--Faecal occult blood testing., Endoscopy, 2012. 44 Suppl 3 (): p. SE65-87., https://pubmed.ncbi.nlm.nih.gov/23012123/
130. Hundt, S., Haug, U., Brenner, H., Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection, Ann Intern Med, 2009. 150(3): p. 162-9., http://www.ncbi.nlm.nih.gov/pubmed/19189905
131. Brenner, H., Haug, U., Hundt, S., Inter-test agreement and quantitative cross-validation of immunochromatographical fecal occult blood tests, Int J Cancer, 2010. 127(7): p. 1643-9., http://www.ncbi.nlm.nih.gov/pubmed/20049840
132. Allison, J. E., Sakoda, L. C., Levin, T. R., Tucker, J. P., Tekawa, I. S., Cuff, T., et.al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics, J Natl Cancer Inst, 2007. 99(19): p. 1462-70., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17895475, http://jnci.oxfordjournals.org/content/99/19/1462.full.pdf
133. Park, D. I., Ryu, S., Kim, Y. H., Lee, S. H., Lee, C. K., Eun, C. S., et.al. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening, Am J Gastroenterol, 2010. 105(9): p. 2017-25., http://www.ncbi.nlm.nih.gov/pubmed/20502450
134. Launoy, G. D., Bertrand, H. J., Berchi, C., Talbourdet, V. Y., Guizard, A. V., Bouvier, V. M., et.al. Evaluation of an immunochemical fecal occult blood test with automated reading in screening for colorectal cancer in a general average-risk population, Int J Cancer, 2005. 115(3): p. 493-6., http://www.ncbi.nlm.nih.gov/pubmed/15700317
135. van Roon, A. H., Wilschut, J. A., Hol, L., van Ballegooijen, M., Reijerink, J. C., t Mannetje, H., et.al. Diagnostic yield improves with collection of 2 samples in fecal immunochemical test screening without affecting attendance, Clin Gastroenterol Hepatol, 2011. 9(4): p. 333-9., http://www.ncbi.nlm.nih.gov/pubmed/21185397
136. Mandel, J. S., Bond, J. H., Church, T. R., Snover, D. C., Bradley, G. M., Schuman, L. M., et.al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study, N Engl J Med, 1993. 328(19): p. 1365-71., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8474513, http://www.nejm.org/doi/pdf/10.1056/NEJM199305133281901
137. Hardcastle, J. D., Chamberlain, J. O., Robinson, M. H., Moss, S. M., Amar, S. S., Balfour, T. W., et.al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer, Lancet, 1996. 348(9040): p. 1472-7., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8942775, http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(96)03386-7/abstract
138. Kronborg, O., Fenger, C., Olsen, J., Jorgensen, O. D., Sondergaard, O., Randomised study of screening for colorectal cancer with faecal-occult-blood test, Lancet, 1996. 348(9040): p. 1467-71.
139. Hewitson, P., Glasziou, P., Irwig, L., Towler, B., Watson, E., Screening for colorectal cancer using the faecal occult blood test, Hemoccult, Cochrane Database Syst Rev, 2007. p. CD001216., http://www.ncbi.nlm.nih.gov/pubmed/17253456
140. Levin, B., Hess, K., Johnson, C., Screening for colorectal cancer. A comparison of 3 fecal occult blood tests, Arch Intern Med, 1997. 157(9): p. 970-6., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9140267, http://archinte.jamanetwork.com/article.aspx?articleid=623273
141. Katalinic, A., Raspe, H., Waldmann, A., [Positive family history of colorectal cancer--use of a questionnaire], Z Gastroenterol, 2009. 47(11): p. 1125-31., http://www.ncbi.nlm.nih.gov/pubmed/19899019
142. Samadder, NJ, Riegert-Johnson, D, Boardman, L, Rhodes, D, Wick, M, Okuno, S, et.al. Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome., JAMA Oncol, 2021. 7 (2)(2): p. 230-237., https://pubmed.ncbi.nlm.nih.gov/33126242/
143. Hampel, H, Yurgelun, MB, Point/Counterpoint: Is It Time for Universal Germline Genetic Testing for All GI Cancers?, J Clin Oncol, 2022. 40 (24)(24): p. 2681-2692., https://pubmed.ncbi.nlm.nih.gov/35649230/
144. Stoffel, EM, Koeppe, E, Everett, J, Ulintz, P, Kiel, M, Osborne, J, et.al. Germline Genetic Features of Young Individuals With Colorectal Cancer., Gastroenterology, 2018. 154 (4)(4): p. 897-905.e1., https://pubmed.ncbi.nlm.nih.gov/29146522/
145. Vos, JR, Fakkert, IE, Spruijt, L, Willems, RW, Langenveld, S, Mensenkamp, AR, et.al. Evaluation of yield and experiences of age-related molecular investigation for heritable and nonheritable causes of mismatch repair deficient colorectal cancer to identify Lynch syndrome., Int J Cancer, 2020. 147 (8)(8): p. 2150-2158., https://pubmed.ncbi.nlm.nih.gov/32510614/
146. Bläker, H, Haupt, S, Morak, M, Holinski-Feder, E, Arnold, A, Horst, D, et.al. Age-dependent performance of BRAF mutation testing in Lynch syndrome diagnostics., Int J Cancer, 2020. 147 (10)(10): p. 2801-2810., https://pubmed.ncbi.nlm.nih.gov/32875553/
147. Bekanntmachungen der Bundesärztekammer: Richtlinien zur prädiktiven genetischen Diagnostik, Dt Ärztebl, 2003. 100(19): p. A1297-1305.
148. Cavestro, GM, Mannucci, A, Balaguer, F, Hampel, H, Kupfer, SS, Repici, A, et.al. Delphi Initiative for Early-Onset Colorectal Cancer (DIRECt) International Management Guidelines., Clin Gastroenterol Hepatol, 2023. 21 (3)(3): p. 581-603.e33., https://pubmed.ncbi.nlm.nih.gov/36549470/
149. Esplin, ED, Nielsen, SM, Bristow, SL, Garber, JE, Hampel, H, Rana, HQ, et.al. Universal Germline Genetic Testing for Hereditary Cancer Syndromes in Patients With Solid Tumor Cancer., JCO Precis Oncol, 2022. 6 (): p. e2100516., https://pubmed.ncbi.nlm.nih.gov/36108258/
150. Uson, PLS, Riegert-Johnson, D, Boardman, L, Kisiel, J, Mountjoy, L, Patel, N, et.al. Germline Cancer Susceptibility Gene Testing in Unselected Patients With Colorectal Adenocarcinoma: A Multicenter Prospective Study., Clin Gastroenterol Hepatol, 2022. 20 (3)(3): p. e508-e528., https://pubmed.ncbi.nlm.nih.gov/33857637/
151. Cercek, A, Chatila, WK, Yaeger, R, Walch, H, Fernandes, GDS, Krishnan, A, et.al. A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers., J Natl Cancer Inst, 2021. 113 (12)(12): p. 1683-1692., https://pubmed.ncbi.nlm.nih.gov/34405229/
152. Stanich, PP, Pelstring, KR, Hampel, H, Pearlman, R, A High Percentage of Early-age Onset Colorectal Cancer Is Potentially Preventable., Gastroenterology, 2021. 160 (5)(5): p. 1850-1852., https://pubmed.ncbi.nlm.nih.gov/33310086/
153. DeRycke, MS, Gunawardena, S, Balcom, JR, Pickart, AM, Waltman, LA, French, AJ, et.al. Targeted sequencing of 36 known or putative colorectal cancer susceptibility genes., Mol Genet Genomic Med, 2017. 5 (5)(5): p. 553-569., https://pubmed.ncbi.nlm.nih.gov/28944238/
154. Pearlman, R, Frankel, WL, Swanson, BJ, Jones, D, Zhao, W, Yilmaz, A, et.al. Prospective Statewide Study of Universal Screening for Hereditary Colorectal Cancer: The Ohio Colorectal Cancer Prevention Initiative., JCO Precis Oncol, 2021. 5 ():, https://pubmed.ncbi.nlm.nih.gov/34250417/
155. Seifert, BA, McGlaughon, JL, Jackson, SA, Ritter, DI, Roberts, ME, Schmidt, RJ, et.al. Determining the clinical validity of hereditary colorectal cancer and polyposis susceptibility genes using the Clinical Genome Resource Clinical Validity Framework., Genet Med, 2019. 21 (7)(7): p. 1507-1516., https://pubmed.ncbi.nlm.nih.gov/30523343/
156. Taylor, A, Brady, AF, Frayling, IM, Hanson, H, Tischkowitz, M, Turnbull, C, et.al. Consensus for genes to be included on cancer panel tests offered by UK genetics services: guidelines of the UK Cancer Genetics Group., J Med Genet, 2018. 55 (6)(6): p. 372-377., https://pubmed.ncbi.nlm.nih.gov/29661970/
157. Nugroho, PP, Ghozali, SAS, Buchanan, DD, Pisano, MI, Reece, JC, Risk of cancer in individuals with Lynch-like syndrome and their families: a systematic review., J Cancer Res Clin Oncol, 2023. 149 (1)(1): p. 25-46., https://pubmed.ncbi.nlm.nih.gov/36251064/
158. Duncan, R. E., Gillam, L., Savulescu, J., Williamson, R., Rogers, J. G., Delatycki, M. B., The challenge of developmentally appropriate care: predictive genetic testing in young people for familial adenomatous polyposis, Fam Cancer, 2010. 9(1): p. 27-35., http://www.ncbi.nlm.nih.gov/pubmed/19760114
159. Douma, K. F., Aaronson, N. K., Vasen, H. F., Bleiker, E. M., Psychosocial issues in genetic testing for familial adenomatous polyposis: a review of the literature, Psychooncology, 2008. 17(8): p. 737-45., http://www.ncbi.nlm.nih.gov/pubmed/18613296
160. Douma, K. F., Aaronson, N. K., Vasen, H. F., Gerritsma, M. A., Gundy, C. M., Janssen, E. P., et.al. Psychological distress and use of psychosocial support in familial adenomatous polyposis, Psychooncology, 2010. 19(3): p. 289-98., http://www.ncbi.nlm.nih.gov/pubmed/19382100
161. Karnes, W.E., Epidemiology and etiology of sporadic colorectal adenocarcinoma, Current opinion in Gastroenterology, 1994. 10: p. 19-26.
162. Rothwell, P. M., Wilson, M., Elwin, C. E., Norrving, B., Algra, A., Warlow, C. P., et.al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials, Lancet, 2010. 376(9754): p. 1741-50.
163. Sandler, R. S., Halabi, S., Baron, J. A., Budinger, S., Paskett, E., Keresztes, R., et.al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer, N Engl J Med, 2003. 348(10): p. 883-90.
164. Burt, R. W., Screening of patients with a positive family history of colorectal cancer, Gastrointest Endosc Clin N Am, 1997. 7(1): p. 65-79.
165. Burn, J, Sheth, H, Elliott, F, Reed, L, Macrae, F, Mecklin, JP, et.al. Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial., Lancet, 2020. 395 (10240)(10240): p. 1855-1863., https://pubmed.ncbi.nlm.nih.gov/32534647/
166. Sassano, M, Mariani, M, Quaranta, G, Pastorino, R, Boccia, S, Polygenic risk prediction models for colorectal cancer: a systematic review., BMC Cancer, 2022. 22 (1)(1): p. 65., https://pubmed.ncbi.nlm.nih.gov/35030997/
167. Baron, J. A., Cole, B. F., Mott, L., Haile, R., Grau, M., Church, T. R., et.al. Neoplastic and antineoplastic effects of beta-carotene on colorectal adenoma recurrence: results of a randomized trial, J Natl Cancer Inst, 2003. 95(10): p. 717-22., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12759389, http://jnci.oxfordjournals.org/content/95/10/717.full.pdf
168. Karnes, W.E., Epidemiology and etiology of sporadic colorectal adenocarcinoma, Current opinion in Gastroenterology, 1994. 10: p. 19-26.
169. Rothwell, P. M., Wilson, M., Elwin, C. E., Norrving, B., Algra, A., Warlow, C. P., et.al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials, Lancet, 2010. 376(9754): p. 1741-50., http://www.ncbi.nlm.nih.gov/pubmed/20970847
170. Dominguez-Valentin, M, Haupt, S, Seppälä, TT, Sampson, JR, Sunde, L, Bernstein, I, et.al. Mortality by age, gene and gender in carriers of pathogenic mismatch repair gene variants receiving surveillance for early cancer diagnosis and treatment: a report from the prospective Lynch syndrome database., EClinicalMedicine, 2023. 58 (): p. 101909., https://pubmed.ncbi.nlm.nih.gov/37181409/
171. Abu-Ghazaleh, N, Kaushik, V, Gorelik, A, Jenkins, M, Macrae, F, Worldwide prevalence of Lynch syndrome in patients with colorectal cancer: Systematic review and meta-analysis., Genet Med, 2022. 24 (5)(5): p. 971-985., https://pubmed.ncbi.nlm.nih.gov/35177335/
172. Engel, C, Vasen, HF, Seppälä, T, Aretz, S, Bigirwamungu-Bargeman, M, de Boer, SY, et.al. No Difference in Colorectal Cancer Incidence or Stage at Detection by Colonoscopy Among 3 Countries With Different Lynch Syndrome Surveillance Policies., Gastroenterology, 2018. 155 (5)(5): p. 1400-1409.e2., https://pubmed.ncbi.nlm.nih.gov/30063918/
173. Vasen, HF, Abdirahman, M, Brohet, R, Langers, AM, Kleibeuker, JH, van Kouwen, M, et.al. One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome., Gastroenterology, 2010. 138 (7)(7): p. 2300-6., https://pubmed.ncbi.nlm.nih.gov/20206180/
174. Bonadona, V, Bonaïti, B, Olschwang, S, Grandjouan, S, Huiart, L, Longy, M, et.al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome., JAMA, 2011. 305 (22)(22): p. 2304-10., https://pubmed.ncbi.nlm.nih.gov/21642682/
175. Møller, P, Seppälä, TT, Bernstein, I, Holinski-Feder, E, Sala, P, Gareth Evans, D, et.al. Cancer risk and survival in , Gut, 2018. 67 (7)(7): p. 1306-1316., https://pubmed.ncbi.nlm.nih.gov/28754778/
176. Lindor, NM, Petersen, GM, Hadley, DW, Kinney, AY, Miesfeldt, S, Lu, KH, et.al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review., JAMA, 2006. 296 (12)(12): p. 1507-17., https://pubmed.ncbi.nlm.nih.gov/17003399/
177. Sánchez, A, Roos, VH, Navarro, M, Pineda, M, Caballol, B, Moreno, L, et.al. Quality of Colonoscopy Is Associated With Adenoma Detection and Postcolonoscopy Colorectal Cancer Prevention in Lynch Syndrome., Clin Gastroenterol Hepatol, 2022. 20 (3)(3): p. 611-621.e9., https://pubmed.ncbi.nlm.nih.gov/33157315/
178. Møller, P, Seppälä, T, Dowty, JG, Haupt, S, Dominguez-Valentin, M, Sunde, L, et.al. Colorectal cancer incidences in Lynch syndrome: a comparison of results from the prospective lynch syndrome database and the international mismatch repair consortium., Hered Cancer Clin Pract, 2022. 20 (1)(1): p. 36., https://pubmed.ncbi.nlm.nih.gov/36182917/
179. Correction: Cancer risk and survival in path _MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database, Gut, 2020. 69 (6)(6): p. e4., https://pubmed.ncbi.nlm.nih.gov/32381558/
180. Ahadova, A, Gallon, R, Gebert, J, Ballhausen, A, Endris, V, Kirchner, M, et.al. Three molecular pathways model colorectal carcinogenesis in Lynch syndrome., Int J Cancer, 2018. 143 (1)(1): p. 139-150., https://pubmed.ncbi.nlm.nih.gov/29424427/
181. Ahadova, A, Stenzinger, A, Seppälä, T, Hüneburg, R, Kloor, M, Bläker, H, A "Two-in-One Hit" Model of Shortcut Carcinogenesis in MLH1 Lynch Syndrome Carriers., Gastroenterology, 2023. 165 (1)(1): p. 267-270.e4., https://pubmed.ncbi.nlm.nih.gov/36907525/
182. Møller, P, Seppälä, T, Bernstein, I, Holinski-Feder, E, Sala, P, Evans, DG, et.al. Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database., Gut, 2017. 66 (3)(3): p. 464-472., https://pubmed.ncbi.nlm.nih.gov/26657901/
183. Jenkins, MA, Dowty, JG, Ait Ouakrim, D, Mathews, JD, Hopper, JL, Drouet, Y, et.al. Short-term risk of colorectal cancer in individuals with lynch syndrome: a meta-analysis., J Clin Oncol, 2015. 33 (4)(4): p. 326-31., https://pubmed.ncbi.nlm.nih.gov/25534380/
184. Lecomte, T, Cellier, C, Meatchi, T, Barbier, JP, Cugnenc, PH, Jian, R, et.al. Chromoendoscopic colonoscopy for detecting preneoplastic lesions in hereditary nonpolyposis colorectal cancer syndrome., Clin Gastroenterol Hepatol, 2005. 3 (9)(9): p. 897-902., https://pubmed.ncbi.nlm.nih.gov/16234028/
185. Huneburg, R., Lammert, F., Rabe, C., Rahner, N., Kahl, P., Buttner, R., et.al. Chromocolonoscopy detects more adenomas than white light colonoscopy or narrow band imaging colonoscopy in hereditary nonpolyposis colorectal cancer screening, Endoscopy, 2009. 41(4): p. 316-22., http://www.ncbi.nlm.nih.gov/pubmed/19340735
186. Rivero-Sánchez, L, Arnau-Collell, C, Herrero, J, Remedios, D, Cubiella, J, García-Cougil, M, et.al. White-Light Endoscopy Is Adequate for Lynch Syndrome Surveillance in a Randomized and Noninferiority Study., Gastroenterology, 2020. 158 (4)(4): p. 895-904.e1., https://pubmed.ncbi.nlm.nih.gov/31520613/
187. Haanstra, JF, Dekker, E, Cats, A, Nagengast, FM, Hardwick, JC, Vanhoutvin, SA, et.al. Effect of chromoendoscopy in the proximal colon on colorectal neoplasia detection in Lynch syndrome: a multicenter randomized controlled trial., Gastrointest Endosc, 2019. 90 (4)(4): p. 624-632., https://pubmed.ncbi.nlm.nih.gov/31028782/
188. Houwen, BBSL, Mostafavi, N, Vleugels, JLA, Hüneburg, R, Lamberti, C, Rivero-Sánchez, L, et.al. Dye-Based Chromoendoscopy in Patients With Lynch Syndrome: An Individual Patient Data Meta-Analysis of Randomized Trials., Am J Gastroenterol, 2021. 116 (4)(4): p. 825-828., https://pubmed.ncbi.nlm.nih.gov/33982955/
189. Hüneburg, R, Bucksch, K, Schmeißer, F, Heling, D, Marwitz, T, Aretz, S, et.al. Real-time use of artificial intelligence (CADEYE) in colorectal cancer surveillance of patients with Lynch syndrome-A randomized controlled pilot trial (CADLY)., United European Gastroenterol J, 2023. 11 (1)(1): p. 60-68., https://pubmed.ncbi.nlm.nih.gov/36571259/
190. Ortiz, O, Daca-Alvarez, M, Rivero-Sanchez, L, Gimeno-Garcia, AZ, Carrillo-Palau, M, Alvarez, V, et.al. An artificial intelligence-assisted system versus white light endoscopy alone for adenoma detection in individuals with Lynch syndrome (TIMELY): an international, multicentre, randomised controlled trial., Lancet Gastroenterol Hepatol, 2024. 9 (9)(9): p. 802-810., https://pubmed.ncbi.nlm.nih.gov/39033774/
191. Kim, J, Braun, D, Ukaegbu, C, Dhingra, TG, Kastrinos, F, Parmigiani, G, et.al. Clinical Factors Associated With Gastric Cancer in Individuals With Lynch Syndrome., Clin Gastroenterol Hepatol, 2020. 18 (4)(4): p. 830-837.e1., https://pubmed.ncbi.nlm.nih.gov/31319185/
192. Engel, C, Loeffler, M, Steinke, V, Rahner, N, Holinski-Feder, E, Dietmaier, W, et.al. Risks of less common cancers in proven mutation carriers with lynch syndrome., J Clin Oncol, 2012. 30 (35)(35): p. 4409-15., https://pubmed.ncbi.nlm.nih.gov/23091106/
193. Ten Broeke, SW, van der Klift, HM, Tops, CMJ, Aretz, S, Bernstein, I, Buchanan, DD, et.al. Cancer Risks for PMS2-Associated Lynch Syndrome., J Clin Oncol, 2018. 36 (29)(29): p. 2961-2968., https://pubmed.ncbi.nlm.nih.gov/30161022/
194. Vangala, DB, Ladigan-Badura, S, Engel, C, Hüneburg, R, Perne, C, Bucksch, K, et.al. Early detection of duodenal cancer by upper gastrointestinal-endoscopy in Lynch syndrome., Int J Cancer, 2021. 149 (12)(12): p. 2052-2062., https://pubmed.ncbi.nlm.nih.gov/34331771/
195. Ladigan-Badura, S, Vangala, DB, Engel, C, Bucksch, K, Hueneburg, R, Perne, C, et.al. Value of upper gastrointestinal endoscopy for gastric cancer surveillance in patients with Lynch syndrome., Int J Cancer, 2021. 148 (1)(1): p. 106-114., https://pubmed.ncbi.nlm.nih.gov/32930401/
196. Emons, G, Steiner, E, Vordermark, D, Uleer, C, Paradies, K, Tempfer, C, et.al. Endometrial Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry Number 032/034-OL, September 2022). Part 1 with Recommendations on the Epidemiology, Screening, Diagnosis and Hereditary Factors of Endometrial Cancer, Geriatric Assessment and Supply Structures., Geburtshilfe Frauenheilkd, 2023. 83 (8)(8): p. 919-962., https://pubmed.ncbi.nlm.nih.gov/37588260/
197. Seufferlein, T, Mayerle, J, Boeck, S, Brunner, T, Ettrich, TJ, Grenacher, L, et.al. [Not Available]., Z Gastroenterol, 2024. 62 (10)(10): p. 1724-1785., https://pubmed.ncbi.nlm.nih.gov/39389105/
198. Seufferlein, T, Mayerle, J, Boeck, S, Brunner, T, Ettrich, TJ, Grenacher, L, et.al. [Correction: AWMF-Registernummer: 032-010OL - Leitlinie (Kurzversion)]., Z Gastroenterol, 2025. 63 (7)(7): p. 783., https://pubmed.ncbi.nlm.nih.gov/40425142/
199. Burn, J., Gerdes, A. M., Macrae, F., Mecklin, J. P., Moeslein, G., Olschwang, S., et.al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial, Lancet, 2011. 378(9809): p. 2081-7.
200. Ait Ouakrim, D, Dashti, SG, Chau, R, Buchanan, DD, Clendenning, M, Rosty, C, et.al. Aspirin, Ibuprofen, and the Risk of Colorectal Cancer in Lynch Syndrome., J Natl Cancer Inst, 2015. 107 (9)(9):, https://pubmed.ncbi.nlm.nih.gov/26109217/
201. Toh, JWT, Hui, N, Collins, G, Phan, K, Survival outcomes associated with Lynch syndrome colorectal cancer and metachronous rate after subtotal/total versus segmental colectomy: Meta-analysis., Surgery, 2022. 172 (5)(5): p. 1315-1322., https://pubmed.ncbi.nlm.nih.gov/36031446/
202. Chang, G. J., Rodriguez-Bigas, M. A., Skibber, J. M., Moyer, V. A., Lymph node evaluation and survival after curative resection of colon cancer: systematic review, J Natl Cancer Inst, 2007. 99(6): p. 433-41., http://www.ncbi.nlm.nih.gov/pubmed/17374833
203. Le Voyer, T. E., Sigurdson, E. R., Hanlon, A. L., Mayer, R. J., Macdonald, J. S., Catalano, P. J., et.al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089, J Clin Oncol, 2003. 21(15): p. 2912-9., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12885809, http://jco.ascopubs.org/content/21/15/2912.long
204. Eikenboom, EL, Moen, S, van Leerdam, ME, Papageorgiou, G, Doukas, M, Tanis, PJ, et.al. Metachronous colorectal cancer risk according to Lynch syndrome pathogenic variant after extensive versus partial colectomy in the Netherlands: a retrospective cohort study., Lancet Gastroenterol Hepatol, 2023. 8 (12)(12): p. 1106-1117., https://pubmed.ncbi.nlm.nih.gov/37865103/
205. Cercek, A, Lumish, M, Sinopoli, J, Weiss, J, Shia, J, Lamendola-Essel, M, et.al. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer., N Engl J Med, 2022. 386 (25)(25): p. 2363-2376., https://pubmed.ncbi.nlm.nih.gov/35660797/
206. King, J. E., Dozois, R. R., Lindor, N. M., Ahlquist, D. A., Care of patients and their families with familial adenomatous polyposis, Mayo Clin Proc, 2000. 75(1): p. 57-67.
207. Church, J. M., McGannon, E., Burke, C., Clark, B., Teenagers with familial adenomatous polyposis: what is their risk for colorectal cancer?, Dis Colon Rectum, 2002. 45(7): p. 887-9., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12130875
208. Monahan, KJ, Bradshaw, N, Dolwani, S, Desouza, B, Dunlop, MG, East, JE, et.al. Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)/Association of Coloproctology of Great Britain and Ireland (ACPGBI)/United Kingdom Cancer Genetics Group (UKCGG)., Gut, 2020. 69 (3)(3): p. 411-444., https://pubmed.ncbi.nlm.nih.gov/31780574/
209. Kennedy, RD, Potter, DD, Moir, CR, El-Youssef, M, The natural history of familial adenomatous polyposis syndrome: a 24 year review of a single center experience in screening, diagnosis, and outcomes., J Pediatr Surg, 2014. 49 (1)(1): p. 82-6., https://pubmed.ncbi.nlm.nih.gov/24439586/
210. Lynch, PM, Morris, JS, Wen, S, Advani, SM, Ross, W, Chang, GJ, et.al. A proposed staging system and stage-specific interventions for familial adenomatous polyposis., Gastrointest Endosc, 2016. 84 (1)(1): p. 115-125.e4., https://pubmed.ncbi.nlm.nih.gov/26769407/
211. Uylas, U, Gundogdu, R, Sumer, F, Samdanci, E, Kayaalp, C, Incidental cancer in colectomy specimens from patients with familial adenomatous polyposis: single centre experience and literature review., Int J Colorectal Dis, 2023. 38 (1)(1): p. 76., https://pubmed.ncbi.nlm.nih.gov/36949302/
212. Lee, CHA, Kalady, MF, Burke, CA, Mankaney, G, Ali Abbass, M, Jia, X, et.al. Incidence and Management of Rectal Cuff and Anal Transitional Zone Neoplasia in Patients With Familial Adenomatous Polyposis., Dis Colon Rectum, 2021. 64 (8)(8): p. 977-985., https://pubmed.ncbi.nlm.nih.gov/33960328/
213. Faul, E, Xhaja, X, Church, J, Correlation Between the Severity of Adhesions and Desmoid Disease in Patients With Familial Adenomatous Polyposis: A Prospective Cohort Study., Dis Colon Rectum, 2024. 67 (2)(2): p. 273-279., https://pubmed.ncbi.nlm.nih.gov/36940315/
214. Pasquer, A, Benech, N, Pioche, M, Breton, A, Rivory, J, Vinet, O, et.al. Prophylactic colectomy and rectal preservation in FAP: systematic endoscopic follow-up and adenoma destruction changes natural history of polyposis., Endosc Int Open, 2021. 9 (7)(7): p. E1014-E1022., https://pubmed.ncbi.nlm.nih.gov/34222624/
215. Bülow, C, Vasen, H, Järvinen, H, Björk, J, Bisgaard, ML, Bülow, S, Ileorectal anastomosis is appropriate for a subset of patients with familial adenomatous polyposis., Gastroenterology, 2000. 119 (6)(6): p. 1454-60., https://pubmed.ncbi.nlm.nih.gov/11113066/
216. Sasaki, K, Nozawa, H, Kawai, K, Murono, K, Emoto, S, Kishikawa, J, et.al. Risk of extracolonic malignancies and metachronous rectal cancer after colectomy and ileorectal anastomosis in familial adenomatous polyposis., Asian J Surg, 2022. 45 (1)(1): p. 396-400., https://pubmed.ncbi.nlm.nih.gov/34330586/
217. M'Koma, AE, Herline, AJ, Adunyah, SE, Subsequent Adenomas of Ileal Pouch and Anorectal Segment after Prophylactic Surgery for Familial Adenomatous Polyposis., World J Colorectal Surg, 2013. 3 (2)(2):, https://pubmed.ncbi.nlm.nih.gov/24817992/
218. Pommaret, E, Vienne, A, Lefevre, JH, Sogni, P, Florent, C, Desaint, B, et.al. Prevalence and risk factors for adenomas in the ileal pouch and the afferent loop after restorative proctocolectomy for patients with familial adenomatous polyposis., Surg Endosc, 2013. 27 (10)(10): p. 3816-22., https://pubmed.ncbi.nlm.nih.gov/23636532/
219. Schulz, AC, Bojarski, C, Buhr, HJ, Kroesen, AJ, Occurrence of adenomas in the pouch and small intestine of FAP patients after proctocolectomy with ileoanal pouch construction., Int J Colorectal Dis, 2008. 23 (4)(4): p. 437-41., https://pubmed.ncbi.nlm.nih.gov/18193239/
220. Bouchiba, H, Aelvoet, AS, Pellisé, M, Bastiaansen, BAJ, van Leerdam, ME, Langers, AMJ, et.al. Risk of Cancer and Reoperation After Ileorectal Anastomosis and Ileal Pouch-Anal Anastomosis in Familial Adenomatous Polyposis., Am J Gastroenterol, 2024. ():, https://pubmed.ncbi.nlm.nih.gov/39787348/
221. Church, J, Burke, C, McGannon, E, Pastean, O, Clark, B, Predicting polyposis severity by proctoscopy: how reliable is it?, Dis Colon Rectum, 2001. 44 (9)(9): p. 1249-54., https://pubmed.ncbi.nlm.nih.gov/11584194/
222. Tatsuta, K, Sakata, M, Iwaizumi, M, Okamoto, K, Yoshii, S, Mori, M, et.al. Long-term prognosis after stapled and hand-sewn ileal pouch-anal anastomoses for familial adenomatous polyposis: a multicenter retrospective study., Int J Colorectal Dis, 2024. 39 (1)(1): p. 32., https://pubmed.ncbi.nlm.nih.gov/38431759/
223. Tajika, M, Tanaka, T, Ishihara, M, Hirayama, Y, Oonishi, S, Mizuno, N, et.al. Long-term outcomes of metachronous neoplasms in the ileal pouch and rectum after surgical treatment in patients with familial adenomatous polyposis., Endosc Int Open, 2019. 7 (5)(5): p. E691-E698., https://pubmed.ncbi.nlm.nih.gov/31073536/
224. Mannucci, A, Puzzono, M, Goel, A, Möslein, G, Balafas, S, Di Serio, MS, et.al. The Spigelman Staging System and the Risk of Duodenal and Papillary Cancer in Familial Adenomatous Polyposis: A Systematic Review and Meta-Analysis., Am J Gastroenterol, 2024. 119 (4)(4): p. 617-624., https://pubmed.ncbi.nlm.nih.gov/38294150/
225. Iwata, K, Kato, M, Sasaki, M, Miyazaki, K, Kubosawa, Y, Masunaga, T, et.al. Intensive endoscopic resection strategy for multiple duodenal polyposis associated with familial adenomatous polyposis., J Gastroenterol Hepatol, 2023. 38 (9)(9): p. 1592-1597., https://pubmed.ncbi.nlm.nih.gov/37423767/
226. Takeuchi, Y, Hamada, K, Nakahira, H, Shimamoto, Y, Sakurai, H, Tani, Y, et.al. Efficacy and safety of intensive downstaging polypectomy (IDP) for multiple duodenal adenomas in patients with familial adenomatous polyposis: a prospective cohort study., Endoscopy, 2023. 55 (6)(6): p. 515-523., https://pubmed.ncbi.nlm.nih.gov/36410678/
227. Singh, AD, Bhatt, A, Joseph, A, Lyu, R, Heald, B, Macaron, C, et.al. Natural history of ampullary adenomas in familial adenomatous polyposis: a long-term follow-up study., Gastrointest Endosc, 2022. 95 (3)(3): p. 455-467.e3., https://pubmed.ncbi.nlm.nih.gov/34624304/
228. Latchford, AR, Neale, KF, Spigelman, AD, Phillips, RK, Clark, SK, Features of duodenal cancer in patients with familial adenomatous polyposis., Clin Gastroenterol Hepatol, 2009. 7 (6)(6): p. 659-63., https://pubmed.ncbi.nlm.nih.gov/19281862/
229. Groves, CJ, Saunders, BP, Spigelman, AD, Phillips, RK, Duodenal cancer in patients with familial adenomatous polyposis (FAP): results of a 10 year prospective study., Gut, 2002. 50 (5)(5): p. 636-41., https://pubmed.ncbi.nlm.nih.gov/11950808/
230. Serrano, PE, Grant, RC, Berk, TC, Kim, D, Al-Ali, H, Cohen, Z, et.al. Progression and Management of Duodenal Neoplasia in Familial Adenomatous Polyposis: A Cohort Study., Ann Surg, 2015. 261 (6)(6): p. 1138-44., https://pubmed.ncbi.nlm.nih.gov/24950262/
231. Sourrouille, I, Lefèvre, JH, Shields, C, Colas, C, Bellanger, J, Desaint, B, et.al. Surveillance of Duodenal Polyposis in Familial Adenomatous Polyposis: Should the Spigelman Score Be Modified?, Dis Colon Rectum, 2017. 60 (11)(11): p. 1137-1146., https://pubmed.ncbi.nlm.nih.gov/28991077/
232. Lepistö, A, Kiviluoto, T, Halttunen, J, Järvinen, HJ, Surveillance and treatment of duodenal adenomatosis in familial adenomatous polyposis., Endoscopy, 2009. 41 (6)(6): p. 504-9., https://pubmed.ncbi.nlm.nih.gov/19533554/
233. Bülow, S, Christensen, IJ, Højen, H, Björk, J, Elmberg, M, Järvinen, H, et.al. Duodenal surveillance improves the prognosis after duodenal cancer in familial adenomatous polyposis., Colorectal Dis, 2012. 14 (8)(8): p. 947-52., https://pubmed.ncbi.nlm.nih.gov/21973191/
234. Park, SY, Ryu, JK, Park, JH, Yoon, H, Kim, JY, Yoon, YB, et.al. Prevalence of gastric and duodenal polyps and risk factors for duodenal neoplasm in korean patients with familial adenomatous polyposis., Gut Liver, 2011. 5 (1)(1): p. 46-51., https://pubmed.ncbi.nlm.nih.gov/21461071/
235. Mathus-Vliegen, EM, Boparai, KS, Dekker, E, van Geloven, N, Progression of duodenal adenomatosis in familial adenomatous polyposis: due to ageing of subjects and advances in technology., Fam Cancer, 2011. 10 (3)(3): p. 491-9., https://pubmed.ncbi.nlm.nih.gov/21416262/
236. Maehata, Y, Esaki, M, Hirahashi, M, Kitazono, T, Matsumoto, T, Duodenal adenomatosis in Japanese patients with familial adenomatous polyposis., Dig Endosc, 2014. 26 Suppl 2 (): p. 30-4., https://pubmed.ncbi.nlm.nih.gov/24750145/
237. Angsuwatcharakon, P, Ahmed, O, Lynch, PM, Lum, P, Gonzalez, GN, Weston, B, et.al. Management of ampullary adenomas in familial adenomatous polyposis syndrome: 16 years of experience from a tertiary cancer center., Gastrointest Endosc, 2020. 92 (2)(2): p. 323-330., https://pubmed.ncbi.nlm.nih.gov/32145286/
238. Campos, FG, Martinez, CAR, Sulbaran, M, Bustamante-Lopez, LA, Safatle-Ribeiro, AV, Upper gastrointestinal neoplasia in familial adenomatous polyposis: prevalence, endoscopic features and management., J Gastrointest Oncol, 2019. 10 (4)(4): p. 734-744., https://pubmed.ncbi.nlm.nih.gov/31392054/
239. Yachida, T, Nakajima, T, Nonaka, S, Nakamura, K, Suzuki, H, Yoshinaga, S, et.al. Characteristics and Clinical Outcomes of Duodenal Neoplasia in Japanese Patients With Familial Adenomatous Polyposis., J Clin Gastroenterol, 2017. 51 (5)(5): p. 407-411., https://pubmed.ncbi.nlm.nih.gov/27306941/
240. Roos, VH, Bastiaansen, BA, Kallenberg, FGJ, Aelvoet, AS, Bossuyt, PMM, Fockens, P, et.al. Endoscopic management of duodenal adenomas in patients with familial adenomatous polyposis., Gastrointest Endosc, 2021. 93 (2)(2): p. 457-466., https://pubmed.ncbi.nlm.nih.gov/32535190/
241. Caillié, F, Paye, F, Desaint, B, Bennis, M, Lefèvre, JH, Parc, Y, et.al. Severe duodenal involvement in familial adenomatous polyposis treated by pylorus-preserving pancreaticoduodenectomy., Ann Surg Oncol, 2012. 19 (9)(9): p. 2924-31., https://pubmed.ncbi.nlm.nih.gov/22311120/
242. Skipworth, JR, Morkane, C, Raptis, DA, Vyas, S, Olde Damink, SW, Imber, CJ, et.al. Pancreaticoduodenectomy for advanced duodenal and ampullary adenomatosis in familial adenomatous polyposis., HPB (Oxford), 2011. 13 (5)(5): p. 342-9., https://pubmed.ncbi.nlm.nih.gov/21492334/
243. Ganschow, P, Hackert, T, Biegler, M, Contin, P, Hinz, U, Büchler, MW, et.al. Postoperative outcome and quality of life after surgery for FAP-associated duodenal adenomatosis., Langenbecks Arch Surg, 2018. 403 (1)(1): p. 93-102., https://pubmed.ncbi.nlm.nih.gov/29075846/
244. Parc, Y., Mabrut, J. Y., Shields, C., Surgical management of the duodenal manifestations of familial adenomatous polyposis, Br J Surg, 2011. 98(4): p. 480-4., http://www.ncbi.nlm.nih.gov/pubmed/21656714
245. Bianchi, LK, Burke, CA, Bennett, AE, Lopez, R, Hasson, H, Church, JM, Fundic gland polyp dysplasia is common in familial adenomatous polyposis., Clin Gastroenterol Hepatol, 2008. 6 (2)(2): p. 180-5., https://pubmed.ncbi.nlm.nih.gov/18237868/
246. Nakamura, K, Nonaka, S, Nakajima, T, Yachida, T, Abe, S, Sakamoto, T, et.al. Clinical outcomes of gastric polyps and neoplasms in patients with familial adenomatous polyposis., Endosc Int Open, 2017. 5 (3)(3): p. E137-E145., https://pubmed.ncbi.nlm.nih.gov/28271094/
247. Leone, PJ, Mankaney, G, Sarvapelli, S, Abushamma, S, Lopez, R, Cruise, M, et.al. Endoscopic and histologic features associated with gastric cancer in familial adenomatous polyposis., Gastrointest Endosc, 2019. 89 (5)(5): p. 961-968., https://pubmed.ncbi.nlm.nih.gov/30597145/
248. Wang, KK, Kim, K, Bancila, L, Lew, D, Larson, BK, Kim, S, et.al. Novel Endoscopic Polypectomy Surveillance Technique for Fundic Gland Polyps in Familial Adenomatous Polyposis Can Improve Early Detection of Dysplasia and Gastric Cancer., Am J Gastroenterol, 2022. 117 (8)(8): p. 1246-1254., https://pubmed.ncbi.nlm.nih.gov/35584332/
249. Sarre, RG, Frost, AG, Jagelman, DG, Petras, RE, Sivak, MV, McGannon, E, Gastric and duodenal polyps in familial adenomatous polyposis: a prospective study of the nature and prevalence of upper gastrointestinal polyps., Gut, 1987. 28 (3)(3): p. 306-14., https://pubmed.ncbi.nlm.nih.gov/3032754/
250. Walton, SJ, Frayling, IM, Clark, SK, Latchford, A, Gastric tumours in FAP., Fam Cancer, 2017. 16 (3)(3): p. 363-369., https://pubmed.ncbi.nlm.nih.gov/28271232/
251. Wood, LD, Salaria, SN, Cruise, MW, Giardiello, FM, Montgomery, EA, Upper GI tract lesions in familial adenomatous polyposis (FAP): enrichment of pyloric gland adenomas and other gastric and duodenal neoplasms., Am J Surg Pathol, 2014. 38 (3)(3): p. 389-93., https://pubmed.ncbi.nlm.nih.gov/24525509/
252. Martin, I, Roos, VH, Anele, C, Walton, SJ, Cuthill, V, Suzuki, N, et.al. Gastric adenomas and their management in familial adenomatous polyposis., Endoscopy, 2021. 53 (8)(8): p. 795-801., https://pubmed.ncbi.nlm.nih.gov/32942317/
253. Sasaki, K, Kawai, K, Nozawa, H, Ishihara, S, Ishida, H, Ishibashi, K, et.al. Risk of gastric adenoma and adenocarcinoma in patients with familial adenomatous polyposis in Japan: a nationwide multicenter study., J Gastroenterol, 2024. 59 (3)(3): p. 187-194., https://pubmed.ncbi.nlm.nih.gov/38263336/
254. Sato, C, Takahashi, K, Sato, H, Naruse, T, Nakajima, N, Takatsuna, M, et.al. Endoscopic Findings and Treatment of Gastric Neoplasms in Familial Adenomatous Polyposis., J Gastric Cancer, 2022. 22 (4)(4): p. 381-394., https://pubmed.ncbi.nlm.nih.gov/36316112/
255. DelSignore, M, Jeong, T, Denmark, G, Feldman, D, Shih, A, Zukerberg, L, et.al. Incidence and natural history of gastric high-grade dysplasia in patients with familial adenomatous polyposis syndrome., Gastrointest Endosc, 2023. 97 (1)(1): p. 25-34.e6., https://pubmed.ncbi.nlm.nih.gov/36113625/
256. Jaganmohan, S, Lynch, PM, Raju, RP, Ross, WA, Lee, JE, Raju, GS, et.al. Endoscopic management of duodenal adenomas in familial adenomatous polyposis--a single-center experience., Dig Dis Sci, 2012. 57 (3)(3): p. 732-7., https://pubmed.ncbi.nlm.nih.gov/21960285/
257. Moussata, D, Napoleon, B, Lepilliez, V, Klich, A, Ecochard, R, Lapalus, MG, et.al. Endoscopic treatment of severe duodenal polyposis as an alternative to surgery for patients with familial adenomatous polyposis., Gastrointest Endosc, 2014. 80 (5)(5): p. 817-25., https://pubmed.ncbi.nlm.nih.gov/24814771/
258. Vu Trung, K, Abou-Ali, E, Caillol, F, Paik, WH, Napoleon, B, Masaryk, V, et.al. Endoscopic papillectomy for ampullary lesions in patients with familial adenomatous polyposis compared with sporadic lesions: a propensity score-matched cohort., Endoscopy, 2023. 55 (8)(8): p. 709-718., https://pubmed.ncbi.nlm.nih.gov/36746390/
259. Walsh, RM, Augustin, T, Aleassa, EM, Simon, R, El-Hayek, KM, Moslim, MA, et.al. Comparison of pancreas-sparing duodenectomy (PSD) and pancreatoduodenectomy (PD) for the management of duodenal polyposis syndromes., Surgery, 2019. 166 (4)(4): p. 496-502., https://pubmed.ncbi.nlm.nih.gov/31474487/
260. de Castro, SM, van Eijck, CH, Rutten, JP, Dejong, CH, van Goor, H, Busch, OR, et.al. Pancreas-preserving total duodenectomy versus standard pancreatoduodenectomy for patients with familial adenomatous polyposis and polyps in the duodenum., Br J Surg, 2008. 95 (11)(11): p. 1380-6., https://pubmed.ncbi.nlm.nih.gov/18844249/
261. Yoon, JY, Mehta, N, Burke, CA, Augustin, T, O'Malley, M, LaGuardia, L, et.al. The Prevalence and Significance of Jejunal and Duodenal Bulb Polyposis After Duodenectomy in Familial Adenomatous Polyposis: Retrospective Cohort Study., Ann Surg, 2021. 274 (6)(6): p. e1071-e1077., https://pubmed.ncbi.nlm.nih.gov/31850977/
262. Naples, R, Simon, R, Moslim, M, Augustin, T, Church, J, Burke, CA, et.al. Long-Term Outcomes of Pancreas-Sparing Duodenectomy for Duodenal Polyposis in Familial Adenomatous Polyposis Syndrome., J Gastrointest Surg, 2021. 25 (5)(5): p. 1233-1240., https://pubmed.ncbi.nlm.nih.gov/32410179/
263. Matsumoto, M, Nakajima, T, Kakugawa, Y, Sakamoto, T, Kuribayashi, S, Otake, Y, et.al. Surveillance using capsule endoscopy is safe in post-colectomy patients with familial adenomatous polyposis: a prospective Japanese study., Fam Cancer, 2016. 15 (1)(1): p. 75-83., https://pubmed.ncbi.nlm.nih.gov/26450841/
264. Aelvoet, AS, Pellisé, M, Miedema, TN, Daca-Alvarez, M, Bastiaansen, BAJ, van Leerdam, ME, et.al. Development of Desmoid Tumors After Ileorectal Anastomosis Versus Ileal Pouch-Anal Anastomosis in Familial Adenomatous Polyposis., Clin Gastroenterol Hepatol, 2024. 22 (11)(11): p. 2319-2326., https://pubmed.ncbi.nlm.nih.gov/38969075/
265. Herraiz, M., Barbesino, G., Faquin, W., Chan-Smutko, G., Patel, D., Shannon, K. M., et.al. Prevalence of thyroid cancer in familial adenomatous polyposis syndrome and the role of screening ultrasound examinations, Clin Gastroenterol Hepatol, 2007. 5(3): p. 367-73., http://www.ncbi.nlm.nih.gov/pubmed/17258512
266. Ghorbanoghli, Z, Bastiaansen, BA, Langers, AM, Nagengast, FM, Poley, JW, Hardwick, JC, et.al. Extracolonic cancer risk in Dutch patients with APC (adenomatous polyposis coli)-associated polyposis., J Med Genet, 2018. 55 (1)(1): p. 11-14., https://pubmed.ncbi.nlm.nih.gov/28490611/
267. Chenbhanich, J, Atsawarungruangkit, A, Korpaisarn, S, Phupitakphol, T, Osataphan, S, Phowthongkum, P, Prevalence of thyroid diseases in familial adenomatous polyposis: a systematic review and meta-analysis., Fam Cancer, 2019. 18 (1)(1): p. 53-62., https://pubmed.ncbi.nlm.nih.gov/29663106/
268. Steinhagen, E, Hui, VW, Levy, RA, Markowitz, AJ, Fish, S, Wong, RJ, et.al. Results of a prospective thyroid ultrasound screening program in adenomatous polyposis patients., Am J Surg, 2014. 208 (5)(5): p. 764-769., https://pubmed.ncbi.nlm.nih.gov/25073656/
269. Sada, H, Hinoi, T, Ueno, H, Yamaguchi, T, Inoue, Y, Konishi, T, et.al. Prevalence of and risk factors for thyroid carcinoma in patients with familial adenomatous polyposis: results of a multicenter study in Japan and a systematic review., Surg Today, 2019. 49 (1)(1): p. 72-81., https://pubmed.ncbi.nlm.nih.gov/30182306/
270. Smith, JR, Kamihara, J, Church, AJ, Asch, E, Cherella, CE, Fox, VL, et.al. Thyroid Nodules in Children With Familial Adenomatous Polyposis., Am J Gastroenterol, 2022. 117 (7)(7): p. 1166-1168., https://pubmed.ncbi.nlm.nih.gov/35333786/
271. Steinhagen, E, Guillem, JG, Chang, G, Salo-Mullen, EE, Shia, J, Fish, S, et.al. The prevalence of thyroid cancer and benign thyroid disease in patients with familial adenomatous polyposis may be higher than previously recognized., Clin Colorectal Cancer, 2012. 11 (4)(4): p. 304-8., https://pubmed.ncbi.nlm.nih.gov/22425061/
272. Monachese, M, Mankaney, G, Lopez, R, O'Malley, M, Laguardia, L, Kalady, MF, et.al. Outcome of thyroid ultrasound screening in FAP patients with a normal baseline exam., Fam Cancer, 2019. 18 (1)(1): p. 75-82., https://pubmed.ncbi.nlm.nih.gov/30003385/
273. Dekker, E, Bleijenberg, A, Balaguer, F, Update on the World Health Organization Criteria for Diagnosis of Serrated Polyposis Syndrome., Gastroenterology, 2020. 158 (6)(6): p. 1520-1523., https://pubmed.ncbi.nlm.nih.gov/31982410/
274. Valle, L, de Voer, RM, Goldberg, Y, Sjursen, W, Försti, A, Ruiz-Ponte, C, et.al. Update on genetic predisposition to colorectal cancer and polyposis., Mol Aspects Med, 2019. 69 (): p. 10-26., https://pubmed.ncbi.nlm.nih.gov/30862463/
275. van Leerdam, ME, Roos, VH, van Hooft, JE, Dekker, E, Jover, R, Kaminski, MF, et.al. Endoscopic management of polyposis syndromes: European Society of Gastrointestinal Endoscopy (ESGE) Guideline., Endoscopy, 2019. 51 (9)(9): p. 877-895., https://pubmed.ncbi.nlm.nih.gov/31342472/
276. Bleijenberg, AGC, IJspeert, JEG, Carballal, S, Pellise, M, Jung, G, van Herwaarden, YJ, et.al. Low Incidence of Advanced Neoplasia in Serrated Polyposis Syndrome After (Sub)total Colectomy: Results of a 5-Year International Prospective Cohort Study., Am J Gastroenterol, 2019. 114 (9)(9): p. 1512-1519., https://pubmed.ncbi.nlm.nih.gov/31403493/
277. Bleijenberg, AG, IJspeert, JE, van Herwaarden, YJ, Carballal, S, Pellisé, M, Jung, G, et.al. Personalised surveillance for serrated polyposis syndrome: results from a prospective 5-year international cohort study., Gut, 2020. 69 (1)(1): p. 112-121., https://pubmed.ncbi.nlm.nih.gov/30981990/
278. Hazewinkel, Y, Koornstra, JJ, Boparai, KS, van Os, TA, Tytgat, KM, Van Eeden, S, et.al. Yield of screening colonoscopy in first-degree relatives of patients with serrated polyposis syndrome., J Clin Gastroenterol, 2015. 49 (5)(5): p. 407-12., https://pubmed.ncbi.nlm.nih.gov/24583756/
279. Beggs, A. D., Latchford, A. R., Vasen, H. F., Moslein, G., Alonso, A., Aretz, S., et.al. Peutz-Jeghers syndrome: a systematic review and recommendations for management, Gut, 2010. 59(7): p. 975-86., http://www.ncbi.nlm.nih.gov/pubmed/20581245
280. Aretz, S., The differential diagnosis and surveillance of hereditary gastrointestinal polyposis syndromes, Dtsch Arztebl Int, 2010. 107(10): p. 163-73.
281. Jasperson, K. W., Tuohy, T. M., Neklason, D. W., Burt, R. W., Hereditary and familial colon cancer, Gastroenterology, 2010. 138(6): p. 2044-58., http://www.ncbi.nlm.nih.gov/pubmed/20420945
282. Andrieu, N., Launoy, G., Guillois, R., Ory-Paoletti, C., Gignoux, M., Familial relative risk of colorectal cancer: a population-based study, Eur J Cancer, 2003. 39(13): p. 1904-11., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12932670, http://www.ejcancer.com/article/S0959-8049(03)00420-9/abstract
283. Johns, L. E., Houlston, R. S., A systematic review and meta-analysis of familial colorectal cancer risk, Am J Gastroenterol, 2001. 96(10): p. 2992-3003., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11693338
284. Lichtenstein, P., Holm, N. V., Verkasalo, P. K., Iliadou, A., Kaprio, J., Koskenvuo, M., et.al. Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland, N Engl J Med, 2000. 343(2): p. 78-85., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10891514, http://www.nejm.org/doi/pdf/10.1056/NEJM200007133430201
285. Winawer, S., Fletcher, R., Rex, D., Bond, J., Burt, R., Ferrucci, J., et.al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence, Gastroenterology, 2003. 124(2): p. 544-60., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12557158, http://www.gastrojournal.org/article/S0016-5085(02)15895-1/pdf
286. Bonelli, L., Martines, H., Conio, M., Bruzzi, P., Aste, H., Family history of colorectal cancer as a risk factor for benign and malignant tumours of the large bowel. A case-control study, Int J Cancer, 1988. 41(4): p. 513-7., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=3356486, http://onlinelibrary.wiley.com/doi/10.1002/ijc.2910410407/abstract
287. Fuchs, C.S., Giovannucci, E.L., Colditz, G.A., Hunter, D.J., Speizer, F.E., Willett, W.C., A prospective study of family history and the risk of colorectal cancer, N Engl J Med, 1994. 331(25): p. 1669-74., http://www.nejm.org/doi/pdf/10.1056/NEJM199412223312501
288. Guillem, JG, Bastar, AL, Ng, J, Huhn, JL, Cohen, AM, Clustering of colorectal cancer in families of probands under 40 years of age., Dis Colon Rectum, 1996. 39 (9)(9): p. 1004-7., https://pubmed.ncbi.nlm.nih.gov/8797650/
289. Guillem, JG, Forde, KA, Treat, MR, Neugut, AI, O'Toole, KM, Diamond, BE, Colonoscopic screening for neoplasms in asymptomatic first-degree relatives of colon cancer patients. A controlled, prospective study., Dis Colon Rectum, 1992. 35 (6)(6): p. 523-9., https://pubmed.ncbi.nlm.nih.gov/1587168/
290. Kune, GA, Kune, S, Watson, LF, The role of heredity in the etiology of large bowel cancer: data from the Melbourne Colorectal Cancer Study., World J Surg, 1989. 13 (1)(1): p. 124-9; discussion 129-31., https://pubmed.ncbi.nlm.nih.gov/2728462/
291. Rozen, P., Fireman, Z., Figer, A., Legum, C., Ron, E., Lynch, H.T., Family history of colorectal cancer as a marker of potential malignancy within a screening programm, Cancer, 1987. 60(2): p. 248-54., http://onlinelibrary.wiley.com/store/10.1002/1097-0142(19870715)60:2<248::AID-CNCR2820600223>3.0.CO;2-G/asset/2820600223_ftp.pdf?v=1&t=ik5892nf&s=00bb78e9114146c76b4808000d9b29f4b363283e
292. Sondergaard, J.O., Bulow, S., Lynge, E., Cancer incidence among parents of patients with colorectal cancer, Int J Cancer, 1991. 47(2): p. 202-6., http://onlinelibrary.wiley.com/doi/10.1002/ijc.2910470207/abstract
293. St John, D.J., McDermott, F.T., Hopper, J.L., Debney, E.A., Johnson, W.R., Hughes, E.S., Cancer risk in relatives of patients with common colorectal cancer, Ann Int Med, 1993. 118(10): p. 785-90., http://annals.org/article.aspx?articleid=706371
294. Butterworth, A. S., Higgins, J. P., Pharoah, P., Relative and absolute risk of colorectal cancer for individuals with a family history: a meta-analysis, Eur J Cancer, 2006. 42(2): p. 216-27., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16338133, http://www.ejcancer.com/article/S0959-8049(05)00945-7/abstract
295. Andrieu, N., Launoy, G., Guillois, R., Ory-Paoletti, C., Gignoux, M., Familial relative risk of colorectal cancer: a population-based study, Eur J Cancer, 2003. 39(13): p. 1904-11.
296. Bonelli, L., Martines, H., Conio, M., Bruzzi, P., Aste, H., Family history of colorectal cancer as a risk factor for benign and malignant tumours of the large bowel. A case-control study, Int J Cancer, 1988. 41(4): p. 513-7.
297. Butterworth, A. S., Higgins, J. P., Pharoah, P., Relative and absolute risk of colorectal cancer for individuals with a family history: a meta-analysis, Eur J Cancer, 2006. 42(2): p. 216-27.
298. Fuchs, C.S., Giovannucci, E.L., Colditz, G.A., Hunter, D.J., Speizer, F.E., Willett, W.C., A prospective study of family history and the risk of colorectal cancer, N Engl J Med, 1994. 331(25): p. 1669-74.
299. Guillem, J.G., Bastar, A.L., Ng, J., Huhn, J.L., Cohen, A.M., Clustering of colorectal cancer in families of probands under 40 years of age, Dis Colon Rectum, 1996. 39(9): p. 1004-7.
300. Guillem, J.G., Forde, K.A., Treat, M.R., Neugut, A.I., O'Toole, K.M., Diamond, B.E., Colonoscopic screening for neoplasms in asymptomatic first-degree relatives of colon cancer patients. A controlled, prospective study, Dis Colon Rectum, 1992. 35(6): p. 523-9.
301. Johns, L. E., Houlston, R. S., A systematic review and meta-analysis of familial colorectal cancer risk, Am J Gastroenterol, 2001. 96(10): p. 2992-3003.
302. Kune, G.A., Kune, S., Watson, L.F., The role of heredity in the etiology of large bowel cancer: data from the Melbourne Colorectal Cancer Study, World J Surg, 1989. 13(1): p. 124-9.
303. Lichtenstein, P., Holm, N. V., Verkasalo, P. K., Iliadou, A., Kaprio, J., Koskenvuo, M., et.al. Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland, N Engl J Med, 2000. 343(2): p. 78-85.
304. Rozen, P., Fireman, Z., Figer, A., Legum, C., Ron, E., Lynch, H.T., Family history of colorectal cancer as a marker of potential malignancy within a screening programm, Cancer, 1987. 60(2): p. 248-54.
305. Slattery, M. L., Levin, T. R., Ma, K., Goldgar, D., Holubkov, R., Edwards, S., Family history and colorectal cancer: predictors of risk, Cancer Causes Control, 2003. 14(9): p. 879-87.
306. Sondergaard, J.O., Bulow, S., Lynge, E., Cancer incidence among parents of patients with colorectal cancer, Int J Cancer, 1991. 47(2): p. 202-6.
307. St John, D.J., McDermott, F.T., Hopper, J.L., Debney, E.A., Johnson, W.R., Hughes, E.S., Cancer risk in relatives of patients with common colorectal cancer, Ann Int Med, 1993. 118(10): p. 785-90.
308. Winawer, S., Fletcher, R., Rex, D., Bond, J., Burt, R., Ferrucci, J., et.al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence, Gastroenterology, 2003. 124(2): p. 544-60.
309. Hall, N. R., Bishop, D. T., Stephenson, B. M., Finan, P. J., Hereditary susceptibility to colorectal cancer. Relatives of early onset cases are particularly at risk, Dis Colon Rectum, 1996. 39(7): p. 739-43.
310. Spier, I, Drichel, D, Kerick, M, Kirfel, J, Horpaopan, S, Laner, A, et.al. Low-level APC mutational mosaicism is the underlying cause in a substantial fraction of unexplained colorectal adenomatous polyposis cases., J Med Genet, 2016. 53 (3)(3): p. 172-9., https://pubmed.ncbi.nlm.nih.gov/26613750/
311. Tian, Y, Kharazmi, E, Brenner, H, Xu, X, Sundquist, K, Sundquist, J, et.al. Importance of Family History of Colorectal Carcinoma In Situ Versus Invasive Colorectal Cancer: A Nationwide Cohort Study., J Natl Compr Canc Netw, 2021. 19 (11)(11): p. 1252-1257., https://pubmed.ncbi.nlm.nih.gov/34517339/
312. Tian, Y, Kharazmi, E, Brenner, H, Xu, X, Sundquist, K, Sundquist, J, et.al. Calculating the Starting Age for Screening in Relatives of Patients With Colorectal Cancer Based on Data From Large Nationwide Data Sets., Gastroenterology, 2020. 159 (1)(1): p. 159-168.e3., https://pubmed.ncbi.nlm.nih.gov/32251666/
313. Ahsan, H., Neugut, A. I., Garbowski, G. C., Jacobson, J. S., Forde, K. A., Treat, M. R., et.al. Family history of colorectal adenomatous polyps and increased risk for colorectal cancer, Ann Intern Med, 1998. 128(11): p. 900-5.
314. Almendingen, K., Hofstad, B., Vatn, M. H., Does a family history of cancer increase the risk of occurrence, growth, and recurrence of colorectal adenomas?, Gut, 2003. 52(5): p. 747-51.
315. Winawer, S.J., O'Brien, M.J., Waye, J.D., Kronborg, O., Bond, J., Fruhmorgen, P., et.al. Risk and surveillance of individuals with colorectal polyps. WHO Collaborating Centre for the Prevention of Colorectal Cancer, Bull World Health Organ, 1990. 68(6): p. 789-95.
316. Hu, Y, Kharazmi, E, Liang, Q, Sundquist, K, Sundquist, J, Fallah, M, Risk of Colorectal Cancer Associated With Frequency of Colorectal Polyp Diagnosis in Relatives., Gastroenterology, 2025. ():, https://pubmed.ncbi.nlm.nih.gov/39800079/
317. Slattery, M. L., Levin, T. R., Ma, K., Goldgar, D., Holubkov, R., Edwards, S., Family history and colorectal cancer: predictors of risk, Cancer Causes Control, 2003. 14(9): p. 879-87., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14682445
318. Winawer, S., Fletcher, R., Rex, D., Bond, J., Burt, R., Ferrucci, J., et.al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence, Gastroenterology, 2003. 124(2): p. 544-60., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12557158, http://www.gastrojournal.org/article/S0016-5085(02)15895-1/pdf
319. Hall, N. R., Bishop, D. T., Stephenson, B. M., Finan, P. J., Hereditary susceptibility to colorectal cancer. Relatives of early onset cases are particularly at risk, Dis Colon Rectum, 1996. 39(7): p. 739-43., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8674364
320. Hunt, L.M., Rooney, P.S., Hardcastle, J.D., Armitage, N.C., Endoscopic screening of relatives of patients with colorectal cancer, Gut, 1998. 42(1): p. 71-5., http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1726961/pdf/v042p00071.pdf
321. Crispin, A, Rehms, R, Hoffmann, S, Lindoerfer, D, Hallsson, LR, Jahn, B, et.al. Colorectal Cancer Screening for Persons With a Positive Family History—Evaluation of the FARKOR Program for the Secondary Prevention of Colorectal Cancer in Persons Aged 25 to 50., Dtsch Arztebl Int, 2023. 120 (46)(46): p. 786-792., https://pubmed.ncbi.nlm.nih.gov/37855423/
322. Winawer, SJ, Zauber, AG, Gerdes, H, O'Brien, MJ, Gottlieb, LS, Sternberg, SS, et.al. Risk of colorectal cancer in the families of patients with adenomatous polyps. National Polyp Study Workgroup., N Engl J Med, 1996. 334 (2)(2): p. 82-7., https://pubmed.ncbi.nlm.nih.gov/8531963/
323. Ahsan, H., Neugut, A. I., Garbowski, G. C., Jacobson, J. S., Forde, K. A., Treat, M. R., et.al. Family history of colorectal adenomatous polyps and increased risk for colorectal cancer, Ann Intern Med, 1998. 128(11): p. 900-5., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9634428, http://annals.org/article.aspx?articleid=711453
324. Nakama, H., Zhang, B., Fukazawa, K., Abdul Fattah, A. S., Family history of colorectal adenomatous polyps as a risk factor for colorectal cancer, Eur J Cancer, 2000. 36(16): p. 2111-4., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11044649, http://www.ejcancer.com/article/S0959-8049(00)00293-8/abstract
325. Almendingen, K., Hofstad, B., Vatn, M. H., Does a family history of cancer increase the risk of occurrence, growth, and recurrence of colorectal adenomas?, Gut, 2003. 52(5): p. 747-51., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12692063, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1773641/pdf/gut05200747.pdf
326. Hadjiliadis, D, Khoruts, A, Zauber, AG, Hempstead, SE, Maisonneuve, P, Lowenfels, AB, Cystic Fibrosis Colorectal Cancer Screening Consensus Recommendations., Gastroenterology, 2018. 154 (3)(3): p. 736-745.e14., https://pubmed.ncbi.nlm.nih.gov/29289528/
327. Spigelman, A. D., Williams, C. B., Talbot, I. C., Domizio, P., Phillips, R. K., Upper gastrointestinal cancer in patients with familial adenomatous polyposis, Lancet, 1989. 2(8666): p. 783-5., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2571019, http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(89)90840-4/abstract
328. Neri, E., Giusti, P., Battolla, L., Vagli, P., Boraschi, P., Lencioni, R., et.al. Colorectal cancer: role of CT colonography in preoperative evaluation after incomplete colonoscopy, Radiology, 2002. 223(3): p. 615-9., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12034925
329. Corley, D. A., Jensen, C. D., Marks, A. R., Zhao, W. K., Lee, J. K., Doubeni, C. A., et.al. Adenoma detection rate and risk of colorectal cancer and death, N Engl J Med, 2014. 370(14): p. 1298-306., http://www.nejm.org/doi/pdf/10.1056/NEJMoa1309086
330. Kaminski, M. F., Regula, J., Kraszewska, E., Polkowski, M., Wojciechowska, U., Didkowska, J., et.al. Quality indicators for colonoscopy and the risk of interval cancer, N Engl J Med, 2010. 362(19): p. 1795-803., http://www.nejm.org/doi/pdf/10.1056/NEJMoa0907667
331. Ferlitsch, M, Hassan, C, Bisschops, R, Bhandari, P, Dinis-Ribeiro, M, Risio, M, et.al. Colorectal polypectomy and endoscopic mucosal resection: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2024., Endoscopy, 2024. 56 (7)(7): p. 516-545., https://pubmed.ncbi.nlm.nih.gov/38670139/
332. Corley, DA, Jensen, CD, Marks, AR, Zhao, WK, Lee, JK, Doubeni, CA, et.al. Adenoma detection rate and risk of colorectal cancer and death., N Engl J Med, 2014. 370 (14)(14): p. 1298-306., https://pubmed.ncbi.nlm.nih.gov/24693890/
333. Kaminski, MF, Thomas-Gibson, S, Bugajski, M, Bretthauer, M, Rees, CJ, Dekker, E, et.al. Performance measures for lower gastrointestinal endoscopy: a European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative., Endoscopy, 2017. 49 (4)(4): p. 378-397., https://pubmed.ncbi.nlm.nih.gov/28268235/
334. Hassan, C, Bretthauer, M, Kaminski, MF, Polkowski, M, Rembacken, B, Saunders, B, et.al. Bowel preparation for colonoscopy: European Society of Gastrointestinal Endoscopy (ESGE) guideline., Endoscopy, 2013. 45 (2)(2): p. 142-50., https://pubmed.ncbi.nlm.nih.gov/23335011/
335. Froehlich, F, Wietlisbach, V, Gonvers, JJ, Burnand, B, Vader, JP, Impact of colonic cleansing on quality and diagnostic yield of colonoscopy: the European Panel of Appropriateness of Gastrointestinal Endoscopy European multicenter study., Gastrointest Endosc, 2005. 61 (3)(3): p. 378-84., https://pubmed.ncbi.nlm.nih.gov/15758907/
336. Sapci, I, Jia, X, Wu, J, Gorgun, E, Liska, D, Church, J, et.al. Does time of day matter for colonoscopy quality? A review of over 13,000 screening colonoscopies in a colorectal surgery unit., Am J Surg, 2022. 223 (3)(3): p. 500-502., https://pubmed.ncbi.nlm.nih.gov/34916039/
337. Thoufeeq, MH, Rembacken, BJ, Meticulous cecal image documentation at colonoscopy is associated with improved polyp detection., Endosc Int Open, 2015. 3 (6)(6): p. E629-33., https://pubmed.ncbi.nlm.nih.gov/26716125/
338. Neilson, LJ, Bevan, R, Panter, S, Thomas-Gibson, S, Rees, CJ, Terminal ileal intubation and biopsy in routine colonoscopy practice., Expert Rev Gastroenterol Hepatol, 2015. 9 (5)(5): p. 567-74., https://pubmed.ncbi.nlm.nih.gov/25582839/
339. Barclay, R. L., Vicari, J. J., Doughty, A. S., Johanson, J. F., Greenlaw, R. L., Colonoscopic withdrawal times and adenoma detection during screening colonoscopy, N Engl J Med, 2006. 355(24): p. 2533-41., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17167136, http://www.nejm.org/doi/pdf/10.1056/NEJMoa055498
340. Barclay, R. L., Vicari, J. J., Greenlaw, R. L., Effect of a time-dependent colonoscopic withdrawal protocol on adenoma detection during screening colonoscopy, Clin Gastroenterol Hepatol, 2008. 6(10): p. 1091-8., http://www.cghjournal.org/article/S1542-3565(08)00351-0/pdf
341. Butterly, L., Robinson, C. M., Anderson, J. C., Weiss, J. E., Goodrich, M., Onega, T. L., et.al. Serrated and adenomatous polyp detection increases with longer withdrawal time: results from the New Hampshire Colonoscopy Registry, Am J Gastroenterol, 2014. 109(3): p. 417-26., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4082336/pdf/nihms588120.pdf
342. Sawhney, M. S., Cury, M. S., Neeman, N., Ngo, L. H., Lewis, J. M., Chuttani, R., et.al. Effect of institution-wide policy of colonoscopy withdrawal time > or = 7 minutes on polyp detection, Gastroenterology, 2008. 135(6): p. 1892-8., http://ac.els-cdn.com/S0016508508015199/1-s2.0-S0016508508015199-main.pdf?_tid=7e93ff40-30fb-11e4-8991-00000aab0f27&acdnat=1409481924_0ea6777a436426dd1d7f321f4d638153
343. Lee, TJ, Blanks, RG, Rees, CJ, Wright, KC, Nickerson, C, Moss, SM, et.al. Longer mean colonoscopy withdrawal time is associated with increased adenoma detection: evidence from the Bowel Cancer Screening Programme in England., Endoscopy, 2013. 45 (1)(1): p. 20-6., https://pubmed.ncbi.nlm.nih.gov/23254403/
344. Robertson, D. J., Greenberg, E. R., Beach, M., Sandler, R. S., Ahnen, D., Haile, R. W., et.al. Colorectal cancer in patients under close colonoscopic surveillance, Gastroenterology, 2005. 129(1): p. 34-41., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16012932, http://www.gastrojournal.org/article/S0016-5085(05)00882-6/pdf
345. Pabby, A., Schoen, R. E., Weissfeld, J. L., Burt, R., Kikendall, J. W., Lance, P., et.al. Analysis of colorectal cancer occurrence during surveillance colonoscopy in the dietary Polyp Prevention Trial, Gastrointest Endosc, 2005. 61(3): p. 385-91., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15758908, http://www.giejournal.org/article/S0016-5107(04)02765-8/abstract
346. Sawhney, M. S., Farrar, W. D., Gudiseva, S., Nelson, D. B., Lederle, F. A., Rector, T. S., et.al. Microsatellite instability in interval colon cancers, Gastroenterology, 2006. 131(6): p. 1700-5., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17087932, http://www.gastrojournal.org/article/S0016-5085(06)02256-6/pdf
347. Brenner, H., Chang-Claude, J., Seiler, C. M., Rickert, A., Hoffmeister, M., Protection from colorectal cancer after colonoscopy: a population-based, case-control study, Ann Intern Med, 2011. 154(1): p. 22-30., http://annals.org/aim/article/746683/protection-from-colorectal-cancer-after-colonoscopy-population-based-case-control
348. Javeri, K., Williams, T. R., Bonnett, J. W., An overview of the method, application, and various findings of computed tomographic colonography in patients after incomplete colonoscopy, Curr Probl Diagn Radiol, 2010. 39(6): p. 262-74., http://www.cpdrjournal.com/article/S0363-0188(09)00077-2/fulltext
349. Copel, L., Sosna, J., Kruskal, J. B., Raptopoulos, V., Farrell, R. J., Morrin, M. M., CT colonography in 546 patients with incomplete colonoscopy, Radiology, 2007. 244(2): p. 471-8.
350. Morrin, M. M., Farrell, R. J., Raptopoulos, V., McGee, J. B., Bleday, R., Kruskal, J. B., Role of virtual computed tomographic colonography in patients with colorectal cancers and obstructing colorectal lesions, Dis Colon Rectum, 2000. 43(3): p. 303-11., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10733110
351. Hartmann, D., Bassler, B., Schilling, D., Pfeiffer, B., Jakobs, R., Eickhoff, A., et.al. Incomplete conventional colonoscopy: magnetic resonance colonography in the evaluation of the proximal colon, Endoscopy, 2005. 37(9): p. 816-20., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16116531, https://www.thieme-connect.com/DOI/DOI?10.1055/s-2005-870309
352. Ajaj, W., Lauenstein, T. C., Pelster, G., Holtmann, G., Ruehm, S. G., Debatin, J. F., et.al. MR colonography in patients with incomplete conventional colonoscopy, Radiology, 2005. 234(2): p. 452-9.
353. Spada, C, Hassan, C, Bellini, D, Burling, D, Cappello, G, Carretero, C, et.al. Imaging alternatives to colonoscopy: CT colonography and colon capsule. European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Gastrointestinal and Abdominal Radiology (ESGAR) Guideline - Update 2020., Endoscopy, 2020. 52 (12)(12): p. 1127-1141., https://pubmed.ncbi.nlm.nih.gov/33105507/
354. Spada, C., Pasha, S. F., Gross, S. A., Leighton, J. A., Schnoll-Sussman, F., Correale, L., et.al. Accuracy of First- and Second-Generation Colon Capsules in Endoscopic Detection of Colorectal Polyps: A Systematic Review and Meta-analysis, Clin Gastroenterol Hepatol, 2016. 14(11): p. 1533-1543.e8., http://ac.els-cdn.com/S1542356516301513/1-s2.0-S1542356516301513-main.pdf?_tid=f419c536-05d5-11e7-96d4-00000aacb35f&acdnat=1489180394_feeff55db0b7ab41a5464f1e468c4437
355. Rex, D. K., Adler, S. N., Aisenberg, J., Burch, W. C., Jr., Carretero, C., Chowers, Y., et.al. Accuracy of capsule colonoscopy in detecting colorectal polyps in a screening population, Gastroenterology, 2015. 148(5): p. 948-957 e2., http://www.gastrojournal.org/article/S0016-5085(15)00110-9/pdf
356. Burgess, NG, Hourigan, LF, Zanati, SA, Brown, GJ, Singh, R, Williams, SJ, et.al. Risk Stratification for Covert Invasive Cancer Among Patients Referred for Colonic Endoscopic Mucosal Resection: A Large Multicenter Cohort., Gastroenterology, 2017. 153 (3)(3): p. 732-742.e1., https://pubmed.ncbi.nlm.nih.gov/28583826/
357. D'Amico, F, Amato, A, Iannone, A, Trovato, C, Romana, C, Angeletti, S, et.al. Risk of Covert Submucosal Cancer in Patients With Granular Mixed Laterally Spreading Tumors., Clin Gastroenterol Hepatol, 2021. 19 (7)(7): p. 1395-1401., https://pubmed.ncbi.nlm.nih.gov/32687977/
358. Moss, A, Bourke, MJ, Williams, SJ, Hourigan, LF, Brown, G, Tam, W, et.al. Endoscopic mucosal resection outcomes and prediction of submucosal cancer from advanced colonic mucosal neoplasia., Gastroenterology, 2011. 140 (7)(7): p. 1909-18., https://pubmed.ncbi.nlm.nih.gov/21392504/
359. Bogie, RMM, Veldman, MHJ, Snijders, LARS, Winkens, B, Kaltenbach, T, Masclee, AAM, et.al. Endoscopic subtypes of colorectal laterally spreading tumors (LSTs) and the risk of submucosal invasion: a meta-analysis., Endoscopy, 2018. 50 (3)(3): p. 263-282., https://pubmed.ncbi.nlm.nih.gov/29179230/
360. Wada, Y, Kashida, H, Kudo, SE, Misawa, M, Ikehara, N, Hamatani, S, Diagnostic accuracy of pit pattern and vascular pattern analyses in colorectal lesions., Dig Endosc, 2010. 22 (3)(3): p. 192-9., https://pubmed.ncbi.nlm.nih.gov/20642608/
361. Kudo, S, Tamura, S, Nakajima, T, Yamano, H, Kusaka, H, Watanabe, H, Diagnosis of colorectal tumorous lesions by magnifying endoscopy., Gastrointest Endosc, 1996. 44 (1)(1): p. 8-14., https://pubmed.ncbi.nlm.nih.gov/8836710/
362. Hayashi, N, Tanaka, S, Hewett, DG, Kaltenbach, TR, Sano, Y, Ponchon, T, et.al. Endoscopic prediction of deep submucosal invasive carcinoma: validation of the narrow-band imaging international colorectal endoscopic (NICE) classification., Gastrointest Endosc, 2013. 78 (4)(4): p. 625-32., https://pubmed.ncbi.nlm.nih.gov/23910062/
363. Sano, Y, Tanaka, S, Kudo, SE, Saito, S, Matsuda, T, Wada, Y, et.al. Narrow-band imaging (NBI) magnifying endoscopic classification of colorectal tumors proposed by the Japan NBI Expert Team., Dig Endosc, 2016. 28 (5)(5): p. 526-33., https://pubmed.ncbi.nlm.nih.gov/26927367/
364. Zhang, Y, Chen, HY, Zhou, XL, Pan, WS, Zhou, XX, Pan, HH, Diagnostic efficacy of the Japan Narrow-band-imaging Expert Team and Pit pattern classifications for colorectal lesions: A meta-analysis., World J Gastroenterol, 2020. 26 (40)(40): p. 6279-6294., https://pubmed.ncbi.nlm.nih.gov/33177800/
365. Saito, Y, Sakamoto, T, Dekker, E, Pioche, M, Probst, A, Ponchon, T, et.al. First report from the International Evaluation of Endoscopic classification Japan NBI Expert Team: International multicenter web trial., Dig Endosc, 2023. ():, https://pubmed.ncbi.nlm.nih.gov/37702082/
366. Wei, MT, Louie, CY, Chen, Y, Pan, JY, Quan, SY, Wong, R, et.al. Randomized Controlled Trial Investigating Cold Snare and Forceps Polypectomy Among Small POLYPs in Rates of Complete Resection: The TINYPOLYP Trial., Am J Gastroenterol, 2022. 117 (8)(8): p. 1305-1310., https://pubmed.ncbi.nlm.nih.gov/35467557/
367. Park, SK, Ko, BM, Han, JP, Hong, SJ, Lee, MS, A prospective randomized comparative study of cold forceps polypectomy by using narrow-band imaging endoscopy versus cold snare polypectomy in patients with diminutive colorectal polyps., Gastrointest Endosc, 2016. 83 (3)(3): p. 527-32.e1., https://pubmed.ncbi.nlm.nih.gov/26358331/
368. de Benito Sanz, M, Hernández, L, Garcia Martinez, MI, Diez-Redondo, P, Joao Matias, D, Gonzalez-Santiago, JM, et.al. Efficacy and safety of cold versus hot snare polypectomy for small (5-9 mm) colorectal polyps: a multicenter randomized controlled trial., Endoscopy, 2022. 54 (1)(1): p. 35-44., https://pubmed.ncbi.nlm.nih.gov/33264811/
369. Kawamura, T, Takeuchi, Y, Asai, S, Yokota, I, Akamine, E, Kato, M, et.al. A comparison of the resection rate for cold and hot snare polypectomy for 4-9 mm colorectal polyps: a multicentre randomised controlled trial (CRESCENT study)., Gut, 2018. 67 (11)(11): p. 1950-1957., https://pubmed.ncbi.nlm.nih.gov/28970290/
370. Qu, J, Jian, H, Li, L, Zhang, Y, Feng, B, Li, Z, et.al. Effectiveness and safety of cold versus hot snare polypectomy: A meta-analysis., J Gastroenterol Hepatol, 2019. 34 (1)(1): p. 49-58., https://pubmed.ncbi.nlm.nih.gov/30176072/
371. Jegadeesan, R, Aziz, M, Desai, M, Sundararajan, T, Gorrepati, VS, Chandrasekar, VT, et.al. Hot snare vs. cold snare polypectomy for endoscopic removal of 4 - 10 mm colorectal polyps during colonoscopy: a systematic review and meta-analysis of randomized controlled studies., Endosc Int Open, 2019. 7 (5)(5): p. E708-E716., https://pubmed.ncbi.nlm.nih.gov/31073538/
372. Winston, K, Maulahela, H, Raharjo, DE, Tjoa, K, Jonlean, R, A Comparative Analysis of the Efficacy and Safety of Hot Snare Polypectomy and Cold Snare Polypectomy for Removing Small Colorectal Polyps: A Systematic Review and Meta-Analysis., Cureus, 2023. 15 (5)(5): p. e38713., https://pubmed.ncbi.nlm.nih.gov/37292560/
373. Mangira, D, Raftopoulos, S, Vogrin, S, Hartley, I, Mack, A, Gazelakis, K, et.al. Effectiveness and safety of cold snare polypectomy and cold endoscopic mucosal resection for nonpedunculated colorectal polyps of 10-19 mm: a multicenter observational cohort study., Endoscopy, 2023. 55 (7)(7): p. 627-635., https://pubmed.ncbi.nlm.nih.gov/36750222/
374. von Renteln, D, Djinbachian, R, Benard, F, Barkun, AN, Bouin, M, Bouchard, S, et.al. Incomplete resection of colorectal polyps of 4-20 mm in size when using a cold snare, and its associated factors., Endoscopy, 2023. 55 (10)(10): p. 929-937., https://pubmed.ncbi.nlm.nih.gov/36377124/
375. Moss, A, Williams, SJ, Hourigan, LF, Brown, G, Tam, W, Singh, R, et.al. Long-term adenoma recurrence following wide-field endoscopic mucosal resection (WF-EMR) for advanced colonic mucosal neoplasia is infrequent: results and risk factors in 1000 cases from the Australian Colonic EMR (ACE) study., Gut, 2015. 64 (1)(1): p. 57-65., https://pubmed.ncbi.nlm.nih.gov/24986245/
376. Klein, A, Tate, DJ, Jayasekeran, V, Hourigan, L, Singh, R, Brown, G, et.al. Thermal Ablation of Mucosal Defect Margins Reduces Adenoma Recurrence After Colonic Endoscopic Mucosal Resection., Gastroenterology, 2019. 156 (3)(3): p. 604-613.e3., https://pubmed.ncbi.nlm.nih.gov/30296436/
377. Steinbrück, I, Ebigbo, A, Kuellmer, A, Schmidt, A, Kouladouros, K, Brand, M, et.al. Cold Versus Hot Snare Endoscopic Resection of Large Nonpedunculated Colorectal Polyps: Randomized Controlled German CHRONICLE Trial., Gastroenterology, 2024. 167 (4)(4): p. 764-777., https://pubmed.ncbi.nlm.nih.gov/38795735/
378. O'Sullivan, T, Cronin, O, van Hattem, WA, Mandarino, FV, Gauci, JL, Kerrison, C, et.al. Cold versus hot snare endoscopic mucosal resection for large (≥15 mm) flat non-pedunculated colorectal polyps: a randomised controlled trial., Gut, 2024. 73 (11)(11): p. 1823-1830., https://pubmed.ncbi.nlm.nih.gov/38964854/
379. Nagl, S, Ebigbo, A, Goelder, SK, Roemmele, C, Neuhaus, L, Weber, T, et.al. Underwater vs Conventional Endoscopic Mucosal Resection of Large Sessile or Flat Colorectal Polyps: A Prospective Randomized Controlled Trial., Gastroenterology, 2021. 161 (5)(5): p. 1460-1474.e1., https://pubmed.ncbi.nlm.nih.gov/34371000/
380. Wang X, Wang Y, Cao X, Zhang C, Miao L., Underwater versus conventional endoscopic mucosal resection for ≥ 10mm sessile or flat colorectal polyps: A systematic review and meta-analysis, PLoS One, 2024., https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0299931
381. Lim, XC, Nistala, KRY, Ng, CH, Lin, SY, Tan, DJH, Ho, KY, et.al. Endoscopic submucosal dissection , World J Gastroenterol, 2021. 27 (25)(25): p. 3925-3939., https://pubmed.ncbi.nlm.nih.gov/34321855/
382. Zhao, HJ, Yin, J, Ji, CY, Wang, X, Wang, N, Endoscopic mucosal resection versus endoscopic submucosal dissection for colorectal laterally spreading tumors: a meta-analysis., Rev Esp Enferm Dig, 2020. 112 (12)(12): p. 941-947., https://pubmed.ncbi.nlm.nih.gov/33207885/
383. Russo, P, Barbeiro, S, Awadie, H, Libânio, D, Dinis-Ribeiro, M, Bourke, M, Management of colorectal laterally spreading tumors: a systematic review and meta-analysis., Endosc Int Open, 2019. 7 (2)(2): p. E239-E259., https://pubmed.ncbi.nlm.nih.gov/30705959/
384. De Ceglie, A, Hassan, C, Mangiavillano, B, Matsuda, T, Saito, Y, Ridola, L, et.al. Endoscopic mucosal resection and endoscopic submucosal dissection for colorectal lesions: A systematic review., Crit Rev Oncol Hematol, 2016. 104 (): p. 138-55., https://pubmed.ncbi.nlm.nih.gov/27370173/
385. Bahin, FF, Heitman, SJ, Rasouli, KN, Mahajan, H, McLeod, D, Lee, EYT, et.al. Wide-field endoscopic mucosal resection versus endoscopic submucosal dissection for laterally spreading colorectal lesions: a cost-effectiveness analysis., Gut, 2018. 67 (11)(11): p. 1965-1973., https://pubmed.ncbi.nlm.nih.gov/28988198/
386. Kuellmer, A, Mueller, J, Caca, K, Aepli, P, Albers, D, Schumacher, B, et.al. Endoscopic full-thickness resection for early colorectal cancer., Gastrointest Endosc, 2019. 89 (6)(6): p. 1180-1189.e1., https://pubmed.ncbi.nlm.nih.gov/30653939/
387. Zwager, LW, Bastiaansen, BAJ, van der Spek, BW, Heine, DN, Schreuder, RM, Perk, LE, et.al. Endoscopic full-thickness resection of T1 colorectal cancers: a retrospective analysis from a multicenter Dutch eFTR registry., Endoscopy, 2022. 54 (5)(5): p. 475-485., https://pubmed.ncbi.nlm.nih.gov/34488228/
388. McCarty, TR, Bazarbashi, AN, Thompson, CC, Aihara, H, Hybrid endoscopic submucosal dissection (ESD) compared with conventional ESD for colorectal lesions: a systematic review and meta-analysis., Endoscopy, 2021. 53 (10)(10): p. 1048-1058., https://pubmed.ncbi.nlm.nih.gov/32947624/
389. Inoue, T, Nakagawa, K, Yamasaki, Y, Shichijo, S, Kanesaka, T, Maekawa, A, et.al. Underwater endoscopic mucosal resection versus endoscopic submucosal dissection for 20-30 mm colorectal polyps., J Gastroenterol Hepatol, 2021. 36 (9)(9): p. 2549-2557., https://pubmed.ncbi.nlm.nih.gov/33724540/
390. Probst, A., Ebigbo, A., Markl, B., Schaller, T., Anthuber, M., Fleischmann, C., et.al. Endoscopic submucosal dissection for early rectal neoplasia: experience from a European center, Endoscopy, 2017. 49(3): p. 222-232., https://www.thieme-connect.com/DOI/DOI?10.1055/s-0042-118449
391. Shahidi, N, Sidhu, M, Vosko, S, van Hattem, WA, Bar-Yishay, I, Schoeman, S, et.al. Endoscopic mucosal resection is effective for laterally spreading lesions at the anorectal junction., Gut, 2020. 69 (4)(4): p. 673-680., https://pubmed.ncbi.nlm.nih.gov/31719129/
392. Probst, A, Ebigbo, A, Märkl, B, Ting, S, Schaller, T, Anthuber, M, et.al. Endoscopic submucosal dissection for rectal neoplasia extending to the dentate line: European experience., Endosc Int Open, 2018. 6 (11)(11): p. E1355-E1362., https://pubmed.ncbi.nlm.nih.gov/30410957/
393. Kouladouros, K, Jakobs, J, Stathopoulos, P, Kähler, G, Belle, S, Denzer, U, Endoscopic submucosal dissection versus endoscopic mucosal resection for the treatment of rectal lesions involving the dentate line., Surg Endosc, 2024. 38 (8)(8): p. 4485-4495., https://pubmed.ncbi.nlm.nih.gov/38914887/
394. McCarty, TR, Bazarbashi, AN, Hathorn, KE, Thompson, CC, Aihara, H, Endoscopic submucosal dissection (ESD) versus transanal endoscopic microsurgery (TEM) for treatment of rectal tumors: a comparative systematic review and meta-analysis., Surg Endosc, 2020. 34 (4)(4): p. 1688-1695., https://pubmed.ncbi.nlm.nih.gov/31292744/
395. Kruger, AJ, Hussan, H, Stanich, PP, Gray, DM, Porter, KM, Hinton, A, et.al. Postoperative Hospital Outcomes of Elective Surgery for Nonmalignant Colorectal Polyps: Does the Burden Justify the Indication?, Am J Gastroenterol, 2021. 116 (9)(9): p. 1938-1945., https://pubmed.ncbi.nlm.nih.gov/34255758/
396. Saade, R, Tsang, T, Kmeid, M, Miller, D, Fu, Z, Litynski, J, et.al. Overutilization of surgical resection for benign colorectal polyps: analysis from a tertiary care center., Endosc Int Open, 2021. 9 (5)(5): p. E706-E712., https://pubmed.ncbi.nlm.nih.gov/33937512/
397. Buchner, AM, Guarner-Argente, C, Ginsberg, GG, Outcomes of EMR of defiant colorectal lesions directed to an endoscopy referral center., Gastrointest Endosc, 2012. 76 (2)(2): p. 255-63., https://pubmed.ncbi.nlm.nih.gov/22657404/
398. Nian, J, Tao, L, Zhou, W, Prior endoscopic resection does not affect the outcome of secondary surgery for T1 colorectal cancer, a systematic review and meta-analysis., Int J Colorectal Dis, 2022. 37 (2)(2): p. 273-281., https://pubmed.ncbi.nlm.nih.gov/34716475/
399. Makinen, M. J., Colorectal serrated adenocarcinoma, Histopathology, 2007. 50(1): p. 131-50., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17204027, http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2559.2006.02548.x/abstract
400. Jass, J. R., Classification of colorectal cancer based on correlation of clinical, morphological and molecular features, Histopathology, 2007. 50(1): p. 113-30., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17204026, http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2559.2006.02549.x/abstract
401. Hamilton, S. R., Aaltonen, L. A., Pathology and Genetics of Tumours of the Digestive SystemIARC Press, World Health Organization Classifecation of Tumours, 2000.
402. Nagtegaal, ID, Odze, RD, Klimstra, D, Paradis, V, Rugge, M, Schirmacher, P, et.al. The 2019 WHO classification of tumours of the digestive system., Histopathology, 2020. 76 (2)(2): p. 182-188., https://pubmed.ncbi.nlm.nih.gov/31433515/
403. Bettington, M, Walker, N, Clouston, A, Brown, I, Leggett, B, Whitehall, V, The serrated pathway to colorectal carcinoma: current concepts and challenges., Histopathology, 2013. 62 (3)(3): p. 367-86., https://pubmed.ncbi.nlm.nih.gov/23339363/
404. Bläker, H, Alwers, E, Arnold, A, Herpel, E, Tagscherer, KE, Roth, W, et.al. The Association Between Mutations in BRAF and Colorectal Cancer-Specific Survival Depends on Microsatellite Status and Tumor Stage., Clin Gastroenterol Hepatol, 2019. 17 (3)(3): p. 455-462.e6., https://pubmed.ncbi.nlm.nih.gov/29660527/
405. Phipps, AI, Limburg, PJ, Baron, JA, Burnett-Hartman, AN, Weisenberger, DJ, Laird, PW, et.al. Association between molecular subtypes of colorectal cancer and patient survival., Gastroenterology, 2015. 148 (1)(1): p. 77-87.e2., https://pubmed.ncbi.nlm.nih.gov/25280443/
406. Bettington, M, Walker, N, Rosty, C, Brown, I, Clouston, A, McKeone, D, et.al. Clinicopathological and molecular features of sessile serrated adenomas with dysplasia or carcinoma., Gut, 2017. 66 (1)(1): p. 97-106., https://pubmed.ncbi.nlm.nih.gov/26475632/
407. Gao, Q, Tsoi, KK, Hirai, HW, Wong, MC, Chan, FK, Wu, JC, et.al. Serrated polyps and the risk of synchronous colorectal advanced neoplasia: a systematic review and meta-analysis., Am J Gastroenterol, 2015. 110 (4)(4): p. 501-9; quiz 510., https://pubmed.ncbi.nlm.nih.gov/25756237/
408. Baretton, G. B., Tannapfel, A., Schmitt, W., [Standardized and structured histopathological evaluation of colorectal polyps: a practical checklist against the background of the new WHO classification], Pathologe, 2011. 32(4): p. 289-96., http://link.springer.com/article/10.1007%2Fs00292-011-1436-0
409. Chen, Y, Jing, W, Chen, M, Wang, Z, Wu, J, Yang, J, et.al. Long-term outcomes of local resection versus surgical resection for high-risk T1 colorectal cancer: a systematic review and meta-analysis., Gastrointest Endosc, 2023. 97 (6)(6): p. 1016-1030.e14., https://pubmed.ncbi.nlm.nih.gov/36863572/
410. Kawachi, H., Eishi, Y., Ueno, H., Nemoto, T., Fujimori, T., Iwashita, A., et.al. A three-tier classification system based on the depth of submucosal invasion and budding/sprouting can improve the treatment strategy for T1 colorectal cancer: a retrospective multicenter study, Mod Pathol, 2015. 28(6): p. 872-9., http://www.nature.com/modpathol/journal/v28/n6/pdf/modpathol201536a.pdf
411. Mou, S, Soetikno, R, Shimoda, T, Rouse, R, Kaltenbach, T, Pathologic predictive factors for lymph node metastasis in submucosal invasive (T1) colorectal cancer: a systematic review and meta-analysis., Surg Endosc, 2013. 27 (8)(8): p. 2692-703., https://pubmed.ncbi.nlm.nih.gov/23392988/
412. Suh, JH, Han, KS, Kim, BC, Hong, CW, Sohn, DK, Chang, HJ, et.al. Predictors for lymph node metastasis in T1 colorectal cancer., Endoscopy, 2012. 44 (6)(6): p. 590-5., https://pubmed.ncbi.nlm.nih.gov/22638780/
413. Oka, S, Tanaka, S, Nakadoi, K, Kanao, H, Chayama, K, Risk analysis of submucosal invasive rectal carcinomas for lymph node metastasis to expand indication criteria for endoscopic resection., Dig Endosc, 2013. 25 Suppl 2 (): p. 21-5., https://pubmed.ncbi.nlm.nih.gov/23617644/
414. Yamaoka, Y, Shiomi, A, Kagawa, H, Hino, H, Manabe, S, Chen, K, et.al. Lymph node metastasis in T1 colorectal cancer with the only high-risk histology of submucosal invasion depth ≥ 1000 μm., Int J Colorectal Dis, 2022. 37 (11)(11): p. 2387-2395., https://pubmed.ncbi.nlm.nih.gov/36283994/
415. Zwager, LW, Bastiaansen, BAJ, Montazeri, NSM, Hompes, R, Barresi, V, Ichimasa, K, et.al. Deep Submucosal Invasion Is Not an Independent Risk Factor for Lymph Node Metastasis in T1 Colorectal Cancer: A Meta-Analysis., Gastroenterology, 2022. 163 (1)(1): p. 174-189., https://pubmed.ncbi.nlm.nih.gov/35436498/
416. Corre, F, Albouys, J, Tran, VT, Lepilliez, V, Ratone, JP, Coron, E, et.al. Impact of surgery after endoscopically resected high-risk T1 colorectal cancer: results of an emulated target trial., Gastrointest Endosc, 2024. 99 (3)(3): p. 408-416.e2., https://pubmed.ncbi.nlm.nih.gov/37793506/
417. Lopez, A, Bouvier, AM, Jooste, V, Cottet, V, Romain, G, Faivre, J, et.al. Outcomes following polypectomy for malignant colorectal polyps are similar to those following surgery in the general population., Gut, 2019. 68 (1)(1): p. 111-117., https://pubmed.ncbi.nlm.nih.gov/29074726/
418. Fields, AC, Lu, P, Hu, F, Hirji, S, Irani, J, Bleday, R, et.al. Lymph Node Positivity in T1/T2 Rectal Cancer: a Word of Caution in an Era of Increased Incidence and Changing Biology for Rectal Cancer., J Gastrointest Surg, 2021. 25 (4)(4): p. 1029-1035., https://pubmed.ncbi.nlm.nih.gov/32246393/
419. Kawachi, H, Eishi, Y, Ueno, H, Nemoto, T, Fujimori, T, Iwashita, A, et.al. A three-tier classification system based on the depth of submucosal invasion and budding/sprouting can improve the treatment strategy for T1 colorectal cancer: a retrospective multicenter study., Mod Pathol, 2015. 28 (6)(6): p. 872-9., https://pubmed.ncbi.nlm.nih.gov/25720321/
420. Ouchi, A, Komori, K, Masahiro, T, Toriyama, K, Kajiwara, Y, Oka, S, et.al. How Does Omitting Additional Surgery After Local Excision Affect the Prognostic Outcome of Patients With High-risk T1 Colorectal Cancer?, Ann Surg, 2024. 279 (2)(2): p. 290-296., https://pubmed.ncbi.nlm.nih.gov/37669045/
421. Zaffalon, D, Daca-Alvarez, M, Saez de Gordoa, K, Pellisé, M, Dilemmas in the Clinical Management of pT1 Colorectal Cancer., Cancers (Basel), 2023. 15 (13)(13):, https://pubmed.ncbi.nlm.nih.gov/37444621/
422. Smits, LJH, Vink-Börger, E, van Lijnschoten, G, Focke-Snieders, I, van der Post, RS, Tuynman, JB, et.al. Diagnostic variability in the histopathological assessment of advanced colorectal adenomas and early colorectal cancer in a screening population., Histopathology, 2022. 80 (5)(5): p. 790-798., https://pubmed.ncbi.nlm.nih.gov/34813117/
423. Shivji, S, Cyr, DP, Pun, C, Duan, K, Sari, A, Tomin, R, et.al. A Novel Combined Tumor Budding-Poorly Differentiated Clusters Grading System Predicts Recurrence and Survival in Stage I-III Colorectal Cancer., Am J Surg Pathol, 2022. 46 (10)(10): p. 1340-1351., https://pubmed.ncbi.nlm.nih.gov/35613045/
424. Baretton, GB, Tannapfel, A, Schmitt, W, [Standardized and structured histopathological evaluation of colorectal polyps: a practical checklist against the background of the new WHO classification]., Pathologe, 2011. 32 (4)(4): p. 289-96., https://pubmed.ncbi.nlm.nih.gov/21678043/
425. Beaton, C., Twine, C. P., Williams, G. L., Radcliffe, A. G., Systematic review and meta-analysis of histopathological factors influencing the risk of lymph node metastasis in early colorectal cancer, Colorectal Dis, 2013. 15(7): p. 788-97., http://onlinelibrary.wiley.com/store/10.1111/codi.12129/asset/codi12129.pdf?v=1&t=j277wpxr&s=a351d25bda0126abbb37c9c0317fefeb930045ac
426. Bosch, S. L., Teerenstra, S., de Wilt, J. H., Cunningham, C., Nagtegaal, I. D., Predicting lymph node metastasis in pT1 colorectal cancer: a systematic review of risk factors providing rationale for therapy decisions, Endoscopy, 2013. 45(10): p. 827-34., https://www.thieme-connect.com/DOI/DOI?10.1055/s-0033-1344238
427. Choi, J. Y., Jung, S. A., Shim, K. N., Cho, W. Y., Keum, B., Byeon, J. S., et.al. Meta-analysis of predictive clinicopathologic factors for lymph node metastasis in patients with early colorectal carcinoma, J Korean Med Sci, 2015. 30(4): p. 398-406.
428. Choi, JY, Jung, SA, Shim, KN, Cho, WY, Keum, B, Byeon, JS, et.al. Meta-analysis of predictive clinicopathologic factors for lymph node metastasis in patients with early colorectal carcinoma., J Korean Med Sci, 2015. 30 (4)(4): p. 398-406., https://pubmed.ncbi.nlm.nih.gov/25829807/
429. Oka, S, Tanaka, S, Kajiwara, Y, Saito, S, Fukunaga, Y, Takamatsu, M, et.al. Treatment Decision for Locally Resected T1 Colorectal Carcinoma-Verification of the Japanese Guideline Criteria for Additional Surgery Based on Long-Term Clinical Outcomes., Am J Gastroenterol, 2024. ():, https://pubmed.ncbi.nlm.nih.gov/38345215/
430. Atkin, W, Wooldrage, K, Brenner, A, Martin, J, Shah, U, Perera, S, et.al. Adenoma surveillance and colorectal cancer incidence: a retrospective, multicentre, cohort study., Lancet Oncol, 2017. 18 (6)(6): p. 823-834., https://pubmed.ncbi.nlm.nih.gov/28457708/
431. Cottet, V., Jooste, V., Fournel, I., Bouvier, A. M., Faivre, J., Bonithon-Kopp, C., Long-term risk of colorectal cancer after adenoma removal: a population-based cohort study, Gut, 2012. 61(8): p. 1180-6., http://gut.bmj.com/content/61/8/1180.long
432. Lee, JK, Jensen, CD, Levin, TR, Doubeni, CA, Zauber, AG, Chubak, J, et.al. Long-term Risk of Colorectal Cancer and Related Death After Adenoma Removal in a Large, Community-based Population., Gastroenterology, 2020. 158 (4)(4): p. 884-894.e5., https://pubmed.ncbi.nlm.nih.gov/31589872/
433. Wieszczy, P, Kaminski, MF, Franczyk, R, Loberg, M, Kobiela, J, Rupinska, M, et.al. Colorectal Cancer Incidence and Mortality After Removal of Adenomas During Screening Colonoscopies., Gastroenterology, 2020. 158 (4)(4): p. 875-883.e5., https://pubmed.ncbi.nlm.nih.gov/31563625/
434. Park, S, Jeon, SR, Kim, HG, Jung, Y, Kwak, MS, Kim, SY, et.al. Risk of Metachronous Colorectal Advanced Neoplasia and Cancer in Patients With 3-4 Nonadvanced Adenomas at Index Colonoscopy: A Systematic Review and Meta-Analysis., Am J Gastroenterol, 2022. 117 (4)(4): p. 588-602., https://pubmed.ncbi.nlm.nih.gov/35169108/
435. Zhang, Y, Wang, X, Zhang, W, Zhou, X, Ren, M, Chen, H, et.al. Incidence of colorectal cancer at different screening intervals after index colonoscopy and post-polypectomy: a meta-analysis of 811,181 participants., Expert Rev Gastroenterol Hepatol, 2022. 16 (11-12)(11-12): p. 1101-1114., https://pubmed.ncbi.nlm.nih.gov/36408602/
436. Cross, AJ, Robbins, EC, Pack, K, Stenson, I, Rutter, MD, Veitch, AM, et.al. Post-polypectomy surveillance interval and advanced neoplasia detection rates: a multicenter, retrospective cohort study., Endoscopy, 2022. 54 (10)(10): p. 948-958., https://pubmed.ncbi.nlm.nih.gov/35405762/
437. Winawer, S. J., Zauber, A. G., O'Brien, M. J., Ho, M. N., Gottlieb, L., Sternberg, S. S., et.al. Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. The National Polyp Study Workgroup, N Engl J Med, 1993. 328(13): p. 901-6., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8446136, http://www.nejm.org/doi/pdf/10.1056/NEJM199304013281301
438. Gupta, S, Lieberman, D, Anderson, JC, Burke, CA, Dominitz, JA, Kaltenbach, T, et.al. Recommendations for Follow-Up After Colonoscopy and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer., Gastrointest Endosc, 2020. 91 (3)(3): p. 463-485.e5., https://pubmed.ncbi.nlm.nih.gov/32044106/
439. Hassan, C, Antonelli, G, Dumonceau, JM, Regula, J, Bretthauer, M, Chaussade, S, et.al. Post-polypectomy colonoscopy surveillance: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2020., Endoscopy, 2020. 52 (8)(8): p. 687-700., https://pubmed.ncbi.nlm.nih.gov/32572858/
440. Zessner-Spitzenberg, J, Jiricka, L, Waldmann, E, Rockenbauer, LM, Cook, J, Hinterberger, A, et.al. Polyp characteristics at screening colonoscopy and post-colonoscopy colorectal cancer mortality: a retrospective cohort study., Gastrointest Endosc, 2023. 97 (6)(6): p. 1109-1118.e2., https://pubmed.ncbi.nlm.nih.gov/36649747/
441. Johnstone, MS, Stoops, R, Lynch, G, Hay, J, Jawny, J, Sloan, W, et.al. Risk stratification for the detection of metachronous polyps after bowel screening polypectomy: clinical outcomes from the Integrated Technologies for Improved Polyp Surveillance (INCISE) study cohort., BJS Open, 2023. 7 (3)(3):, https://pubmed.ncbi.nlm.nih.gov/37158435/
442. He, X, Hang, D, Wu, K, Nayor, J, Drew, DA, Giovannucci, EL, et.al. Long-term Risk of Colorectal Cancer After Removal of Conventional Adenomas and Serrated Polyps., Gastroenterology, 2020. 158 (4)(4): p. 852-861.e4., https://pubmed.ncbi.nlm.nih.gov/31302144/
443. Rouphael, C, El Halabi, J, Bena, J, McMichael, J, Burke, CA, Impact of Clinical and Endoscopic Features on the Development of Metachronous Colorectal Advanced Serrated Lesions., Clin Gastroenterol Hepatol, 2023. ():, https://pubmed.ncbi.nlm.nih.gov/37544421/
444. Anderson, JC, Butterly, LF, Robinson, CM, Weiss, JE, Amos, C, Srivastava, A, Risk of Metachronous High-Risk Adenomas and Large Serrated Polyps in Individuals With Serrated Polyps on Index Colonoscopy: Data From the New Hampshire Colonoscopy Registry., Gastroenterology, 2018. 154 (1)(1): p. 117-127.e2., https://pubmed.ncbi.nlm.nih.gov/28927878/
445. Dang, H, Dekkers, N, le Cessie, S, van Hooft, JE, van Leerdam, ME, Oldenburg, PP, et.al. Risk and Time Pattern of Recurrences After Local Endoscopic Resection of T1 Colorectal Cancer: A Meta-analysis., Clin Gastroenterol Hepatol, 2022. 20 (2)(2): p. e298-e314., https://pubmed.ncbi.nlm.nih.gov/33271339/
446. Agarwal, A, Garimall, S, Scott, FI, Ahmad, NA, Kochman, ML, Ginsberg, GG, et.al. En bloc endoscopic mucosal resection is equally effective for sessile serrated polyps and conventional adenomas., Surg Endosc, 2018. 32 (4)(4): p. 1871-1878., https://pubmed.ncbi.nlm.nih.gov/28940106/
447. Arimoto, J, Higurashi, T, Chiba, H, Misawa, N, Yoshihara, T, Kato, T, et.al. Investigation of the Local Recurrence Rate after Colorectal Endoscopic Mucosal Resection: Is Incomplete Polyp Resection Really a Clinically Important Problem? Analysis of the Rationale for the "Resect and Discard" Strategy., Can J Gastroenterol Hepatol, 2019. 2019 (): p. 7243515., https://pubmed.ncbi.nlm.nih.gov/30729100/
448. Higaki, S., Hashimoto, S., Harada, K., Nohara, H., Saito, Y., Gondo, T., et.al. Long-term follow-up of large flat colorectal tumors resected endoscopically, Endoscopy, 2003. 35(10): p. 845-9., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14551863, https://www.thieme-connect.com/DOI/DOI?10.1055/s-2003-42622
449. Regula, J., Wronska, E., Polkowski, M., Nasierowska-Guttmejer, A., Pachlewski, J., Rupinski, M., et.al. Argon plasma coagulation after piecemeal polypectomy of sessile colorectal adenomas: long-term follow-up study, Endoscopy, 2003. 35(3): p. 212-8., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12584639, https://www.thieme-connect.com/DOI/DOI?10.1055/s-2003-37254
450. Seitz, U., Bohnacker, S., Seewald, S., Thonke, F., Soehendra, N., Long-term results of endoscopic removal of large colorectal adenomas, Endoscopy, 2003. 35(8): p. S41-4., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12929053, https://www.thieme-connect.com/DOI/DOI?10.1055/s-2003-41535
451. Hurlstone, D. P., Sanders, D. S., Cross, S. S., George, R., Shorthouse, A. J., Brown, S., A prospective analysis of extended endoscopic mucosal resection for large rectal villous adenomas: an alternative technique to transanal endoscopic microsurgery, Colorectal Dis, 2005. 7(4): p. 339-44., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15932555, http://onlinelibrary.wiley.com/doi/10.1111/j.1463-1318.2005.00813.x/abstract
452. Boix, J., Lorenzo-Zuniga, V., Moreno de Vega, V., Ananos, F. E., Domenech, E., Ojanguren, I., et.al. Endoscopic removal of large sessile colorectal adenomas: is it safe and effective?, Dig Dis Sci, 2007. 52(3): p. 840-4., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17253129, http://link.springer.com/article/10.1007%2Fs10620-006-9617-z
453. Troelsen, FS, Sørensen, HT, Pedersen, L, Brix, LD, Grode, LB, Dekker, E, et.al. Root-cause Analysis of 762 Danish Post-colonoscopy Colorectal Cancer Patients., Clin Gastroenterol Hepatol, 2023. 21 (12)(12): p. 3160-3169.e5., https://pubmed.ncbi.nlm.nih.gov/37031719/
454. Moss, A., Williams, S. J., Hourigan, L. F., Brown, G., Tam, W., Singh, R., et.al. Long-term adenoma recurrence following wide-field endoscopic mucosal resection (WF-EMR) for advanced colonic mucosal neoplasia is infrequent: results and risk factors in 1000 cases from the Australian Colonic EMR (ACE) study, Gut, 2015. 64(1): p. 57-65., http://gut.bmj.com/content/64/1/57.long
455. Hassan, C, Repici, A, Sharma, P, Correale, L, Zullo, A, Bretthauer, M, et.al. Efficacy and safety of endoscopic resection of large colorectal polyps: a systematic review and meta-analysis., Gut, 2016. 65 (5)(5): p. 806-20., https://pubmed.ncbi.nlm.nih.gov/25681402/
456. Abu Arisha, M, Scapa, E, Wishahi, E, Korytny, A, Gorelik, Y, Mazzawi, F, et.al. Impact of margin ablation after EMR of large nonpedunculated colonic polyps in routine clinical practice., Gastrointest Endosc, 2023. 97 (3)(3): p. 559-567., https://pubmed.ncbi.nlm.nih.gov/36328207/
457. Motchum, L, Levenick, JM, Djinbachian, R, Moyer, MT, Bouchard, S, Taghiakbari, M, et.al. EMR combined with hybrid argon plasma coagulation to prevent recurrence of large nonpedunculated colorectal polyps (with videos)., Gastrointest Endosc, 2022. 96 (5)(5): p. 840-848.e2., https://pubmed.ncbi.nlm.nih.gov/35724695/
458. Djinbachian, R, Iratni, R, Durand, M, Marques, P, von Renteln, D, Rates of Incomplete Resection of 1- to 20-mm Colorectal Polyps: A Systematic Review and Meta-Analysis., Gastroenterology, 2020. 159 (3)(3): p. 904-914.e12., https://pubmed.ncbi.nlm.nih.gov/32437747/
459. Okagawa, Y, Sumiyoshi, T, Tomita, Y, Uozumi, T, Iida, R, Sakano, H, et.al. Association of second surveillance colonoscopy findings with index and first surveillance colonoscopy results., J Dig Dis, 2020. 21 (5)(5): p. 272-278., https://pubmed.ncbi.nlm.nih.gov/32338818/
460. Park, H. W., Han, S., Lee, J. Y., Chang, H. S., Choe, J., Choi, Y., et.al. Probability of high-risk colorectal neoplasm recurrence based on the results of two previous colonoscopies, Dig Dis Sci, 2015. 60(1): p. 226-33.
461. Crockett, SD, Barry, EL, Mott, LA, Ahnen, DJ, Robertson, DJ, Anderson, JC, et.al. Calcium and vitamin D supplementation and increased risk of serrated polyps: results from a randomised clinical trial., Gut, 2019. 68 (3)(3): p. 475-486., https://pubmed.ncbi.nlm.nih.gov/29496722/
462. Fielding, L. P., Arsenault, P. A., Chapuis, P. H., Dent, O., Gathright, B., Hardcastle, J. D., et.al. Clinicopathological staging for colorectal cancer: an International Documentation System (IDS) and an International Comprehensive Anatomical Terminology (ICAT), J Gastroenterol Hepatol, 1991. 6(4): p. 325-44., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1912440, http://onlinelibrary.wiley.com/doi/10.1111/j.1440-1746.1991.tb00867.x/abstract
463. Soreide, O., Norstein, J., Fielding, L.P., Silen, W., International standardization and documentation of the treatment of rectal cancer., in Rectal cancer surgery. Optimisation - standardization - documentation., Soreide, O. and Norstein, J., Editors. 1997, Springer: Berlin Heidelberg New York. p. 405-45.
464. James D. Brierley, TNM Classification of Malignant Tumours, 8th Edition, 2016.
465. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer, Jama, 1990. 264(11): p. 1444-50., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2202842, http://jama.jamanetwork.com/article.aspx?articleid=383259
466. Nelson, H., Petrelli, N., Carlin, A., Couture, J., Fleshman, J., Guillem, J., et.al. Guidelines 2000 for colon and rectal cancer surgery, J Natl Cancer Inst, 2001. 93(8): p. 583-96., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11309435, http://jnci.oxfordjournals.org/content/93/8/583.full.pdf
467. Pilipshen, S. J., Heilweil, M., Quan, S. H., Sternberg, S. S., Enker, W. E., Patterns of pelvic recurrence following definitive resections of rectal cancer, Cancer, 1984. 53(6): p. 1354-62., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=6692324, http://onlinelibrary.wiley.com/store/10.1002/1097-0142(19840315)53:6<1354::AID-CNCR2820530623>3.0.CO;2-J/asset/2820530623_ftp.pdf?v=1&t=ik581dpu&s=0065343d161161c51387053d673106b8ee47c2d1
468. Burton, S., Brown, G., Daniels, I. R., Norman, A. R., Mason, B., Cunningham, D., MRI directed multidisciplinary team preoperative treatment strategy: the way to eliminate positive circumferential margins?, Br J Cancer, 2006. 94(3): p. 351-7., http://www.ncbi.nlm.nih.gov/pubmed/16465171
469. Segelman, J., Singnomklao, T., Hellborg, H., Martling, A., Differences in multidisciplinary team assessment and treatment between patients with stage IV colon and rectal cancer, Colorectal Dis, 2009. 11(7): p. 768-74., http://www.ncbi.nlm.nih.gov/pubmed/18662241
470. MacDermid, E., Hooton, G., MacDonald, M., McKay, G., Grose, D., Mohammed, N., et.al. Improving patient survival with the colorectal cancer multi-disciplinary team, Colorectal Dis, 2009. 11(3): p. 291-5., http://www.ncbi.nlm.nih.gov/pubmed/18477019
471. Barillari, P., Ramacciato, G., De Angelis, R., Gozzo, P., Indinnimeo, M., Valabrega, S., et.al. Effect of preoperative colonoscopy on the incidence of synchronous and metachronous neoplasms, Acta Chir Scand, 1990. 156(2): p. 163-6., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2330795
472. Faivre, J., [Endoscopic monitoring after excision of colorectal cancer], J Chir (Paris), 1997. 134(7-8): p. 283-5., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9772990
473. Chen, H. S., Sheen-Chen, S. M., Synchronous and "early" metachronous colorectal adenocarcinoma: analysis of prognosis and current trends, Dis Colon Rectum, 2000. 43(8): p. 1093-9., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10950007
474. Floriani, I., Torri, V., Rulli, E., Garavaglia, D., Compagnoni, A., Salvolini, L., et.al. Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: a systematic review and meta-analysis, J Magn Reson Imaging, 2010. 31(1): p. 19-31., http://www.ncbi.nlm.nih.gov/pubmed/20027569
475. Glynne-Jones, R, Wyrwicz, L, Tiret, E, Brown, G, Rödel, C, Cervantes, A, et.al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up., Ann Oncol, 2017. 28 (suppl_4)(suppl_4): p. iv22-iv40., https://pubmed.ncbi.nlm.nih.gov/28881920/
476. Korngold, EK, Moreno, C, Kim, DH, Fowler, KJ, Cash, BD, Chang, KJ, et.al. ACR Appropriateness Criteria® Staging of Colorectal Cancer: 2021 Update., J Am Coll Radiol, 2022. 19 (5S)(5S): p. S208-S222., https://pubmed.ncbi.nlm.nih.gov/35550803/
477. Niekel, M. C., Bipat, S., Stoker, J., Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment, Radiology, 2010. 257(3): p. 674-84., http://www.ncbi.nlm.nih.gov/pubmed/20829538
478. Mao, Y, Chen, B, Wang, H, Zhang, Y, Yi, X, Liao, W, et.al. Diagnostic performance of magnetic resonance imaging for colorectal liver metastasis: A systematic review and meta-analysis., Sci Rep, 2020. 10 (1)(1): p. 1969., https://pubmed.ncbi.nlm.nih.gov/32029809/
479. Choi, SH, Kim, SY, Park, SH, Kim, KW, Lee, JY, Lee, SS, et.al. Diagnostic performance of CT, gadoxetate disodium-enhanced MRI, and PET/CT for the diagnosis of colorectal liver metastasis: Systematic review and meta-analysis., J Magn Reson Imaging, 2018. 47 (5)(5): p. 1237-1250., https://pubmed.ncbi.nlm.nih.gov/28901685/
480. Cervantes, A, Adam, R, Roselló, S, Arnold, D, Normanno, N, Taïeb, J, et.al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up., Ann Oncol, 2023. 34 (1)(1): p. 10-32., https://pubmed.ncbi.nlm.nih.gov/36307056/
481. Strobel, D, Seitz, K, Blank, W, Schuler, A, Dietrich, C, von Herbay, A, et.al. Contrast-enhanced ultrasound for the characterization of focal liver lesions--diagnostic accuracy in clinical practice (DEGUM multicenter trial)., Ultraschall Med, 2008. 29 (5)(5): p. 499-505., https://pubmed.ncbi.nlm.nih.gov/19241506/
482. Bernatik, T, Schuler, A, Kunze, G, Mauch, M, Dietrich, CF, Dirks, K, et.al. Benefit of Contrast-Enhanced Ultrasound (CEUS) in the Follow-Up Care of Patients with Colon Cancer: A Prospective Multicenter Study., Ultraschall Med, 2015. 36 (6)(6): p. 590-3., https://pubmed.ncbi.nlm.nih.gov/26544634/
483. Sawatzki, M, Güller, U, Güsewell, S, Husarik, DB, Semela, D, Brand, S, Contrast-enhanced ultrasound can guide the therapeutic strategy by improving the detection of colorectal liver metastases., J Hepatol, 2021. 74 (2)(2): p. 419-427., https://pubmed.ncbi.nlm.nih.gov/33065168/
484. Dighe, S., Purkayastha, S., Swift, I., Tekkis, P. P., Darzi, A., A'Hern, R., et.al. Diagnostic precision of CT in local staging of colon cancers: a meta-analysis, Clin Radiol, 2010. 65(9): p. 708-19., http://www.ncbi.nlm.nih.gov/pubmed/20696298
485. Abdel-Nabi, H., Doerr, R. J., Lamonica, D. M., Cronin, V. R., Galantowicz, P. J., Carbone, G. M., et.al. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings, Radiology, 1998. 206(3): p. 755-60., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9494497
486. Akiyoshi, T., Oya, M., Fujimoto, Y., Kuroyanagi, H., Ueno, M., Yamaguchi, T., et.al. Comparison of preoperative whole-body positron emission tomography with MDCT in patients with primary colorectal cancer, Colorectal Dis, 2009. 11(5): p. 464-9., http://www.ncbi.nlm.nih.gov/pubmed/18637927
487. Furukawa, H., Ikuma, H., Seki, A., Yokoe, K., Yuen, S., Aramaki, T., et.al. Positron emission tomography scanning is not superior to whole body multidetector helical computed tomography in the preoperative staging of colorectal cancer, Gut, 2006. 55(7): p. 1007-11., http://www.ncbi.nlm.nih.gov/pubmed/16361308
488. Kam, M. H., Wong, D. C., Siu, S., Stevenson, A. R., Lai, J., Phillips, G. E., Comparison of magnetic resonance imaging-fluorodeoxy- glucose positron emission tomography fusion with pathological staging in rectal cancer, Br J Surg, 2010. 97(2): p. 266-8., http://www.ncbi.nlm.nih.gov/pubmed/20035542
489. Kinner, S., Antoch, G., Bockisch, A., Veit-Haibach, P., Whole-body PET/CT-colonography: a possible new concept for colorectal cancer staging, Abdom Imaging, 2007. 32(5): p. 606-12., http://www.ncbi.nlm.nih.gov/pubmed/17387540
490. Llamas-Elvira, J. M., Rodriguez-Fernandez, A., Gutierrez-Sainz, J., Gomez-Rio, M., Bellon-Guardia, M., Ramos-Font, C., et.al. Fluorine-18 fluorodeoxyglucose PET in the preoperative staging of colorectal cancer, Eur J Nucl Med Mol Imaging, 2007. 34(6): p. 859-67., http://www.ncbi.nlm.nih.gov/pubmed/17195075
491. Ono, K., Ochiai, R., Yoshida, T., Kitagawa, M., Omagari, J., Kobayashi, H., et.al. Comparison of diffusion-weighted MRI and 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for detecting primary colorectal cancer and regional lymph node metastases, J Magn Reson Imaging, 2009. 29(2): p. 336-40., http://www.ncbi.nlm.nih.gov/pubmed/19161185
492. Tateishi, U., Maeda, T., Morimoto, T., Miyake, M., Arai, Y., Kim, E. E., Non-enhanced CT versus contrast-enhanced CT in integrated PET/CT studies for nodal staging of rectal cancer, Eur J Nucl Med Mol Imaging, 2007. 34(10): p. 1627-34., http://www.ncbi.nlm.nih.gov/pubmed/17530248
493. Veit-Haibach, P., Kuehle, C. A., Beyer, T., Stergar, H., Kuehl, H., Schmidt, J., et.al. Diagnostic accuracy of colorectal cancer staging with whole-body PET/CT colonography, JAMA, 2006. 296(21): p. 2590-600., http://www.ncbi.nlm.nih.gov/pubmed/17148724
494. Bassi, M. C., Turri, L., Sacchetti, G., Loi, G., Cannillo, B., La Mattina, P., et.al. FDG-PET/CT imaging for staging and target volume delineation in preoperative conformal radiotherapy of rectal cancer, Int J Radiat Oncol Biol Phys, 2008. 70(5): p. 1423-6., http://www.ncbi.nlm.nih.gov/pubmed/17931795
495. Davey, K., Heriot, A. G., Mackay, J., Drummond, E., Hogg, A., Ngan, S., et.al. The impact of 18-fluorodeoxyglucose positron emission tomography-computed tomography on the staging and management of primary rectal cancer, Dis Colon Rectum, 2008. 51(7): p. 997-1003., http://www.ncbi.nlm.nih.gov/pubmed/18461399
496. Gearhart, S. L., Frassica, D., Rosen, R., Choti, M., Schulick, R., Wahl, R., Improved staging with pretreatment positron emission tomography/computed tomography in low rectal cancer, Ann Surg Oncol, 2006. 13(3): p. 397-404., http://www.ncbi.nlm.nih.gov/pubmed/16485158
497. Kantorova, I., Lipska, L., Belohlavek, O., Visokai, V., Trubac, M., Schneiderova, M., Routine (18)F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making, J Nucl Med, 2003. 44(11): p. 1784-8., http://www.ncbi.nlm.nih.gov/pubmed/14602860
498. Nagata, K., Ota, Y., Okawa, T., Endo, S., Kudo, S. E., PET/CT colonography for the preoperative evaluation of the colon proximal to the obstructive colorectal cancer, Dis Colon Rectum, 2008. 51(6): p. 882-90., http://www.ncbi.nlm.nih.gov/pubmed/18330647
499. Park, I. J., Kim, H. C., Yu, C. S., Ryu, M. H., Chang, H. M., Kim, J. H., et.al. Efficacy of PET/CT in the accurate evaluation of primary colorectal carcinoma, Eur J Surg Oncol, 2006. 32(9): p. 941-7., http://www.ncbi.nlm.nih.gov/pubmed/16843635
500. Paskeviciute, B., Bolling, T., Brinkmann, M., Rudykina, G., Ernst, I., Stegger, L., et.al. Impact of (18)F-FDG-PET/CT on staging and irradiation of patients with locally advanced rectal cancer, Strahlenther Onkol, 2009. 185(4): p. 260-5., http://www.ncbi.nlm.nih.gov/pubmed/19370430
501. Engel, R, Kudura, K, Antwi, K, Denhaerynck, K, Steinemann, D, Wullschleger, S, et.al. Diagnostic accuracy and treatment benefit of PET/CT in staging of colorectal cancer compared to conventional imaging., Surg Oncol, 2024. 57 (): p. 102151., https://pubmed.ncbi.nlm.nih.gov/39418774/
502. Kido, H, Kato, S, Funahashi, K, Shibuya, K, Sasaki, Y, Urita, Y, et.al. The metabolic parameters based on volume in PET/CT are associated with clinicopathological N stage of colorectal cancer and can predict prognosis., EJNMMI Res, 2021. 11 (1)(1): p. 87., https://pubmed.ncbi.nlm.nih.gov/34487264/
503. Mona, CE, Benz, MR, Hikmat, F, Grogan, TR, Lueckerath, K, Razmaria, A, et.al. Correlation of 68Ga-FAPi-46 PET Biodistribution with FAP Expression by Immunohistochemistry in Patients with Solid Cancers: Interim Analysis of a Prospective Translational Exploratory Study, J Nucl Med, 2022. 63 (7)(7): p. 1021-1026., https://pubmed.ncbi.nlm.nih.gov/34740953/
504. Zhang, X, Lin, Z, Feng, Y, Lin, Z, Tao, K, Zhang, T, et.al. Predicting Pathologic Complete Response in Locally Advanced Rectal Cancer with [, J Nucl Med, 2024. 65 (10)(10): p. 1548-1556., https://pubmed.ncbi.nlm.nih.gov/39353648/
505. Compton, C., Fenoglio-Preiser, C. M., Pettigrew, N., Fielding, L. P., American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group, Cancer, 2000. 88(7): p. 1739-57.
506. Compton, C. C., Updated protocol for the examination of specimens from patients with carcinomas of the colon and rectum, excluding carcinoid tumors, lymphomas, sarcomas, and tumors of the vermiform appendix: a basis for checklists. Cancer Committee, Arch Pathol Lab Med, 2000. 124(7): p. 1016-25.
507. IQWIG, Positronenemissionstomographie (PET und PET/CT) bei rezidivierendem kolorektalen Karzinom - Vorbericht (vorläufige Nutzenbewertung), 2011.
508. Moulton, CA, Gu, CS, Law, CH, Tandan, VR, Hart, R, Quan, D, et.al. Effect of PET before liver resection on surgical management for colorectal adenocarcinoma metastases: a randomized clinical trial., JAMA, 2014. 311 (18)(18): p. 1863-9., https://pubmed.ncbi.nlm.nih.gov/24825641/
509. Patel, S., McCall, M., Ohinmaa, A., Bigam, D., Dryden, D. M., Positron emission tomography/computed tomographic scans compared to computed tomographic scans for detecting colorectal liver metastases: a systematic review, Ann Surg, 2011. 253(4): p. 666-71., http://www.ncbi.nlm.nih.gov/pubmed/21475005
510. Glazer, E. S., Beaty, K., Abdalla, E. K., Vauthey, J. N., Curley, S. A., Effectiveness of positron emission tomography for predicting chemotherapy response in colorectal cancer liver metastases, Arch Surg, 2010. 145(4): p. 340-5; discussion 345., http://www.ncbi.nlm.nih.gov/pubmed/20404283
511. Spatz, J., Holl, G., Sciuk, J., Anthuber, M., Arnholdt, H. M., Markl, B., Neoadjuvant chemotherapy affects staging of colorectal liver metastasis--a comparison of PET, CT and intraoperative ultrasound, Int J Colorectal Dis, 2011. 26(2): p. 165-71., http://www.ncbi.nlm.nih.gov/pubmed/20960208
512. Ruers, T. J., Wiering, B., van der Sijp, J. R., Roumen, R. M., de Jong, K. P., Comans, E. F., et.al. Improved selection of patients for hepatic surgery of colorectal liver metastases with (18)F-FDG PET: a randomized study, J Nucl Med, 2009. 50(7): p. 1036-41., http://www.ncbi.nlm.nih.gov/pubmed/19525451
513. Adie, S., Yip, C., Chu, F., Morris, D. L., Resection of liver metastases from colorectal cancer: does preoperative chemotherapy affect the accuracy of PET in preoperative planning?, ANZ J Surg, 2009. 79(5): p. 358-61., http://www.ncbi.nlm.nih.gov/pubmed/19566517
514. Lubezky, N., Metser, U., Geva, R., Nakache, R., Shmueli, E., Klausner, J. M., et.al. The role and limitations of 18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) scan and computerized tomography (CT) in restaging patients with hepatic colorectal metastases following neoadjuvant chemotherapy: comparison with operative and pathological findings, J Gastrointest Surg, 2007. 11(4): p. 472-8., http://www.ncbi.nlm.nih.gov/pubmed/17436132
515. Levy, M., Visokai, V., Lipska, L., Topolcan, O., Tumor markers in staging and prognosis of colorectal carcinoma, Neoplasma, 2008. 55(2): p. 138-42., http://www.ncbi.nlm.nih.gov/pubmed/18237252
516. Lewis, M. R., Euscher, E. D., Deavers, M. T., Silva, E. G., Malpica, A., Metastatic colorectal adenocarcinoma involving the ovary with elevated serum CA125: a potential diagnostic pitfall, Gynecol Oncol, 2007. 105(2): p. 395-8., http://www.ncbi.nlm.nih.gov/pubmed/17335881
517. Chen, C. C., Yang, S. H., Lin, J. K., Lin, T. C., Chen, W. S., Jiang, J. K., et.al. Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer?, J Surg Res, 2005. 124(2): p. 169-74.
518. Björkman, K, Mustonen, H, Kaprio, T, Kekki, H, Pettersson, K, Haglund, C, et.al. CA125: A superior prognostic biomarker for colorectal cancer compared to CEA, CA19-9 or CA242., Tumour Biol, 2021. 43 (1)(1): p. 57-70., https://pubmed.ncbi.nlm.nih.gov/33935125/
519. You, W, Sheng, N, Yan, L, Chen, H, Gong, J, He, Z, et.al. The difference in prognosis of stage II and III colorectal cancer based on preoperative serum tumor markers., J Cancer, 2019. 10 (16)(16): p. 3757-3766., https://pubmed.ncbi.nlm.nih.gov/31333793/
520. Li, C, Zhao, K, Zhang, D, Pang, X, Pu, H, Lei, M, et.al. Prediction models of colorectal cancer prognosis incorporating perioperative longitudinal serum tumor markers: a retrospective longitudinal cohort study., BMC Med, 2023. 21 (1)(1): p. 63., https://pubmed.ncbi.nlm.nih.gov/36803500/
521. Li, Z, Zhu, H, Pang, X, Mao, Y, Yi, X, Li, C, et.al. Preoperative serum CA19-9 should be routinely measured in the colorectal patients with preoperative normal serum CEA: a multicenter retrospective cohort study., BMC Cancer, 2022. 22 (1)(1): p. 962., https://pubmed.ncbi.nlm.nih.gov/36076189/
522. Beom, SH, Shin, SJ, Kim, CG, Kim, JH, Hur, H, Min, BS, et.al. Clinical Significance of Preoperative Serum Carcinoembryonic Antigen Within the Normal Range in Colorectal Cancer Patients Undergoing Curative Resection., Ann Surg Oncol, 2020. 27 (8)(8): p. 2774-2783., https://pubmed.ncbi.nlm.nih.gov/32180063/
523. Ren, G, Li, R, Zheng, G, Du, K, Dan, H, Wu, H, et.al. Prognostic value of normal levels of preoperative tumor markers in colorectal cancer., Sci Rep, 2023. 13 (1)(1): p. 22830., https://pubmed.ncbi.nlm.nih.gov/38129505/
524. Tanaka, A, Sadahiro, S, Suzuki, T, Okada, K, Saito, G, Comparisons of Rigid Proctoscopy, Flexible Colonoscopy, and Digital Rectal Examination for Determining the Localization of Rectal Cancers., Dis Colon Rectum, 2018. 61 (2)(2): p. 202-206., https://pubmed.ncbi.nlm.nih.gov/29337775/
525. Jacobs, L, Meek, DB, van Heukelom, J, Bollen, TL, Siersema, PD, Smits, AB, et.al. Comparison of MRI and colonoscopy in determining tumor height in rectal cancer., United European Gastroenterol J, 2018. 6 (1)(1): p. 131-137., https://pubmed.ncbi.nlm.nih.gov/29435323/
526. Merkel, S., Mansmann, U., Siassi, M., Papadopoulos, T., Hohenberger, W., Hermanek, P., The prognostic inhomogeneity in pT3 rectal carcinomas, Int J Colorectal Dis, 2001. 16(5): p. 298-304., http://www.ncbi.nlm.nih.gov/pubmed/11686527
527. Nagtegaal, I. D., Quirke, P., What is the role for the circumferential margin in the modern treatment of rectal cancer?, J Clin Oncol, 2008. 26(2): p. 303-12.
528. Chen, S, Li, N, Tang, Y, Shi, J, Zhao, Y, Ma, H, et.al. The prognostic value of MRI-detected extramural vascular invasion (mrEMVI) for rectal cancer patients treated with neoadjuvant therapy: a meta-analysis., Eur Radiol, 2021. 31 (12)(12): p. 8827-8837., https://pubmed.ncbi.nlm.nih.gov/33993333/
529. Tan, JJ, Carten, RV, Babiker, A, Abulafi, M, Lord, AC, Brown, G, Prognostic Importance of MRI-Detected Extramural Venous Invasion in Rectal Cancer: A Literature Review and Systematic Meta-Analysis., Int J Radiat Oncol Biol Phys, 2021. 111 (2)(2): p. 385-394., https://pubmed.ncbi.nlm.nih.gov/34119593/
530. Bipat, S., Glas, A. S., Slors, F. J., Zwinderman, A. H., Bossuyt, P. M., Stoker, J., Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging--a meta-analysis, Radiology, 2004. 232(3): p. 773-83., http://www.ncbi.nlm.nih.gov/pubmed/15273331
531. Ahmetoglu, A., Cansu, A., Baki, D., Kul, S., Cobanoglu, U., Alhan, E., et.al. MDCT with multiplanar reconstruction in the preoperative local staging of rectal tumor, Abdom Imaging, 2011. 36(1): p. 31-7., http://www.ncbi.nlm.nih.gov/pubmed/19949791
532. Kim, C. K., Kim, S. H., Chun, H. K., Lee, W. Y., Yun, S. H., Song, S. Y., et.al. Preoperative staging of rectal cancer: accuracy of 3-Tesla magnetic resonance imaging, Eur Radiol, 2006. 16(5): p. 972-80., http://www.ncbi.nlm.nih.gov/pubmed/16416276
533. Kim, Y. W., Kim, N. K., Min, B. S., Kim, H., Pyo, J., Kim, M. J., et.al. A prospective comparison study for predicting circumferential resection margin between preoperative MRI and whole mount sections in mid-rectal cancer: significance of different scan planes, Eur J Surg Oncol, 2008. 34(6): p. 648-54., http://www.ncbi.nlm.nih.gov/pubmed/17574368
534. Kim, Y. W., Cha, S. W., Pyo, J., Kim, N. K., Min, B. S., Kim, M. J., et.al. Factors related to preoperative assessment of the circumferential resection margin and the extent of mesorectal invasion by magnetic resonance imaging in rectal cancer: a prospective comparison study, World J Surg, 2009. 33(9): p. 1952-60., http://www.ncbi.nlm.nih.gov/pubmed/19603224
535. Matsuoka, H., Nakamura, A., Sugiyama, M., Hachiya, J., Atomi, Y., Masaki, T., MRI diagnosis of mesorectal lymph node metastasis in patients with rectal carcinoma. what is the optimal criterion?, Anticancer Res, 2004. 24(6): p. 4097-101., http://www.ncbi.nlm.nih.gov/pubmed/15736458
536. Wolberink, S. V., Beets-Tan, R. G., de Haas-Kock, D. F., van de Jagt, E. J., Span, M. M., Wiggers, T., Multislice CT as a primary screening tool for the prediction of an involved mesorectal fascia and distant metastases in primary rectal cancer: a multicenter study, Dis Colon Rectum, 2009. 52(5): p. 928-34., http://www.ncbi.nlm.nih.gov/pubmed/19502858
537. Purkayastha, S., Athanasiou, T., Tekkis, P. P., Constantinides, V., Teare, J., Darzi, A. W., Magnetic resonance colonography vs computed tomography colonography for the diagnosis of colorectal cancer: an indirect comparison, Colorectal Dis, 2007. 9(2): p. 100-11., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17223933, http://onlinelibrary.wiley.com/doi/10.1111/j.1463-1318.2006.01126.x/abstract
538. Puli, S. R., Reddy, J. B., Bechtold, M. L., Choudhary, A., Antillon, M. R., Brugge, W. R., Accuracy of endoscopic ultrasound to diagnose nodal invasion by rectal cancers: a meta-analysis and systematic review, Ann Surg Oncol, 2009. 16(5): p. 1255-65., http://www.ncbi.nlm.nih.gov/pubmed/19219506
539. Torzilli, G., Del Fabbro, D., Palmisano, A., Donadon, M., Bianchi, P., Roncalli, M., et.al. Contrast-enhanced intraoperative ultrasonography during hepatectomies for colorectal cancer liver metastases, J Gastrointest Surg, 2005. 9(8): p. 1148-53; discussion 1153-4., http://www.ncbi.nlm.nih.gov/pubmed/16269386
540. Zirngibl, H., Husemann, B., Hermanek, P., Intraoperative spillage of tumor cells in surgery for rectal cancer, Dis Colon Rectum, 1990. 33(7): p. 610-4., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2361432
541. Goligher, J.C., Incidence and pathology of carcinoma of the colon and rectum, in Surgery of the anus, rectum and colon., 1984, Balliére Tindall: London. p. S. 445.
542. Toyota, S., Ohta, H., Anazawa, S., Rationale for extent of lymph node dissection for right colon cancer, Dis Colon Rectum, 1995. 38(7): p. 705-11., http://www.ncbi.nlm.nih.gov/pubmed/7607029
543. Tan, K. Y., Kawamura, Y. J., Mizokami, K., Sasaki, J., Tsujinaka, S., Maeda, T., et.al. Distribution of the first metastatic lymph node in colon cancer and its clinical significance, Colorectal Dis, 2010. 12(1): p. 44-7., http://www.ncbi.nlm.nih.gov/pubmed/19438890
544. Lan, Y. T., Lin, J. K., Jiang, J. K., Chang, S. C., Liang, W. Y., Yang, S. H., Significance of lymph node retrieval from the terminal ileum for patients with cecal and ascending colonic cancers, Ann Surg Oncol, 2011. 18(1): p. 146-52., http://www.ncbi.nlm.nih.gov/pubmed/20734151
545. Van Damme, J-P., Vascular anatomy in abdominal surgeryThieme, 1990.
546. Kanemitsu, Y., Hirai, T., Komori, K., Kato, T., Survival benefit of high ligation of the inferior mesenteric artery in sigmoid colon or rectal cancer surgery, Br J Surg, 2006. 93(5): p. 609-15., http://www.ncbi.nlm.nih.gov/pubmed/16607682
547. Chin, C. C., Wang, J. Y., Changchien, C. R., Huang, W. S., Tang, R., Carcinoma obstruction of the proximal colon cancer and long-term prognosis--obstruction is a predictor of worse outcome in TNM stage II tumor, Int J Colorectal Dis, 2010. 25(7): p. 817-22., http://www.ncbi.nlm.nih.gov/pubmed/20135321
548. Struys, M, Ceelen, W, Incidence of lymph node recurrence after primary surgery for non-metastatic colon cancer: A systematic review., Eur J Surg Oncol, 2022. 48 (8)(8): p. 1679-1684., https://pubmed.ncbi.nlm.nih.gov/35513966/
549. Brown, KGM, Ng, KS, Solomon, MJ, Chapuis, PH, Koh, CE, Ahmadi, N, et.al. Complete mesocolic excision for colon cancer: current status and controversies., ANZ J Surg, 2024. 94 (3)(3): p. 309-319., https://pubmed.ncbi.nlm.nih.gov/37850417/
550. Anania, G, Davies, RJ, Bagolini, F, Vettoretto, N, Randolph, J, Cirocchi, R, et.al. Right hemicolectomy with complete mesocolic excision is safe, leads to an increased lymph node yield and to increased survival: results of a systematic review and meta-analysis., Tech Coloproctol, 2021. 25 (10)(10): p. 1099-1113., https://pubmed.ncbi.nlm.nih.gov/34120270/
551. Díaz-Vico, T, Fernández-Hevia, M, Suárez-Sánchez, A, García-Gutiérrez, C, Mihic-Góngora, L, Fernández-Martínez, D, et.al. Complete Mesocolic Excision and D3 Lymphadenectomy versus Conventional Colectomy for Colon Cancer: A Systematic Review and Meta-Analysis., Ann Surg Oncol, 2021. 28 (13)(13): p. 8823-8837., https://pubmed.ncbi.nlm.nih.gov/34089109/
552. Seow-En, I, Chen, WT, Complete mesocolic excision with central venous ligation/D3 lymphadenectomy for colon cancer - A comprehensive review of the evidence., Surg Oncol, 2022. 42 (): p. 101755., https://pubmed.ncbi.nlm.nih.gov/35405620/
553. Sica, GS, Vinci, D, Siragusa, L, Sensi, B, Guida, AM, Bellato, V, et.al. Definition and reporting of lymphadenectomy and complete mesocolic excision for radical right colectomy: a systematic review., Surg Endosc, 2023. 37 (2)(2): p. 846-861., https://pubmed.ncbi.nlm.nih.gov/36097099/
554. Karachun, A, Panaiotti, L, Chernikovskiy, I, Achkasov, S, Gevorkyan, Y, Savanovich, N, et.al. Short-term outcomes of a multicentre randomized clinical trial comparing D2 versus D3 lymph node dissection for colonic cancer (COLD trial)., Br J Surg, 2020. 107 (5)(5): p. 499-508., https://pubmed.ncbi.nlm.nih.gov/31872869/
555. Xu, L, Su, X, He, Z, Zhang, C, Lu, J, Zhang, G, et.al. Short-term outcomes of complete mesocolic excision versus D2 dissection in patients undergoing laparoscopic colectomy for right colon cancer (RELARC): a randomised, controlled, phase 3, superiority trial., Lancet Oncol, 2021. 22 (3)(3): p. 391-401., https://pubmed.ncbi.nlm.nih.gov/33587893/
556. Keller, M., Sommerfeldt, S., Fischer, C., Knight, L., Riesbeck, M., Lowe, B., et.al. Recognition of distress and psychiatric morbidity in cancer patients: a multi-method approach, Ann Oncol, 2004. 15(8): p. 1243-9.
557. Sharpe, M., Strong, V., Allen, K., Rush, R., Postma, K., Tulloh, A., et.al. Major depression in outpatients attending a regional cancer centre: screening and unmet treatment needs, Br J Cancer, 2004. 90(2): p. 314-20.
558. Singer, S., Das-Munshi, J., Brahler, E., Prevalence of mental health conditions in cancer patients in acute care--a meta-analysis, Ann Oncol, 2010. 21(5): p. 925-30.
559. Abdalla, M, Collings, AT, Dirks, R, Onkendi, E, Nelson, D, Ozair, A, et.al. Surgical approach to microwave and radiofrequency liver ablation for hepatocellular carcinoma and colorectal liver metastases less than 5 cm: a systematic review and meta-analysis., Surg Endosc, 2023. 37 (5)(5): p. 3340-3353., https://pubmed.ncbi.nlm.nih.gov/36542137/
560. (NICE), National Institute for Clinical Excellence, Radiofrequency ablation for the treatment of colorectal metastases in the liver., 2011.
561. Kim, K. H., Yoon, Y. S., Yu, C. S., Kim, T. W., Kim, H. J., Kim, P. N., et.al. Comparative analysis of radiofrequency ablation and surgical resection for colorectal liver metastases, J Korean Surg Soc, 2011. 81(1): p. 25-34., http://www.ncbi.nlm.nih.gov/pubmed/22066097
562. Mulier, S., Ni, Y., Jamart, J., Michel, L., Marchal, G., Ruers, T., Radiofrequency ablation versus resection for resectable colorectal liver metastases: time for a randomized trial?, Ann Surg Oncol, 2008. 15(1): p. 144-57., http://www.ncbi.nlm.nih.gov/pubmed/17906898
563. Heald, R. J., Husband, E. M., Ryall, R. D., The mesorectum in rectal cancer surgery--the clue to pelvic recurrence?, Br J Surg, 1982. 69(10): p. 613-6., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=6751457, http://onlinelibrary.wiley.com/doi/10.1002/bjs.1800691019/abstract
564. Bokey, E. L., Ojerskog, B., Chapuis, P. H., Dent, O. F., Newland, R. C., Sinclair, G., Local recurrence after curative excision of the rectum for cancer without adjuvant therapy: role of total anatomical dissection, Br J Surg, 1999. 86(9): p. 1164-70., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10504371, http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2168.1999.01216.x/abstract
565. Hermanek, P. jun., Multiviszerale Resektion beim kolorektalen Karzinom. Erfahrungen der SGKRK-Studie., Langenbecks Arch Surg, 1992. Kongressband: p. 95-100.
566. Havenga, K., Enker, W. E., McDermott, K., Cohen, A. M., Minsky, B. D., Guillem, J., Male and female sexual and urinary function after total mesorectal excision with autonomic nerve preservation for carcinoma of the rectum, J Am Coll Surg, 1996. 182(6): p. 495-502., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8646349
567. Enker, W. E., Havenga, K., Polyak, T., Thaler, H., Cranor, M., Abdominoperineal resection via total mesorectal excision and autonomic nerve preservation for low rectal cancer, World J Surg, 1997. 21(7): p. 715-20., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9276702
568. Georgiou, P., Tan, E., Gouvas, N., Antoniou, A., Brown, G., Nicholls, R. J., et.al. Extended lymphadenectomy versus conventional surgery for rectal cancer: a meta-analysis, Lancet Oncol, 2009. 10(11): p. 1053-62., http://www.ncbi.nlm.nih.gov/pubmed/19767239
569. Gohl, J., Hohenberger, W., Merkel, S., Lymph node dissection in rectal carcinoma: TME and what else?, Onkologie, 2009. 32(1-2): p. 57-61., http://www.ncbi.nlm.nih.gov/pubmed/19209023
570. Mortenson, M. M., Khatri, V. P., Bennett, J. J., Petrelli, N. J., Total mesorectal excision and pelvic node dissection for rectal cancer: an appraisal, Surg Oncol Clin N Am, 2007. 16(1): p. 177-97., http://www.ncbi.nlm.nih.gov/pubmed/17336243
571. Koch, M., Kienle, P., Antolovic, D., Buchler, M. W., Weitz, J., Is the lateral lymph node compartment relevant?, Recent Results Cancer Res, 2005. 165: p. 40-5., http://www.ncbi.nlm.nih.gov/pubmed/15865019
572. Herschbach, P., Weis, J., Screeningverfahren in der PsychoonkologieDeutsche Krebsgesellschaft, 2008.
573. Osborn, R. L., Demoncada, A. C., Feuerstein, M., Psychosocial interventions for depression, anxiety, and quality of life in cancer survivors: meta-analyses, Int J Psychiatry Med, 2006. 36(1): p. 13-34.
574. Rehse, B., Pukrop, R., Effects of psychosocial interventions on quality of life in adult cancer patients: meta analysis of 37 published controlled outcome studies, Patient Educ Couns, 2003. 50(2): p. 179-86.
575. Uitterhoeve, R. J., Vernooy, M., Litjens, M., Potting, K., Bensing, J., De Mulder, P., et.al. Psychosocial interventions for patients with advanced cancer - a systematic review of the literature, Br J Cancer, 2004. 91(6): p. 1050-62.
576. Williams, S., Dale, J., The effectiveness of treatment for depression/depressive symptoms in adults with cancer: a systematic review, Br J Cancer, 2006. 94(3): p. 372-90.
577. Iwashyna, T. J., Lamont, E. B., Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer, J Clin Oncol, 2002. 20(19): p. 3992-8.
578. Abcarian, H., Pearl, R. K., Simple technique for high ligation of the inferior mesenteric artery and vein, Dis Colon Rectum, 1991. 34(12): p. 1138., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1959468
579. Buunen, M., Lange, M. M., Ditzel, M., Kleinrensink, G. J., van de Velde, C. J., Lange, J. F., Level of arterial ligation in total mesorectal excision (TME): an anatomical study, Int J Colorectal Dis, 2009. 24(11): p. 1317-20., http://www.ncbi.nlm.nih.gov/pubmed/19609537
580. Pezim, M. E., Nicholls, R. J., Survival after high or low ligation of the inferior mesenteric artery during curative surgery for rectal cancer, Ann Surg, 1984. 200(6): p. 729-33., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=6508403, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1250590/pdf/annsurg00118-0057.pdf
581. Surtees, P., Ritchie, J. K., Phillips, R. K., High versus low ligation of the inferior mesenteric artery in rectal cancer, Br J Surg, 1990. 77(6): p. 618-21., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2383724, http://onlinelibrary.wiley.com/doi/10.1002/bjs.1800770607/abstract
582. Slanetz, C. A., Jr., Grimson, R., Effect of high and intermediate ligation on survival and recurrence rates following curative resection of colorectal cancer, Dis Colon Rectum, 1997. 40(10): p. 1205-18; discussion 1218-9., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9336116
583. Lange, M. M., Buunen, M., van de Velde, C. J., Lange, J. F., Level of arterial ligation in rectal cancer surgery: low tie preferred over high tie. A review, Dis Colon Rectum, 2008. 51(7): p. 1139-45., http://www.ncbi.nlm.nih.gov/pubmed/18483828
584. Zaheer, S., Pemberton, J. H., Farouk, R., Dozois, R. R., Wolff, B. G., Ilstrup, D., Surgical treatment of adenocarcinoma of the rectum, Ann Surg, 1998. 227(6): p. 800-11., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9637543, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1191380/pdf/annsurg00016-0034.pdf
585. Leong, A. F., Selective total mesorectal excision for rectal cancer, Dis Colon Rectum, 2000. 43(9): p. 1237-40., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11005489
586. Heald, R. J., Karanjia, N. D., Results of radical surgery for rectal cancer, World J Surg, 1992. 16(5): p. 848-57., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1462619
587. Enker, W. E., Total mesorectal excision--the new golden standard of surgery for rectal cancer, Ann Med, 1997. 29(2): p. 127-33., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9187227
588. Nagtegaal, ID, Marijnen, CA, Kranenbarg, EK, van de Velde, CJ, van Krieken, JH, Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma: not one millimeter but two millimeters is the limit., Am J Surg Pathol, 2002. 26 (3)(3): p. 350-7., https://pubmed.ncbi.nlm.nih.gov/11859207/
589. Glynne-Jones, R, Mawdsley, S, Novell, JR, The clinical significance of the circumferential resection margin following preoperative pelvic chemo-radiotherapy in rectal cancer: why we need a common language., Colorectal Dis, 2006. 8 (9)(9): p. 800-7., https://pubmed.ncbi.nlm.nih.gov/17032329/
590. Kiran, R. P., Lian, L., Lavery, I. C., Does a subcentimeter distal resection margin adversely influence oncologic outcomes in patients with rectal cancer undergoing restorative proctectomy?, Dis Colon Rectum, 2011. 54(2): p. 157-63., http://www.ncbi.nlm.nih.gov/pubmed/21228662
591. Yan, H, Wang, PY, Wu, YC, Liu, YC, Is a Distal Resection Margin of ≤ 1 cm Safe in Patients with Intermediate- to Low-Lying Rectal Cancer? A Systematic Review and Meta-Analysis., J Gastrointest Surg, 2022. 26 (8)(8): p. 1791-1803., https://pubmed.ncbi.nlm.nih.gov/35501549/
592. Liu, H, Xiong, M, Zeng, Y, Shi, Y, Pei, Z, Liao, C, Comparison of complications and bowel function among different reconstruction techniques after low anterior resection for rectal cancer: a systematic review and network meta-analysis., World J Surg Oncol, 2023. 21 (1)(1): p. 87., https://pubmed.ncbi.nlm.nih.gov/36899350/
593. Mathew, A, Ramachandra, D, Goyal, A, Nariampalli Karthyarth, M, Joseph, P, Raj Rakesh, N, et.al. Reconstructive techniques following low anterior resection for carcinoma of the rectum: meta-analysis., Br J Surg, 2023. 110 (3)(3): p. 313-323., https://pubmed.ncbi.nlm.nih.gov/36630589/
594. Zaman, S, Mohamedahmed, AYY, Ayeni, AA, Peterknecht, E, Mawji, S, Albendary, M, et.al. Comparison of the colonic J-pouch versus straight (end-to-end) anastomosis following low anterior resection: a systematic review and meta-analysis., Int J Colorectal Dis, 2022. 37 (4)(4): p. 919-938., https://pubmed.ncbi.nlm.nih.gov/35306586/
595. Hüttner, FJ, Tenckhoff, S, Jensen, K, Uhlmann, L, Kulu, Y, Büchler, MW, et.al. Meta-analysis of reconstruction techniques after low anterior resection for rectal cancer., Br J Surg, 2015. 102 (7)(7): p. 735-45., https://pubmed.ncbi.nlm.nih.gov/25833333/
596. Hohenberger, W., Lahmer, G., Fietkau, R., Croner, R. S., Merkel, S., Gohl, J., et.al. [Neoadjuvant radiochemotherapy for rectal cancer], Chirurg, 2009. 80(4): p. 294-302., http://www.ncbi.nlm.nih.gov/pubmed/19350306
597. Artioukh, D. Y., Controversial aspects of rectal cancer surgery following preoperative chemoradiation, Colorectal Dis, 2010. 12 Suppl 2: p. 25-9., http://www.ncbi.nlm.nih.gov/pubmed/20618364
598. Maas, M, Beets-Tan, RG, Lambregts, DM, Lammering, G, Nelemans, PJ, Engelen, SM, et.al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer., J Clin Oncol, 2011. 29 (35)(35): p. 4633-40., https://pubmed.ncbi.nlm.nih.gov/22067400/
599. Smith, JJ, Chow, OS, Gollub, MJ, Nash, GM, Temple, LK, Weiser, MR, et.al. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management., BMC Cancer, 2015. 15 (): p. 767., https://pubmed.ncbi.nlm.nih.gov/26497495/
600. Fokas, E, Appelt, A, Glynne-Jones, R, Beets, G, Perez, R, Garcia-Aguilar, J, et.al. International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer., Nat Rev Clin Oncol, 2021. 18 (12)(12): p. 805-816., https://pubmed.ncbi.nlm.nih.gov/34349247/
601. Custers, PA, Beets, GL, Bach, SP, Blomqvist, LK, Figueiredo, N, Gollub, MJ, et.al. An International Expert-Based Consensus on the Definition of a Clinical Near-Complete Response After Neoadjuvant (Chemo)radiotherapy for Rectal Cancer., Dis Colon Rectum, 2024. 67 (6)(6): p. 782-795., https://pubmed.ncbi.nlm.nih.gov/38701503/
602. Thompson, HM, Omer, DM, Lin, S, Kim, JK, Yuval, JB, Verheij, FS, et.al. Organ Preservation and Survival by Clinical Response Grade in Patients With Rectal Cancer Treated With Total Neoadjuvant Therapy: A Secondary Analysis of the OPRA Randomized Clinical Trial., JAMA Netw Open, 2024. 7 (1)(1): p. e2350903., https://pubmed.ncbi.nlm.nih.gov/38194231/
603. Zhang, Y, Wang, D, Zhu, L, Wang, B, Ma, X, Shi, B, et.al. Standard versus extralevator abdominoperineal excision and oncologic outcomes for patients with distal rectal cancer: A meta-analysis., Medicine (Baltimore), 2017. 96 (52)(52): p. e9150., https://pubmed.ncbi.nlm.nih.gov/29384902/
604. Yu, HC, Peng, H, He, XS, Zhao, RS, Comparison of short- and long-term outcomes after extralevator abdominoperineal excision and standard abdominoperineal excision for rectal cancer: a systematic review and meta-analysis., Int J Colorectal Dis, 2014. 29 (2)(2): p. 183-91., https://pubmed.ncbi.nlm.nih.gov/24271080/
605. Bianco, F, Romano, G, Tsarkov, P, Stanojevic, G, Shroyer, K, Giuratrabocchetta, S, et.al. Extralevator with vs nonextralevator abdominoperineal excision for rectal cancer: the RELAPe randomized controlled trial., Colorectal Dis, 2017. 19 (2)(2): p. 148-157., https://pubmed.ncbi.nlm.nih.gov/27369739/
606. Seshadri, RA, West, NP, Sundersingh, S, A pilot randomized study comparing extralevator with conventional abdominoperineal excision for low rectal cancer after neoadjuvant chemoradiation., Colorectal Dis, 2017. 19 (7)(7): p. O253-O262., https://pubmed.ncbi.nlm.nih.gov/28503808/
607. Han, JG, Wang, ZJ, Wei, GH, Gao, ZG, Yang, Y, Zhao, BC, Randomized clinical trial of conventional versus cylindrical abdominoperineal resection for locally advanced lower rectal cancer., Am J Surg, 2012. 204 (3)(3): p. 274-82., https://pubmed.ncbi.nlm.nih.gov/22920402/
608. Riva, CG, Kelly, ME, Vitellaro, M, Rottoli, M, Aiolfi, A, Ferrari, D, et.al. A comparison of surgical techniques for perineal wound closure following perineal excision: a systematic review and network meta-analysis., Tech Coloproctol, 2023. 27 (12)(12): p. 1351-1366., https://pubmed.ncbi.nlm.nih.gov/37843643/
609. Nisar, P. J., Scott, H. J., Myocutaneous flap reconstruction of the pelvis after abdominoperineal excision, Colorectal Dis, 2009. 11(8): p. 806-16., http://www.ncbi.nlm.nih.gov/pubmed/19055518
610. Emile, SH, Khan, SM, Garoufalia, Z, Silva-Alvarenga, E, Gefen, R, Horesh, N, et.al. When Is a Diverting Stoma Indicated after Low Anterior Resection? A Meta-analysis of Randomized Trials and Meta-Regression of the Risk Factors of Leakage and Complications in Non-Diverted Patients., J Gastrointest Surg, 2022. 26 (11)(11): p. 2368-2379., https://pubmed.ncbi.nlm.nih.gov/35915378/
611. Du, R, Zhou, J, Tong, G, Chang, Y, Li, D, Wang, F, et.al. Postoperative morbidity and mortality after anterior resection with preventive diverting loop ileostomy versus loop colostomy for rectal cancer: A updated systematic review and meta-analysis., Eur J Surg Oncol, 2021. 47 (7)(7): p. 1514-1525., https://pubmed.ncbi.nlm.nih.gov/33622575/
612. Lindgren, R., Hallbook, O., Rutegard, J., Sjodahl, R., Matthiessen, P., What is the risk for a permanent stoma after low anterior resection of the rectum for cancer? A six-year follow-up of a multicenter trial, Dis Colon Rectum, 2011. 54(1): p. 41-7., http://www.ncbi.nlm.nih.gov/pubmed/21160312
613. Ambe, PC, Kugler, CM, Breuing, J, Grohmann, E, Friedel, J, Hess, S, et.al. The effect of preoperative stoma site marking on risk of stoma-related complications in patients with intestinal ostomy - A systematic review and meta-analysis., Colorectal Dis, 2022. 24 (8)(8): p. 904-917., https://pubmed.ncbi.nlm.nih.gov/35297146/
614. Zwiep, TM, Helewa, RM, Robertson, R, Moloo, H, Hill, R, Chaplain, V, et.al. Preoperative stoma site marking for fecal diversions (ileostomy and colostomy): position statement of the Canadian Society of Colon and Rectal Surgeons and Nurses Specialized in Wound, Ostomy and Continence Canada., Can J Surg, 2022. 65 (3)(3): p. E359-E363., https://pubmed.ncbi.nlm.nih.gov/35613718/
615. Fachgesellschaft Stoma, Kontinenz und Wunde (FgSKW), Die präoperative Stomamarkierung – ein „alter Hut“?MagSI – Fachzeitschrift für Pflege, Fortbildung und Berufspolitik, 2023. 91:
616. Bass, E. M., Del Pino, A., Tan, A., Pearl, R. K., Orsay, C. P., Abcarian, H., Does preoperative stoma marking and education by the enterostomal therapist affect outcome?, Dis Colon Rectum, 1997. 40(4): p. 440-2., http://www.ncbi.nlm.nih.gov/pubmed/9106693
617. Millan, M., Tegido, M., Biondo, S., Garcia-Granero, E., Preoperative stoma siting and education by stomatherapists of colorectal cancer patients: a descriptive study in twelve Spanish colorectal surgical units, Colorectal Dis, 2010. 12(7 Online): p. e88-92., http://www.ncbi.nlm.nih.gov/pubmed/19799617
618. Chaudhri, S., Brown, L., Hassan, I., Horgan, A. F., Preoperative intensive, community-based vs. traditional stoma education: a randomized, controlled trial, Dis Colon Rectum, 2005. 48(3): p. 504-9., http://www.ncbi.nlm.nih.gov/pubmed/15768181
619. Hermanek, P., Marzoli, G.P., Lokale Therapie des Rektumkarzinoms. Verfahren in kurativer Intention.Springer, 1994.
620. Winde, G., Nottberg, H., Keller, R., Schmid, K. W., Bunte, H., Surgical cure for early rectal carcinomas (T1). Transanal endoscopic microsurgery vs. anterior resection, Dis Colon Rectum, 1996. 39(9): p. 969-76., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8797643
621. Sengupta, S., Tjandra, J. J., Local excision of rectal cancer: what is the evidence?, Dis Colon Rectum, 2001. 44(9): p. 1345-61., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11584215
622. Matzel, K. E., Merkel, S., Hohenberger, W., Lokale Therapieprinzipien beim Rektumkarzinom., Chirurg, 2003. 74(10): p. 897-904., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14605731, http://link.springer.com/article/10.1007%2Fs00104-003-0745-0
623. Ptok, H., Marusch, F., Meyer, F., Schubert, D., Koeckerling, F., Gastinger, I., et.al. Oncological outcome of local vs radical resection of low-risk pT1 rectal cancer, Arch Surg, 2007. 142(7): p. 649-55; discussion 656., http://www.ncbi.nlm.nih.gov/pubmed/17638803
624. You, Y. N., Baxter, N. N., Stewart, A., Nelson, H., Is the increasing rate of local excision for stage I rectal cancer in the United States justified?: a nationwide cohort study from the National Cancer Database, Ann Surg, 2007. 245(5): p. 726-33., http://www.ncbi.nlm.nih.gov/pubmed/17457165
625. Willett, CG, Compton, CC, Shellito, PC, Efird, JT, Selection factors for local excision or abdominoperineal resection of early stage rectal cancer., Cancer, 1994. 73 (11)(11): p. 2716-20., https://pubmed.ncbi.nlm.nih.gov/8194011/
626. Benson, AB, Venook, AP, Al-Hawary, MM, Azad, N, Chen, YJ, Ciombor, KK, et.al. Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology., J Natl Compr Canc Netw, 2022. 20 (10)(10): p. 1139-1167., https://pubmed.ncbi.nlm.nih.gov/36240850/
627. Ebbehøj, AL, Jørgensen, LN, Krarup, PM, Smith, HG, Histopathological risk factors for lymph node metastases in T1 colorectal cancer: meta-analysis., Br J Surg, 2021. 108 (7)(7): p. 769-776., https://pubmed.ncbi.nlm.nih.gov/34244752/
628. Dykstra, MA, Gimon, TI, Ronksley, PE, Buie, WD, MacLean, AR, Classic and Novel Histopathologic Risk Factors for Lymph Node Metastasis in T1 Colorectal Cancer: A Systematic Review and Meta-analysis., Dis Colon Rectum, 2021. 64 (9)(9): p. 1139-1150., https://pubmed.ncbi.nlm.nih.gov/34397562/
629. Bach, S. P., Hill, J., Monson, J. R., Simson, J. N., Lane, L., Merrie, A., et.al. A predictive model for local recurrence after transanal endoscopic microsurgery for rectal cancer, Br J Surg, 2009. 96(3): p. 280-90., http://www.ncbi.nlm.nih.gov/pubmed/19224520
630. Hahnloser, D., Wolff, B. G., Larson, D. W., Ping, J., Nivatvongs, S., Immediate radical resection after local excision of rectal cancer: an oncologic compromise?, Dis Colon Rectum, 2005. 48(3): p. 429-37., http://www.ncbi.nlm.nih.gov/pubmed/15747069
631. Schwenk, W., Haase, O., Neudecker, J., Muller, J. M., Short term benefits for laparoscopic colorectal resection, Cochrane Database Syst Rev, 2005. p. CD003145., http://www.ncbi.nlm.nih.gov/pubmed/16034888
632. Liang, Y., Li, G., Chen, P., Yu, J., Laparoscopic versus open colorectal resection for cancer: a meta-analysis of results of randomized controlled trials on recurrence, Eur J Surg Oncol, 2008. 34(11): p. 1217-24., http://www.ncbi.nlm.nih.gov/pubmed/18155389
633. Kuhry, E., Schwenk, W. F., Gaupset, R., Romild, U., Bonjer, H. J., Long-term results of laparoscopic colorectal cancer resection, Cochrane Database Syst Rev, 2008. p. CD003432., http://www.ncbi.nlm.nih.gov/pubmed/18425886
634. Guillou, P. J., Quirke, P., Thorpe, H., Walker, J., Jayne, D. G., Smith, A. M., et.al. Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial, Lancet, 2005. 365(9472): p. 1718-26., http://www.ncbi.nlm.nih.gov/pubmed/15894098
635. Jayne, D. G., Thorpe, H. C., Copeland, J., Quirke, P., Brown, J. M., Guillou, P. J., Five-year follow-up of the Medical Research Council CLASICC trial of laparoscopically assisted versus open surgery for colorectal cancer, Br J Surg, 2010. 97(11): p. 1638-45., http://www.ncbi.nlm.nih.gov/pubmed/20629110
636. Luo, W, Wu, M, Chen, Y, Laparoscopic versus open surgery for elderly patients with colorectal cancer: a systematic review and meta-analysis of matched studies., ANZ J Surg, 2022. 92 (9)(9): p. 2003-2017., https://pubmed.ncbi.nlm.nih.gov/35969025/
637. Kong, M, Chen, H, Shan, K, Sheng, H, Li, L, Comparison of Survival Among Adults With Rectal Cancer Who Have Undergone Laparoscopic vs Open Surgery: A Meta-analysis., JAMA Netw Open, 2022. 5 (5)(5): p. e2210861., https://pubmed.ncbi.nlm.nih.gov/35532937/
638. Flynn, J, Larach, JT, Kong, JCH, Waters, PS, McCormick, JJ, Warrier, SK, et.al. Patient-Related Functional Outcomes After Robotic-Assisted Rectal Surgery Compared With a Laparoscopic Approach: A Systematic Review and Meta-analysis., Dis Colon Rectum, 2022. 65 (10)(10): p. 1191-1204., https://pubmed.ncbi.nlm.nih.gov/35853177/
639. Martins, RS, Fatimi, AS, Mahmud, O, Jahangir, A, Mahar, MU, Aamir, SR, et.al. Multidimensional Quality of Life After Robotic Versus Laparoscopic Surgery for Rectal Cancer: A Systematic Review and Meta-Analysis., World J Surg, 2023. 47 (5)(5): p. 1310-1319., https://pubmed.ncbi.nlm.nih.gov/36788148/
640. Flynn, J, Larach, JT, Kong, JCH, Rahme, J, Waters, PS, Warrier, SK, et.al. Operative and oncological outcomes after robotic rectal resection compared with laparoscopy: a systematic review and meta-analysis., ANZ J Surg, 2023. 93 (3)(3): p. 510-521., https://pubmed.ncbi.nlm.nih.gov/36214098/
641. Saltz, L. B., Niedzwiecki, D., Hollis, D., Goldberg, R. M., Hantel, A., Thomas, J. P., et.al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803, J Clin Oncol, 2007. 25(23): p. 3456-61.
642. Twelves, C., Wong, A., Nowacki, M. P., Abt, M., Burris, H., 3rd, Carrato, A., et.al. Capecitabine as adjuvant treatment for stage III colon cancer, N Engl J Med, 2005. 352(26): p. 2696-704.
643. Lembersky, B. C., Wieand, H. S., Petrelli, N. J., O'Connell, M. J., Colangelo, L. H., Smith, R. E., et.al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06, J Clin Oncol, 2006. 24(13): p. 2059-64.
644. Sakamoto, J., Ohashi, Y., Hamada, C., Buyse, M., Burzykowski, T., Piedbois, P., Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials, J Clin Oncol, 2004. 22(3): p. 484-92.
645. Cao, C., Yan, T. D., Black, D., Morris, D. L., A systematic review and meta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin, Ann Surg Oncol, 2009. 16(8): p. 2152-65., http://www.ncbi.nlm.nih.gov/pubmed/19434455
646. Cotte, E, Passot, G, Mohamed, F, Vaudoyer, D, Gilly, FN, Glehen, O, Management of peritoneal carcinomatosis from colorectal cancer: current state of practice., Cancer J, 2009. 15 (3)(3): p. 243-8., https://pubmed.ncbi.nlm.nih.gov/19556911/
647. Elias, D, Lefevre, JH, Chevalier, J, Brouquet, A, Marchal, F, Classe, JM, et.al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin., J Clin Oncol, 2009. 27 (5)(5): p. 681-5., https://pubmed.ncbi.nlm.nih.gov/19103728/
648. Verwaal, V. J., van Ruth, S., de Bree, E., van Sloothen, G. W., van Tinteren, H., Boot, H., et.al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer, J Clin Oncol, 2003. 21(20): p. 3737-43., http://www.ncbi.nlm.nih.gov/pubmed/14551293
649. Khot, U. P., Lang, A. W., Murali, K., Parker, M. C., Systematic review of the efficacy and safety of colorectal stents, Br J Surg, 2002. 89(9): p. 1096-102., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12190673, http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2168.2002.02148.x/abstract
650. Gumiero, JL, Oliveira, BMS, Neto, PAO, Pandini, RV, Gerbasi, LS, Figueiredo, MN, et.al. Timing of resection of synchronous colorectal liver metastasis: A systematic review and meta-analysis., J Surg Oncol, 2022. 126 (1)(1): p. 175-188., https://pubmed.ncbi.nlm.nih.gov/35689576/
651. Wang, SH, Song, L, Tang, JY, Sun, WP, Li, Z, Safety and long-term prognosis of simultaneous versus staged resection in synchronous colorectal cancer with liver metastasis: a systematic review and meta-analysis., Eur J Med Res, 2022. 27 (1)(1): p. 297., https://pubmed.ncbi.nlm.nih.gov/36529740/
652. Liu, J, Xia, Y, Pan, X, Yan, Z, Zhang, L, Yang, Z, et.al. Simultaneous versus staged major hepatectomy (≥3 liver segments) for outcomes of synchronous colorectal liver metastases: A systematic review and meta-analysis., Cancer Rep (Hoboken), 2022. 5 (8)(8): p. e1617., https://pubmed.ncbi.nlm.nih.gov/35753719/
653. Stillwell, A. P., Buettner, P. G., Ho, Y. H., Meta-analysis of survival of patients with stage IV colorectal cancer managed with surgical resection versus chemotherapy alone, World J Surg, 2010. 34(4): p. 797-807., http://www.ncbi.nlm.nih.gov/pubmed/20054541
654. Poultsides, G. A., Servais, E. L., Saltz, L. B., Patil, S., Kemeny, N. E., Guillem, J. G., et.al. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment, J Clin Oncol, 2009. 27(20): p. 3379-84., http://www.ncbi.nlm.nih.gov/pubmed/19487380
655. Xu, H, Xia, Z, Jia, X, Chen, K, Li, D, Dai, Y, et.al. Primary Tumor Resection Is Associated with Improved Survival in Stage IV Colorectal Cancer: An Instrumental Variable Analysis., Sci Rep, 2015. 5 (): p. 16516., https://pubmed.ncbi.nlm.nih.gov/26563729/
656. Faron, M, Pignon, JP, Malka, D, Bourredjem, A, Douillard, JY, Adenis, A, et.al. Is primary tumour resection associated with survival improvement in patients with colorectal cancer and unresectable synchronous metastases? A pooled analysis of individual data from four randomised trials., Eur J Cancer, 2015. 51 (2)(2): p. 166-76., https://pubmed.ncbi.nlm.nih.gov/25465185/
657. Yi, C, Li, J, Tang, F, Ning, Z, Tian, H, Xiao, L, et.al. Is Primary Tumor Excision and Specific Metastases Sites Resection Associated With Improved Survival in Stage Ⅳ Colorectal Cancer? Results From SEER Database Analysis., Am Surg, 2020. 86 (5)(5): p. 499-507., https://pubmed.ncbi.nlm.nih.gov/32684032/
658. Kanemitsu, Y, Shitara, K, Mizusawa, J, Hamaguchi, T, Shida, D, Komori, K, et.al. Primary Tumor Resection Plus Chemotherapy Versus Chemotherapy Alone for Colorectal Cancer Patients With Asymptomatic, Synchronous Unresectable Metastases (JCOG1007; iPACS): A Randomized Clinical Trial., J Clin Oncol, 2021. 39 (10)(10): p. 1098-1107., https://pubmed.ncbi.nlm.nih.gov/33560877/
659. Koopman, Miriam, van der Kruijssen, Dave Eduard Wilhelm, Elias, Sjoerd G., van de Ven, Peter M., Mol, Linda, Punt, Cornelis J. A., et.al. Upfront palliative resection of primary tumor versus no resection in patients with synchronous metastatic colorectal cancer: The randomized phase 3 CAIRO4 study of the Dutch Colorectal Cancer Group (DCCG).Wolters Kluwer, Journal of Clinical Oncology, 2023. 41(16_suppl): p. 3517 - 3517., https://doi.org/10.1200/JCO.2023.41.16_suppl.3517
660. Rahbari, NN, Biondo, S, Frago, R, Feißt, M, Kreisler, E, Rossion, I, et.al. Primary Tumor Resection Before Systemic Therapy in Patients With Colon Cancer and Unresectable Metastases: Combined Results of the SYNCHRONOUS and CCRe-IV Trials., J Clin Oncol, 2024. (): p. JCO2301540., https://pubmed.ncbi.nlm.nih.gov/38412408/
661. Seppälä, TT, Latchford, A, Negoi, I, Sampaio Soares, A, Jimenez-Rodriguez, R, Sánchez-Guillén, L, et.al. European guidelines from the EHTG and ESCP for Lynch syndrome: an updated third edition of the Mallorca guidelines based on gene and gender., Br J Surg, 2021. 108 (5)(5): p. 484-498., https://pubmed.ncbi.nlm.nih.gov/34043773/
662. Will, O. C., Man, R. F., Phillips, R. K., Tomlinson, I. P., Clark, S. K., Familial adenomatous polyposis and the small bowel: a loco-regional review and current management strategies, Pathol Res Pract, 2008. 204(7): p. 449-58.
663. Dworak, O., Keilholz, L., Hoffmann, A., Pathological features of rectal cancer after preoperative radiochemotherapy, Int J Colorectal Dis, 1997. 12(1): p. 19-23., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9112145
664. Bläker, H, Hildebrandt, B, Riess, H, von Winterfeld, M, Ingold-Heppner, B, Roth, W, et.al. Lymph node count and prognosis in colorectal cancer: the influence of examination quality., Int J Cancer, 2015. 136 (8)(8): p. 1957-66., https://pubmed.ncbi.nlm.nih.gov/25231924/
665. Prandi, M., Lionetto, R., Bini, A., Francioni, G., Accarpio, G., Anfossi, A., et.al. Prognostic evaluation of stage B colon cancer patients is improved by an adequate lymphadenectomy: results of a secondary analysis of a large scale adjuvant trial, Ann Surg, 2002. 235(4): p. 458-63., http://www.ncbi.nlm.nih.gov/pubmed/11923600
666. Ogino, S., Nosho, K., Irahara, N., Shima, K., Baba, Y., Kirkner, G. J., et.al. Negative lymph node count is associated with survival of colorectal cancer patients, independent of tumoral molecular alterations and lymphocytic reaction, Am J Gastroenterol, 2010. 105(2): p. 420-33., http://www.ncbi.nlm.nih.gov/pubmed/19809407
667. Swanson, R. S., Compton, C. C., Stewart, A. K., Bland, K. I., The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined, Ann Surg Oncol, 2003. 10(1): p. 65-71., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12513963
668. Carloss, H., Huang, B., Cohen, A., Carloss, E., Wyatt, S., Tucker, T., The impact of number of lymph nodes removed on five-year survival in stage II colon and rectal cancer, J Ky Med Assoc, 2004. 102(8): p. 345-7., http://www.ncbi.nlm.nih.gov/pubmed/15384384
669. Fazio, L., Cotterchio, M., Manno, M., McLaughlin, J., Gallinger, S., Association between colonic screening, subject characteristics, and stage of colorectal cancer, Am J Gastroenterol, 2005. 100(11): p. 2531-9., http://www.ncbi.nlm.nih.gov/pubmed/16279911
670. Wong, S. L., Ji, H., Hollenbeck, B. K., Morris, A. M., Baser, O., Birkmeyer, J. D., Hospital lymph node examination rates and survival after resection for colon cancer, JAMA, 2007. 298(18): p. 2149-54., http://www.ncbi.nlm.nih.gov/pubmed/18000198
671. Wang, J., Kulaylat, M., Rockette, H., Hassett, J., Rajput, A., Dunn, K. B., et.al. Should total number of lymph nodes be used as a quality of care measure for stage III colon cancer?, Ann Surg, 2009. 249(4): p. 559-63., http://www.ncbi.nlm.nih.gov/pubmed/19300237
672. Chen, S. L., Steele, S. R., Eberhardt, J., Zhu, K., Bilchik, A., Stojadinovic, A., Lymph node ratio as a quality and prognostic indicator in stage III colon cancer, Ann Surg, 2011. 253(1): p. 82-7., http://www.ncbi.nlm.nih.gov/pubmed/21135690
673. Qiu, H. B., Zhang, L. Y., Li, Y. F., Zhou, Z. W., Keshari, R. P., Xu, R. H., Ratio of metastatic to resected lymph nodes enhances to predict survival in patients with stage III colorectal cancer, Ann Surg Oncol, 2011. 18(6): p. 1568-74., http://www.ncbi.nlm.nih.gov/pubmed/21207155
674. Ha, Y. H., Jeong, S. Y., Lim, S. B., Choi, H. S., Hong, Y. S., Chang, H. J., et.al. Influence of preoperative chemoradiotherapy on the number of lymph nodes retrieved in rectal cancer, Ann Surg, 2010. 252(2): p. 336-40., http://www.ncbi.nlm.nih.gov/pubmed/20647928
675. West, N. P., Hohenberger, W., Weber, K., Perrakis, A., Finan, P. J., Quirke, P., Complete mesocolic excision with central vascular ligation produces an oncologically superior specimen compared with standard surgery for carcinoma of the colon, J Clin Oncol, 2010. 28(2): p. 272-8., http://www.ncbi.nlm.nih.gov/pubmed/19949013
676. Leite, J. S., Martins, S. C., Oliveira, J., Cunha, M. F., Castro-Sousa, F., Clinical significance of macroscopic completeness of mesorectal resection in rectal cancer, Colorectal Dis, 2011. 13(4): p. 381-6., http://www.ncbi.nlm.nih.gov/pubmed/20002696
677. Quirke, P., Steele, R., Monson, J., Grieve, R., Khanna, S., Couture, J., et.al. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial, Lancet, 2009. 373(9666): p. 821-8.
678. West, N. P., Finan, P. J., Anderin, C., Lindholm, J., Holm, T., Quirke, P., Evidence of the oncologic superiority of cylindrical abdominoperineal excision for low rectal cancer, J Clin Oncol, 2008. 26(21): p. 3517-22., http://www.ncbi.nlm.nih.gov/pubmed/18541901
679. Tilney, H. S., Rasheed, S., Northover, J. M., Tekkis, P. P., The influence of circumferential resection margins on long-term outcomes following rectal cancer surgery, Dis Colon Rectum, 2009. 52(10): p. 1723-9., http://www.ncbi.nlm.nih.gov/pubmed/19966604
680. Bernstein, T. E., Endreseth, B. H., Romundstad, P., Wibe, A., Circumferential resection margin as a prognostic factor in rectal cancer, Br J Surg, 2009. 96(11): p. 1348-57., http://www.ncbi.nlm.nih.gov/pubmed/19847867
681. Luchini, C, Bibeau, F, Ligtenberg, MJL, Singh, N, Nottegar, A, Bosse, T, et.al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach., Ann Oncol, 2019. 30 (8)(8): p. 1232-1243., https://pubmed.ncbi.nlm.nih.gov/31056702/
682. André, T, Shiu, KK, Kim, TW, Jensen, BV, Jensen, LH, Punt, C, et.al. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer., N Engl J Med, 2020. 383 (23)(23): p. 2207-2218., https://pubmed.ncbi.nlm.nih.gov/33264544/
683. Lenz, HJ, Van Cutsem, E, Luisa Limon, M, Wong, KYM, Hendlisz, A, Aglietta, M, et.al. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study., J Clin Oncol, 2022. 40 (2)(2): p. 161-170., https://pubmed.ncbi.nlm.nih.gov/34637336/
684. Argilés, G, Tabernero, J, Labianca, R, Hochhauser, D, Salazar, R, Iveson, T, et.al. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up., Ann Oncol, 2020. 31 (10)(10): p. 1291-1305., https://pubmed.ncbi.nlm.nih.gov/32702383/
685. Ribic, C. M., Sargent, D. J., Moore, M. J., Thibodeau, S. N., French, A. J., Goldberg, R. M., et.al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer, N Engl J Med, 2003. 349(3): p. 247-57., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12867608, http://www.nejm.org/doi/pdf/10.1056/NEJMoa022289
686. Sargent, DJ, Marsoni, S, Monges, G, Thibodeau, SN, Labianca, R, Hamilton, SR, et.al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer., J Clin Oncol, 2010. 28 (20)(20): p. 3219-26., https://pubmed.ncbi.nlm.nih.gov/20498393/
687. Sinicrope, FA, Foster, NR, Thibodeau, SN, Marsoni, S, Monges, G, Labianca, R, et.al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy., J Natl Cancer Inst, 2011. 103 (11)(11): p. 863-75., https://pubmed.ncbi.nlm.nih.gov/21597022/
688. Kim, JE, Hong, YS, Kim, HJ, Kim, KP, Lee, JL, Park, SJ, et.al. Defective Mismatch Repair Status was not Associated with DFS and OS in Stage II Colon Cancer Treated with Adjuvant Chemotherapy., Ann Surg Oncol, 2015. 22 Suppl 3 (): p. S630-7., https://pubmed.ncbi.nlm.nih.gov/26271397/
689. Cercek, Andrea, Lumish, Melissa Amy, Sinopoli, Jenna Cohen, Weiss, Jill A., Shia, Jinru, Stadler, Zsofia Kinga, et.al. Single agent PD-1 blockade as curative-intent treatment in mismatch repair deficient locally advanced rectal cancer.Wolters Kluwer, Journal of Clinical Oncology, 2022. 40(17_suppl): p. LBA5 - LBA5., https://doi.org/10.1200/JCO.2022.40.17_suppl.LBA5
690. Chalabi, M, Fanchi, LF, Dijkstra, KK, Van den Berg, JG, Aalbers, AG, Sikorska, K, et.al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers., Nat Med, 2020. 26 (4)(4): p. 566-576., https://pubmed.ncbi.nlm.nih.gov/32251400/
691. Verschoor, Yara L., van den Berg, José, Beets, Geerard, Sikorska, Karolina, Aalbers, Arend, van Lent, Anja, et.al. Neoadjuvant nivolumab, ipilimumab, and celecoxib in MMR-proficient and MMR-deficient colon cancers: Final clinical analysis of the NICHE study.Wolters Kluwer, Journal of Clinical Oncology, 2022. 40(16_suppl): p. 3511 - 3511., https://doi.org/10.1200/JCO.2022.40.16_suppl.3511
692. Jia, LL, Zhao, JX, Zhao, LP, Tian, JH, Huang, G, Current status and quality of radiomic studies for predicting KRAS mutations in colorectal cancer patients: A systematic review and meta‑analysis., Eur J Radiol, 2023. 158 (): p. 110640., https://pubmed.ncbi.nlm.nih.gov/36525703/
693. Pikouli, A, Papaconstantinou, D, Wang, J, Kavezou, F, Pararas, N, Nastos, C, et.al. Reevaluating the prognostic role of BRAF mutation in colorectal cancer liver metastases., Am J Surg, 2022. 223 (5)(5): p. 879-883., https://pubmed.ncbi.nlm.nih.gov/34544580/
694. Hampel, H, Pearlman, R, Beightol, M, Zhao, W, Jones, D, Frankel, WL, et.al. Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer., JAMA Oncol, 2018. 4 (6)(6): p. 806-813., https://pubmed.ncbi.nlm.nih.gov/29596542/
695. Van Cutsem, E., Lenz, H. J., Kohne, C. H., Heinemann, V., Tejpar, S., Melezinek, I., et.al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer, J Clin Oncol, 2015. 33(7): p. 692-700.
696. Kopetz, S, Grothey, A, Yaeger, R, Van Cutsem, E, Desai, J, Yoshino, T, et.al. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer, N Engl J Med, 2019. 381 (17)(17): p. 1632-1643., https://pubmed.ncbi.nlm.nih.gov/31566309/
697. Fakih, MG, Kopetz, S, Kuboki, Y, Kim, TW, Munster, PN, Krauss, JC, et.al. Sotorasib for previously treated colorectal cancers with KRAS G12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial, Lancet Oncol, 2022. 23 (1)(1): p. 115-124., https://pubmed.ncbi.nlm.nih.gov/34919824/
698. Fakih, MG, Salvatore, L, Esaki, T, Modest, DP, Lopez-Bravo, DP, Taieb, J, et.al. Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C, N Engl J Med, 2023. 389 (23)(23): p. 2125-2139., https://pubmed.ncbi.nlm.nih.gov/37870968/
699. Yaeger, R, Weiss, J, Pelster, MS, Spira, AI, Barve, M, Ou, SI, et.al. Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C, N Engl J Med, 2023. 388 (1)(1): p. 44-54., https://pubmed.ncbi.nlm.nih.gov/36546659/
700. Tran, B., Kopetz, S., Tie, J., Gibbs, P., Jiang, Z. Q., Lieu, C. H., et.al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer, Cancer, 2011. 117(20): p. 4623-32.
701. Tveit, K. M., Guren, T., Glimelius, B., Pfeiffer, P., Sorbye, H., Pyrhonen, S., et.al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study, J Clin Oncol, 2012. 30(15): p. 1755-62.
702. Pietrantonio, F., Petrelli, F., Coinu, A., Di Bartolomeo, M., Borgonovo, K., Maggi, C., et.al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis, Eur J Cancer, 2015. 51(5): p. 587-94.
703. Venderbosch, S., Nagtegaal, I. D., Maughan, T. S., Smith, C. G., Cheadle, J. P., Fisher, D., et.al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies, Clin Cancer Res, 2014. 20(20): p. 5322-30.
704. Domingo, E., Niessen, R. C., Oliveira, C., Alhopuro, P., Moutinho, C., Espin, E., et.al. BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes, Oncogene, 2005. 24(24): p. 3995-8.
705. Cremolini, C., Di Bartolomeo, M., Amatu, A., Antoniotti, C., Moretto, R., Berenato, R., et.al. BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis, Ann Oncol, 2015. 26(10): p. 2092-7.
706. Douillard, J. Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., et.al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer, N Engl J Med, 2013. 369(11): p. 1023-34., http://www.nejm.org/doi/pdf/10.1056/NEJMoa1305275
707. Sorich, M. J., Wiese, M. D., Rowland, A., Kichenadasse, G., McKinnon, R. A., Karapetis, C. S., Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials, Ann Oncol, 2015. 26(1): p. 13-21.
708. Stintzing, S., Modest, D. P., Rossius, L., Lerch, M. M., von Weikersthal, L. F., Decker, T., et.al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial, Lancet Oncol, 2016. 17(10): p. 1426-1434.
709. Frattini, M., Saletti, P., Romagnani, E., Martin, V., Molinari, F., Ghisletta, M., et.al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients, Br J Cancer, 2007. 97(8): p. 1139-45.
710. Bokemeyer, C., Kohne, C. H., Ciardiello, F., Lenz, H. J., Heinemann, V., Klinkhardt, U., et.al. FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer, Eur J Cancer, 2015. 51(10): p. 1243-52.
711. Peeters, M., Price, T. J., Cervantes, A., Sobrero, A. F., Ducreux, M., Hotko, Y., et.al. Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer, Ann Oncol, 2014. 25(1): p. 107-16., https://academic.oup.com/annonc/article/25/1/107/166332
712. Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., et.al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer, N Engl J Med, 2008. 359(17): p. 1757-65.
713. Neumann, J, Zeindl-Eberhart, E, Kirchner, T, Jung, A, Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer., Pathol Res Pract, 2009. 205 (12)(12): p. 858-62., https://pubmed.ncbi.nlm.nih.gov/19679400/
714. Jones, RP, Sutton, PA, Evans, JP, Clifford, R, McAvoy, A, Lewis, J, et.al. Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer., Br J Cancer, 2017. 116 (7)(7): p. 923-929., https://pubmed.ncbi.nlm.nih.gov/28208157/
715. Wiesweg, M, Kasper, S, Worm, K, Herold, T, Reis, H, Sara, L, et.al. Impact of RAS mutation subtype on clinical outcome-a cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancer., Oncogene, 2019. 38 (16)(16): p. 2953-2966., https://pubmed.ncbi.nlm.nih.gov/30568222/
716. Nollmann, FI, Ruess, DA, Targeting Mutant KRAS in Pancreatic Cancer: Futile or Promising?, Biomedicines, 2020. 8 (8)(8):, https://pubmed.ncbi.nlm.nih.gov/32796566/
717. Nassar, AH, Adib, E, Kwiatkowski, DJ, Distribution of KRAS G12C Somatic Mutations across Race, Sex, and Cancer Type, N Engl J Med, 2021. 384 (2)(2): p. 185-187., https://pubmed.ncbi.nlm.nih.gov/33497555/
718. Loes, I. M., Immervoll, H., Sorbye, H., Angelsen, J. H., Horn, A., Knappskog, S., et.al. Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases, Int J Cancer, 2016. 139(3): p. 647-56., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5071774/pdf/IJC-139-647.pdf
719. Van Cutsem, E, Cervantes, A, Adam, R, Sobrero, A, Van Krieken, JH, Aderka, D, et.al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer., Ann Oncol, 2016. 27 (8)(8): p. 1386-422., https://pubmed.ncbi.nlm.nih.gov/27380959/
720. Knijn, N, Mekenkamp, LJ, Klomp, M, Vink-Börger, ME, Tol, J, Teerenstra, S, et.al. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients., Br J Cancer, 2011. 104 (6)(6): p. 1020-6., https://pubmed.ncbi.nlm.nih.gov/21364579/
721. Loes, I. M., Immervoll, H., Sorbye, H., Angelsen, J. H., Horn, A., Knappskog, S., et.al. Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases, Int J Cancer, 2016. 139(3): p. 647-56., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5071774/pdf/IJC-139-647.pdf
722. Holch, JW, Ricard, I, Stintzing, S, Modest, DP, Heinemann, V, The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials., Eur J Cancer, 2017. 70 (): p. 87-98., https://pubmed.ncbi.nlm.nih.gov/27907852/
723. Arnold, D., Lueza, B., Douillard, J. Y., Peeters, M., Lenz, H. J., Venook, A., et.al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials, Ann Oncol, 2017. 28(8): p. 1713-1729., https://www.ncbi.nlm.nih.gov/pubmed/28407110
724. Tejpar, S, Stintzing, S, Ciardiello, F, Tabernero, J, Van Cutsem, E, Beier, F, et.al. Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials., JAMA Oncol, 2017. 3 (2)(2): p. 194-201., https://pubmed.ncbi.nlm.nih.gov/27722750/
725. Loupakis, F, Yang, D, Yau, L, Feng, S, Cremolini, C, Zhang, W, et.al. Primary tumor location as a prognostic factor in metastatic colorectal cancer., J Natl Cancer Inst, 2015. 107 (3)(3):, https://pubmed.ncbi.nlm.nih.gov/25713148/
726. Watanabe, J, Muro, K, Shitara, K, Yamazaki, K, Shiozawa, M, Ohori, H, et.al. Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial., JAMA, 2023. 329 (15)(15): p. 1271-1282., https://pubmed.ncbi.nlm.nih.gov/37071094/
727. Cremolini, C, Rossini, D, Dell'Aquila, E, Lonardi, S, Conca, E, Del Re, M, et.al. Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial., JAMA Oncol, 2019. 5 (3)(3): p. 343-350., https://pubmed.ncbi.nlm.nih.gov/30476968/
728. Martinelli, E, Martini, G, Famiglietti, V, Troiani, T, Napolitano, S, Pietrantonio, F, et.al. Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial., JAMA Oncol, 2021. 7 (10)(10): p. 1529-1535., https://pubmed.ncbi.nlm.nih.gov/34382998/
729. Sartore-Bianchi, A, Pietrantonio, F, Lonardi, S, Mussolin, B, Rua, F, Crisafulli, G, et.al. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial., Nat Med, 2022. 28 (8)(8): p. 1612-1618., https://pubmed.ncbi.nlm.nih.gov/35915157/
730. Aoki, Y, Nakamura, Y, Denda, T, Ohta, T, Esaki, T, Shiozawa, M, et.al. Clinical Validation of Plasma-Based Genotyping for RAS and BRAF V600E Mutation in Metastatic Colorectal Cancer: SCRUM-Japan GOZILA Substudy, JCO Precis Oncol, 2023. 7 (): p. e2200688., https://pubmed.ncbi.nlm.nih.gov/37343204/
731. Osumi, H, Vecchione, L, Keilholz, U, Vollbrecht, C, Alig, AHS, von Einem, JC, et.al. NeoRAS wild-type in metastatic colorectal cancer: Myth or truth?-Case series and review of the literature., Eur J Cancer, 2021. 153 (): p. 86-95., https://pubmed.ncbi.nlm.nih.gov/34153718/
732. Sartore-Bianchi, A, Trusolino, L, Martino, C, Bencardino, K, Lonardi, S, Bergamo, F, et.al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial., Lancet Oncol, 2016. 17 (6)(6): p. 738-746., https://pubmed.ncbi.nlm.nih.gov/27108243/
733. Javle, M, Borad, MJ, Azad, NS, Kurzrock, R, Abou-Alfa, GK, George, B, et.al. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study., Lancet Oncol, 2021. 22 (9)(9): p. 1290-1300., https://pubmed.ncbi.nlm.nih.gov/34339623/
734. Siena, S, Di Bartolomeo, M, Raghav, K, Masuishi, T, Loupakis, F, Kawakami, H, et.al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial., Lancet Oncol, 2021. 22 (6)(6): p. 779-789., https://pubmed.ncbi.nlm.nih.gov/33961795/
735. Strickler, JH, Cercek, A, Siena, S, André, T, Ng, K, Van Cutsem, E, et.al. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study., Lancet Oncol, 2023. 24 (5)(5): p. 496-508., https://pubmed.ncbi.nlm.nih.gov/37142372/
736. Sartore-Bianchi, A, Amatu, A, Porcu, L, Ghezzi, S, Lonardi, S, Leone, F, et.al. HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer., Oncologist, 2019. 24 (10)(10): p. 1395-1402., https://pubmed.ncbi.nlm.nih.gov/30952821/
737. Baretton, G, Dietel, M, Gaiser, T, Kirchner, T, Kreipe, HH, Quaas, A, et.al. [HER2 testing in gastric cancer : Results of a meeting of German experts]., Pathologe, 2016. 37 (4)(4): p. 361-6., https://pubmed.ncbi.nlm.nih.gov/27376648/
738. Valtorta, E, Martino, C, Sartore-Bianchi, A, Penaullt-Llorca, F, Viale, G, Risio, M, et.al. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study., Mod Pathol, 2015. 28 (11)(11): p. 1481-91., https://pubmed.ncbi.nlm.nih.gov/26449765/
739. Ahcene Djaballah, S, Daniel, F, Milani, A, Ricagno, G, Lonardi, S, HER2 in Colorectal Cancer: The Long and Winding Road From Negative Predictive Factor to Positive Actionable Target., Am Soc Clin Oncol Educ Book, 2022. 42 (): p. 1-14., https://pubmed.ncbi.nlm.nih.gov/35580290/
740. Pietrantonio, F, Di Nicolantonio, F, Schrock, AB, Lee, J, Tejpar, S, Sartore-Bianchi, A, et.al. ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer., J Natl Cancer Inst, 2017. 109 (12)(12):, https://pubmed.ncbi.nlm.nih.gov/29370427/
741. Marchiò, C, Scaltriti, M, Ladanyi, M, Iafrate, AJ, Bibeau, F, Dietel, M, et.al. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research., Ann Oncol, 2019. 30 (9)(9): p. 1417-1427., https://pubmed.ncbi.nlm.nih.gov/31268127/
742. Hong, DS, DuBois, SG, Kummar, S, Farago, AF, Albert, CM, Rohrberg, KS, et.al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials., Lancet Oncol, 2020. 21 (4)(4): p. 531-540., https://pubmed.ncbi.nlm.nih.gov/32105622/
743. Doebele, RC, Drilon, A, Paz-Ares, L, Siena, S, Shaw, AT, Farago, AF, et.al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials., Lancet Oncol, 2020. 21 (2)(2): p. 271-282., https://pubmed.ncbi.nlm.nih.gov/31838007/
744. Hechtman, JF, Benayed, R, Hyman, DM, Drilon, A, Zehir, A, Frosina, D, et.al. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions., Am J Surg Pathol, 2017. 41 (11)(11): p. 1547-1551., https://pubmed.ncbi.nlm.nih.gov/28719467/
745. Stintzing, Sebastian, Heinemann, Volker, Fischer von Weikersthal, Ludwig, Fuchs, Martin, Kaiser, Florian, Heinrich, Kathrin, et.al. Phase III FIRE-4 study (AIO KRK-0114): Influence of baseline liquid biopsy results in first-line treatment efficacy of FOLFIRI/cetuximab in patients with tissue RAS-WT mCRC.Wolters Kluwer, Journal of Clinical Oncology, 2023. 41(16_suppl): p. 3507 - 3507., https://doi.org/10.1200/JCO.2023.41.16_suppl.3507
746. Callesen, LB, Hamfjord, J, Boysen, AK, Pallisgaard, N, Guren, TK, Kure, EH, et.al. Circulating tumour DNA and its clinical utility in predicting treatment response or survival in patients with metastatic colorectal cancer: a systematic review and meta-analysis., Br J Cancer, 2022. 127 (3)(3): p. 500-513., https://pubmed.ncbi.nlm.nih.gov/35440666/
747. Dawood, ZS, Alaimo, L, Lima, HA, Moazzam, Z, Shaikh, C, Ahmed, AS, et.al. Circulating Tumor DNA, Imaging, and Carcinoembryonic Antigen: Comparison of Surveillance Strategies Among Patients Who Underwent Resection of Colorectal Cancer-A Systematic Review and Meta-analysis., Ann Surg Oncol, 2023. 30 (1)(1): p. 259-274., https://pubmed.ncbi.nlm.nih.gov/36219278/
748. Faulkner, LG, Howells, LM, Pepper, C, Shaw, JA, Thomas, AL, The utility of ctDNA in detecting minimal residual disease following curative surgery in colorectal cancer: a systematic review and meta-analysis., Br J Cancer, 2023. 128 (2)(2): p. 297-309., https://pubmed.ncbi.nlm.nih.gov/36347967/
749. Tie, J, Wang, Y, Tomasetti, C, Li, L, Springer, S, Kinde, I, et.al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer., Sci Transl Med, 2016. 8 (346)(346): p. 346ra92., https://pubmed.ncbi.nlm.nih.gov/27384348/
750. Wang, Y, Li, L, Cohen, JD, Kinde, I, Ptak, J, Popoli, M, et.al. Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal Cancer., JAMA Oncol, 2019. 5 (8)(8): p. 1118-1123., https://pubmed.ncbi.nlm.nih.gov/31070668/
751. Reinert, T, Henriksen, TV, Christensen, E, Sharma, S, Salari, R, Sethi, H, et.al. Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer., JAMA Oncol, 2019. 5 (8)(8): p. 1124-1131., https://pubmed.ncbi.nlm.nih.gov/31070691/
752. Tarazona, N, Gimeno-Valiente, F, Gambardella, V, Zuñiga, S, Rentero-Garrido, P, Huerta, M, et.al. Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer., Ann Oncol, 2019. 30 (11)(11): p. 1804-1812., https://pubmed.ncbi.nlm.nih.gov/31562764/
753. Tie, J, Cohen, JD, Wang, Y, Christie, M, Simons, K, Lee, M, et.al. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer., JAMA Oncol, 2019. 5 (12)(12): p. 1710-1717., https://pubmed.ncbi.nlm.nih.gov/31621801/
754. Tie, J, Lo, SN, Gibbs, P, Circulating Tumor DNA Guiding Adjuvant Therapy in Colon Cancer. Reply., N Engl J Med, 2022. 387 (8)(8): p. 760., https://pubmed.ncbi.nlm.nih.gov/36001722/
755. Parikh, AR, Van Seventer, EE, Siravegna, G, Hartwig, AV, Jaimovich, A, He, Y, et.al. Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer., Clin Cancer Res, 2021. 27 (20)(20): p. 5586-5594., https://pubmed.ncbi.nlm.nih.gov/33926918/
756. Henriksen, TV, Tarazona, N, Frydendahl, A, Reinert, T, Gimeno-Valiente, F, Carbonell-Asins, JA, et.al. Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences., Clin Cancer Res, 2022. 28 (3)(3): p. 507-517., https://pubmed.ncbi.nlm.nih.gov/34625408/
757. Kotani, D, Oki, E, Nakamura, Y, Yukami, H, Mishima, S, Bando, H, et.al. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer., Nat Med, 2023. 29 (1)(1): p. 127-134., https://pubmed.ncbi.nlm.nih.gov/36646802/
758. Misale, S, Yaeger, R, Hobor, S, Scala, E, Janakiraman, M, Liska, D, et.al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer., Nature, 2012. 486 (7404)(7404): p. 532-6., https://pubmed.ncbi.nlm.nih.gov/22722830/
759. Diaz, LA, Williams, RT, Wu, J, Kinde, I, Hecht, JR, Berlin, J, et.al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers., Nature, 2012. 486 (7404)(7404): p. 537-40., https://pubmed.ncbi.nlm.nih.gov/22722843/
760. Menarini-Gruppe, Fachinformation Menarini zu Elacestrant, 2023.
761. Bundesärztekammer (BÄK), Bundesärztekammer Bekanntmachungen, Deutsches Ärzteblatt, 2023., www.aerzteblatt.de/archiv/231574/Aktualisierung-der-Richtlinie-der-Bundesaerztekammer-zur-Qualitaetssicherung-laboratoriumsmedizinischer-Untersuchungen-Rili-BAeK
762. Merkel, S., Weber, K., Matzel, K. E., Agaimy, A., Gohl, J., Hohenberger, W., Prognosis of patients with colonic carcinoma before, during and after implementation of complete mesocolic excision, Br J Surg, 2016. 103(9): p. 1220-9., http://onlinelibrary.wiley.com/doi/10.1002/bjs.10183/abstract?systemMessage=Wiley+Online+Library+Journal+subscribe+and+renew+pages+for+some+journals+will+be+unavailable+on+Wednesday+11th+January+2017+from+06%3A00-12%3A00+GMT+%2F+01%3A00-07%3A00+EST+%2F+14%3A00-20%3A00+SGT+for+essential+maintenance.+Apologies+for+the+inconvenience
763. Biagi, J. J., Raphael, M. J., Mackillop, W. J., Kong, W., King, W. D., Booth, C. M., Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis, JAMA, 2011. 305(22): p. 2335-42., http://jama.jamanetwork.com/article.aspx?articleid=221033
764. Des Guetz, G., Nicolas, P., Perret, G. Y., Morere, J. F., Uzzan, B., Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysis, Eur J Cancer, 2010. 46(6): p. 1049-55., http://www.ejcancer.com/article/S0959-8049(10)00039-0/abstract
765. Bos, A. C., van Erning, F. N., van Gestel, Y. R., Creemers, G. J., Punt, C. J., van Oijen, M. G., et.al. Timing of adjuvant chemotherapy and its relation to survival among patients with stage III colon cancer, Eur J Cancer, 2015. 51(17): p. 2553-61., http://www.ejcancer.com/article/S0959-8049(15)00806-0/abstract
766. Bayraktar, U. D., Chen, E., Bayraktar, S., Sands, L. R., Marchetti, F., Montero, A. J., et.al. Does delay of adjuvant chemotherapy impact survival in patients with resected stage II and III colon adenocarcinoma?, Cancer, 2011. 117(11): p. 2364-70., http://onlinelibrary.wiley.com/store/10.1002/cncr.25720/asset/25720_ftp.pdf?v=1&t=ik43xw36&s=f73ad5791582665da6a7110562e9135e2a2d2363
767. Lima, I. S., Yasui, Y., Scarfe, A., Winget, M., Association between receipt and timing of adjuvant chemotherapy and survival for patients with stage III colon cancer in Alberta, Canada, Cancer, 2011. 117(16): p. 3833-40., http://onlinelibrary.wiley.com/store/10.1002/cncr.25954/asset/25954_ftp.pdf?v=1&t=ik43yiqz&s=a63ed3883443dcf570d7242ed28b2dcd03a3acf2
768. Nachiappan, S., Askari, A., Mamidanna, R., Munasinghe, A., Currie, A., Stebbing, J., et.al. Initiation of adjuvant chemotherapy within 8 weeks of elective colorectal resection improves overall survival regardless of reoperation, Colorectal Dis, 2016. 18(11): p. 1041-1049., http://onlinelibrary.wiley.com/doi/10.1111/codi.13308/abstract?systemMessage=WOL+Usage+report+download+page+will+be+unavailable+on+Friday+27th+January+2017+at+23%3A00+GMT%2F+18%3A00+EST%2F+07%3A00+SGT+%28Saturday+28th+Jan+for+SGT%29++for+up+to+2+hours+due+to+essential+server+maintenance.+Apologies+for+the+inconvenience.
769. Yang, Y, Lu, Y, Tan, H, Bai, M, Wang, X, Ge, S, et.al. The optimal time of starting adjuvant chemotherapy after curative surgery in patients with colorectal cancer., BMC Cancer, 2023. 23 (1)(1): p. 422., https://pubmed.ncbi.nlm.nih.gov/37161562/
770. Dube, S., Heyen, F., Jenicek, M., Adjuvant chemotherapy in colorectal carcinoma: results of a meta-analysis, Dis Colon Rectum, 1997. 40(1): p. 35-41., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9102259
771. Gill, S., Loprinzi, C. L., Sargent, D. J., Thome, S. D., Alberts, S. R., Haller, D. G., et.al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?, J Clin Oncol, 2004. 22(10): p. 1797-806., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15067028, http://jco.ascopubs.org/content/22/10/1797.full.pdf
772. Sargent, D. J., Goldberg, R. M., Jacobson, S. D., Macdonald, J. S., Labianca, R., Haller, D. G., et.al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients, N Engl J Med, 2001. 345(15): p. 1091-7., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11596588, http://www.nejm.org/doi/pdf/10.1056/NEJMoa010957
773. Francini, G., Petrioli, R., Lorenzini, L., Mancini, S., Armenio, S., Tanzini, G., et.al. Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer, Gastroenterology, 1994. 106(4): p. 899-906., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8143995
774. O'Connell, MJ, Mailliard, JA, Kahn, MJ, Macdonald, JS, Haller, DG, Mayer, RJ, et.al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer., J Clin Oncol, 1997. 15 (1)(1): p. 246-50., https://pubmed.ncbi.nlm.nih.gov/8996149/
775. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators, Lancet, 1995. 345(8955): p. 939-44., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7715291, http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(95)90696-7/abstract
776. Booth, C. M., Nanji, S., Wei, X., Peng, Y., Biagi, J. J., Hanna, T. P., et.al. Use and Effectiveness of Adjuvant Chemotherapy for Stage III Colon Cancer: A Population-Based Study, J Natl Compr Canc Netw, 2016. 14(1): p. 47-56., http://www.jnccn.org/content/14/1/47.long
777. Tournigand, C., Andre, T., Bonnetain, F., Chibaudel, B., Lledo, G., Hickish, T., et.al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial, J Clin Oncol, 2012. 30(27): p. 3353-60., http://jco.ascopubs.org/content/30/27/3353.full.pdf
778. Haller, D. G., O'Connell, M. J., Cartwright, T. H., Twelves, C. J., McKenna, E. F., Sun, W., et.al. Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials, Ann Oncol, 2015. 26(4): p. 715-24., http://annonc.oxfordjournals.org/content/26/4/715, http://annonc.oxfordjournals.org/content/26/4/715.long
779. Schmoll, H. J., Tabernero, J., Maroun, J., de Braud, F., Price, T., Van Cutsem, E., et.al. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial, J Clin Oncol, 2015. 33(32): p. 3733-40., http://jco.ascopubs.org/content/33/32/3733.long
780. McCleary, N. J., Meyerhardt, J. A., Green, E., Yothers, G., de Gramont, A., Van Cutsem, E., et.al. Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database, J Clin Oncol, 2013. 31(20): p. 2600-6., http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699725/pdf/zlj2600.pdf
781. Fata, F., Mirza, A., Craig, G., Nair, S., Law, A., Gallagher, J., et.al. Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colon carcinoma: a 10-year experience of the Geisinger Medical Center, Cancer, 2002. 94(7): p. 1931-8., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11932894, http://onlinelibrary.wiley.com/store/10.1002/cncr.10430/asset/10430_ftp.pdf?v=1&t=ik52ga69&s=9cc708acb03fae62cb8f1d2c6ead3a2e27b9e6fd
782. Gallois, C, Shi, Q, Pederson, LD, André, T, Iveson, TJ, Sobrero, AF, et.al. Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials., J Clin Oncol, 2024. 42 (19)(19): p. 2295-2305., https://pubmed.ncbi.nlm.nih.gov/38547438/
783. Figueredo, A., Germond, C., Maroun, J., Browman, G., Walker-Dilks, C., Wong, S., Adjuvant therapy for stage II colon cancer after complete resection. Provincial Gastrointestinal Disease Site Group, Cancer Prev Control, 1997. 1(5): p. 379-92., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9765760
784. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators, J Clin Oncol, 1999. 17(5): p. 1356-63., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10334519, http://jco.ascopubs.org/content/17/5/1356.long
785. Mamounas, E., Wieand, S., Wolmark, N., Bear, H. D., Atkins, J. N., Song, K., et.al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04), J Clin Oncol, 1999. 17(5): p. 1349-55., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10334518, http://jco.ascopubs.org/content/17/5/1349.long
786. Benson, A. B., 3rd, Schrag, D., Somerfield, M. R., Cohen, A. M., Figueredo, A. T., Flynn, P. J., et.al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer, J Clin Oncol, 2004. 22(16): p. 3408-19., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15199089, http://jco.ascopubs.org/content/22/16/3408.full.pdf
787. Quasar Collaborative, Group, Gray, R., Barnwell, J., McConkey, C., Hills, R. K., Williams, N. S., et.al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study, Lancet, 2007. 370(9604): p. 2020-9., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18083404, http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(07)61866-2/abstract
788. O'Connor, E. S., Greenblatt, D. Y., LoConte, N. K., Gangnon, R. E., Liou, J. I., Heise, C. P., et.al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features, J Clin Oncol, 2011. 29(25): p. 3381-8., http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3164243/pdf/zlj3381.pdf
789. Andre, T., de Gramont, A., Vernerey, D., Chibaudel, B., Bonnetain, F., Tijeras-Raballand, A., et.al. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study, J Clin Oncol, 2015. 33(35): p. 4176-87., http://jco.ascopubs.org/content/33/35/4176.long
790. Moertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., Tangen, C. M., et.al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer, J Clin Oncol, 1995. 13(12): p. 2936-43., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8523058
791. Taal, B. G., Van Tinteren, H., Zoetmulder, F. A., Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III, Br J Cancer, 2001. 85(10): p. 1437-43., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11720425, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363941/pdf/85-6692117a.pdf
792. Caplin, S., Cerottini, J. P., Bosman, F. T., Constanda, M. T., Givel, J. C., For patients with Dukes' B (TNM Stage II) colorectal carcinoma, examination of six or fewer lymph nodes is related to poor prognosis, Cancer, 1998. 83(4): p. 666-72., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9708929
793. Schrag, D., Rifas-Shiman, S., Saltz, L., Bach, P. B., Begg, C. B., Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer, J Clin Oncol, 2002. 20(19): p. 3999-4005., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12351597, http://jco.ascopubs.org/content/20/19/3999.long
794. Merkel, S., Wein, A., Gunther, K., Papadopoulos, T., Hohenberger, W., Hermanek, P., High-risk groups of patients with Stage II colon carcinoma, Cancer, 2001. 92(6): p. 1435-43., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11745220
795. Petersen, V. C., Baxter, K. J., Love, S. B., Shepherd, N. A., Identification of objective pathological prognostic determinants and models of prognosis in Dukes' B colon cancer, Gut, 2002. 51(1): p. 65-9., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12077094, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1773289/pdf/gut05100065.pdf
796. Morris, M., Platell, C., de Boer, B., McCaul, K., Iacopetta, B., Population-based study of prognostic factors in stage II colonic cancer, Br J Surg, 2006. 93(7): p. 866-71., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16622901, http://onlinelibrary.wiley.com/doi/10.1002/bjs.5345/abstract
797. Burdy, G., Panis, Y., Alves, A., Nemeth, J., Lavergne-Slove, A., Valleur, P., Identifying patients with T3-T4 node-negative colon cancer at high risk of recurrence, Dis Colon Rectum, 2001. 44(11): p. 1682-8., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11711742
798. Jestin, P., Nilsson, J., Heurgren, M., Pahlman, L., Glimelius, B., Gunnarsson, U., Emergency surgery for colonic cancer in a defined population, Br J Surg, 2005. 92(1): p. 94-100., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15521083, http://onlinelibrary.wiley.com/doi/10.1002/bjs.4780/abstract
799. McArdle, C. S., McMillan, D. C., Hole, D. J., The impact of blood loss, obstruction and perforation on survival in patients undergoing curative resection for colon cancer, Br J Surg, 2006. 93(4): p. 483-8., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16555262, http://onlinelibrary.wiley.com/doi/10.1002/bjs.5269/abstract
800. George, S., Primrose, J., Talbot, R., Smith, J., Mullee, M., Bailey, D., et.al. Will Rogers revisited: prospective observational study of survival of 3592 patients with colorectal cancer according to number of nodes examined by pathologists, Br J Cancer, 2006. 95(7): p. 841-7., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16969342, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360535/pdf/95-6603352a.pdf
801. Chen, S. L., Bilchik, A. J., More extensive nodal dissection improves survival for stages I to III of colon cancer: a population-based study, Ann Surg, 2006. 244(4): p. 602-10., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16998369, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1856560/pdf/20061000s00015p602.pdf
802. O'Connell, M. J., Mailliard, J. A., Kahn, M. J., Macdonald, J. S., Haller, D. G., Mayer, R. J., et.al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer, J Clin Oncol, 1997. 15(1): p. 246-50.
803. Sargent, D. J., Marsoni, S., Monges, G., Thibodeau, S. N., Labianca, R., Hamilton, S. R., et.al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer, J Clin Oncol, 2010. 28(20): p. 3219-26., http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2903323/pdf/zlj3219.pdf
804. Jover, R., Zapater, P., Castells, A., Llor, X., Andreu, M., Cubiella, J., et.al. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer, Gut, 2006. 55(6): p. 848-55., http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1856227/pdf/848.pdf
805. Kim, J. E., Hong, Y. S., Kim, H. J., Kim, K. P., Lee, J. L., Park, S. J., et.al. Defective Mismatch Repair Status was not Associated with DFS and OS in Stage II Colon Cancer Treated with Adjuvant Chemotherapy, Ann Surg Oncol, 2015. 22 Suppl 3: p. 630-7., http://link.springer.com/article/10.1245%2Fs10434-015-4807-6
806. Moertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., Goodman, P. J., et.al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma, N Engl J Med, 1990. 322(6): p. 352-8., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2300087, http://www.nejm.org/doi/pdf/10.1056/NEJM199002083220602
807. Compton, C., Fenoglio-Preiser, C. M., Pettigrew, N., Fielding, L. P., American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group, Cancer, 2000. 88(7): p. 1739-57., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10738234
808. Hermanek, P., Hutter, R. V., Sobin, L. H., Prognostic grouping: the next step in tumor classification, J Cancer Res Clin Oncol, 1990. 116(5): p. 513-6., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2229143
809. Klingbiel, D., Saridaki, Z., Roth, A. D., Bosman, F. T., Delorenzi, M., Tejpar, S., Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial, Ann Oncol, 2015. 26(1): p. 126-32., http://annonc.oxfordjournals.org/content/26/1/126.full.pdf
810. Lanza, G., Gafa, R., Santini, A., Maestri, I., Guerzoni, L., Cavazzini, L., Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients, J Clin Oncol, 2006. 24(15): p. 2359-67., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16710035, http://jco.ascopubs.org/content/24/15/2359.full.pdf
811. Sinicrope, F. A., Rego, R. L., Halling, K. C., Foster, N., Sargent, D. J., La Plant, B., et.al. Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients, Gastroenterology, 2006. 131(3): p. 729-37., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16952542, http://www.gastrojournal.org/article/S0016-5085(06)01234-0/pdf
812. Elsaleh, H., Iacopetta, B., Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma, Clin Colorectal Cancer, 2001. 1(2): p. 104-9., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12445368, http://www.clinical-colorectal-cancer.com/article/S1533-0028(11)70545-X/abstract
813. Thomas, M. L., Hewett, P. J., Ruszkiewicz, A. R., Moore, J. W., Clinicopathological predictors of benefit from adjuvant chemotherapy for stage C colorectal cancer: Microsatellite unstable cases benefit, Asia Pac J Clin Oncol, 2015. 11(4): p. 343-51., http://onlinelibrary.wiley.com/store/10.1111/ajco.12411/asset/ajco12411.pdf?v=1&t=ik43s60r&s=81fffb5b1f20a4ec6c2edc3d45197e3231ec9b1a
814. Baxter, NN, Kennedy, EB, Bergsland, E, Berlin, J, George, TJ, Gill, S, et.al. Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update., J Clin Oncol, 2022. 40 (8)(8): p. 892-910., https://pubmed.ncbi.nlm.nih.gov/34936379/
815. Dalerba, P., Sahoo, D., Paik, S., Guo, X., Yothers, G., Song, N., et.al. CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer, N Engl J Med, 2016. 374(3): p. 211-22., http://www.nejm.org/doi/pdf/10.1056/NEJMoa1506597
816. Tie, J., Wang, Y., Tomasetti, C., Li, L., Springer, S., Kinde, I., et.al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer, Sci Transl Med, 2016. 8(346): p. 346ra92., http://stm.sciencemag.org/content/8/346/346ra92
817. Turner, N., Wong, H. L., Templeton, A., Tripathy, S., Whiti Rogers, T., Croxford, M., et.al. Analysis of local chronic inflammatory cell infiltrate combined with systemic inflammation improves prognostication in stage II colon cancer independent of standard clinicopathologic criteria, Int J Cancer, 2016. 138(3): p. 671-8., http://onlinelibrary.wiley.com/doi/10.1002/ijc.29805/abstract
818. Andre, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J., Hickish, T., et.al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer, N Engl J Med, 2004. 350(23): p. 2343-51., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15175436, http://www.nejm.org/doi/pdf/10.1056/NEJMoa032709
819. Kuebler, J. P., Wieand, H. S., O'Connell, M. J., Smith, R. E., Colangelo, L. H., Yothers, G., et.al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07, J Clin Oncol, 2007. 25(16): p. 2198-204., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17470851, http://jco.ascopubs.org/content/25/16/2198.full.pdf
820. Kidwell, K. M., Yothers, G., Ganz, P. A., Land, S. R., Ko, C. Y., Cecchini, R. S., et.al. Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01, Cancer, 2012. 118(22): p. 5614-22., http://onlinelibrary.wiley.com/store/10.1002/cncr.27593/asset/27593_ftp.pdf?v=1&t=j27898it&s=0b111b798a9bba319dae3050ad35f7c7e45c02a6
821. de Gramont, A., Boni, C., Navarro, M., Tabernero, J., Hickish, T., Topham, C., et.al. Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years, Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition) Vol 25, No 18S (June 20 Supplement), 2007: 4007, 2007.
822. Schmoll, H. J., Twelves, C., Sun, W., O'Connell, M. J., Cartwright, T., McKenna, E., et.al. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials, Lancet Oncol, 2014. 15(13): p. 1481-92., http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4435787/pdf/nihms687271.pdf
823. Sanoff, HK, Carpenter, WR, Stürmer, T, Goldberg, RM, Martin, CF, Fine, JP, et.al. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years., J Clin Oncol, 2012. 30 (21)(21): p. 2624-34., https://pubmed.ncbi.nlm.nih.gov/22665536/
824. Yothers, G., O'Connell, M. J., Allegra, C. J., Kuebler, J. P., Colangelo, L. H., Petrelli, N. J., et.al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses, J Clin Oncol, 2011. 29(28): p. 3768-74., http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3188282/pdf/zlj3768.pdf
825. Lund, C. M., Nielsen, D., Dehlendorff, C., Christiansen, A. B., Ronholt, F., Johansen, J. S., et.al. Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colorectal cancer: the ACCORE study, ESMO Open, 2016. 1(5): p. e000087., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5115815/pdf/esmoopen-2016-000087.pdf
826. Sanoff, H. K., Carpenter, W. R., Sturmer, T., Goldberg, R. M., Martin, C. F., Fine, J. P., et.al. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years, J Clin Oncol, 2012. 30(21): p. 2624-34.
827. Kim, C. A., Spratlin, J. L., Armstrong, D. E., Ghosh, S., Mulder, K. E., Efficacy and safety of single agent or combination adjuvant chemotherapy in elderly patients with colon cancer: a Canadian cancer institute experience, Clin Colorectal Cancer, 2014. 13(3): p. 199-206.
828. Twelves, C., Wong, A., Nowacki, M. P., Abt, M., Burris, H., 3rd, Carrato, A., et.al. Capecitabine as adjuvant treatment for stage III colon cancer, N Engl J Med, 2005. 352(26): p. 2696-704., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15987918, http://www.nejm.org/doi/pdf/10.1056/NEJMoa043116
829. Andre, T., Quinaux, E., Louvet, C., Gamelin, E., Bouche, O., Achille, E., et.al. Updated results at 6 year of the GERCOR C96.1 phase III study comparing LV5FU2 to monthly 5FU-leucovorin (mFufol) as adjuvant treatment for Dukes B2 and C colon cancer patients, Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No 16S (June 1 Supplement), 2005: 3522, 2005.
830. Carrato, A., Köhne, C., Bedenne, L., Popov, I., Bouche, O., Gaspar, E., et.al. Folinic acid modulated bolus 5-FU or infusional 5-FU for adjuvant treatment of patients of UICC stage III colon cancer: Preliminary analysis of the PETACC-2-study, Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 24, No 18S (June 20 Supplement), 2006: 3563, 2006.
831. Andre, T., Colin, P., Louvet, C., Gamelin, E., Bouche, O., Achille, E., et.al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial, J Clin Oncol, 2003. 21(15): p. 2896-903., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12885807, http://jco.ascopubs.org/content/21/15/2896.long
832. Arkenau, H. T., Rettig, K., Porschen, R., Adjuvant chemotherapy in curative resected colon carcinoma: 5-fluorouracil/leucovorin versus high-dose 5-fluorouracil 24-h infusion/leucovorin versus high-dose 5-fluorouracil 24-h infusion, Int J Colorectal Dis, 2005. 20(3): p. 258-61., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15549327, http://link.springer.com/article/10.1007%2Fs00384-004-0657-6
833. Chau, I., Norman, A. R., Cunningham, D., Tait, D., Ross, P. J., Iveson, T., et.al. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer, Ann Oncol, 2005. 16(4): p. 549-57., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15695501, http://annonc.oxfordjournals.org/content/16/4/549.full.pdf
834. Lembersky, B. C., Wieand, H. S., Petrelli, N. J., O'Connell, M. J., Colangelo, L. H., Smith, R. E., et.al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06, J Clin Oncol, 2006. 24(13): p. 2059-64., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16648506, http://jco.ascopubs.org/content/24/13/2059.full.pdf
835. Sakamoto, J., Ohashi, Y., Hamada, C., Buyse, M., Burzykowski, T., Piedbois, P., Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials, J Clin Oncol, 2004. 22(3): p. 484-92., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14752071, http://jco.ascopubs.org/content/22/3/484.full.pdf
836. Poplin, E. A., Benedetti, J. K., Estes, N. C., Haller, D. G., Mayer, R. J., Goldberg, R. M., et.al. Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer, J Clin Oncol, 2005. 23(9): p. 1819-25., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15774775, http://jco.ascopubs.org/content/23/9/1819.full.pdf
837. O'Connell, M. J., Laurie, J. A., Kahn, M., Fitzgibbons, R. J., Jr., Erlichman, C., Shepherd, L., et.al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer, J Clin Oncol, 1998. 16(1): p. 295-300.
838. Haller, D. G., Catalano, P. J., Macdonald, J. S., O'Rourke, M. A., Frontiera, M. S., Jackson, D. V., et.al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089, J Clin Oncol, 2005. 23(34): p. 8671-8.
839. Van Cutsem, E., Labianca, R., Bodoky, G., Barone, C., Aranda, E., Nordlinger, B., et.al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3, J Clin Oncol, 2009. 27(19): p. 3117-25., http://jco.ascopubs.org/content/27/19/3117.full.pdf
840. Ychou, M., Raoul, J. L., Douillard, J. Y., Gourgou-Bourgade, S., Bugat, R., Mineur, L., et.al. A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802), Ann Oncol, 2009. 20(4): p. 674-80., http://annonc.oxfordjournals.org/content/20/4/674.full.pdf
841. Saltz, L. B., Niedzwiecki, D., Hollis, D., Goldberg, R. M., Hantel, A., Thomas, J. P., et.al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803, J Clin Oncol, 2007. 25(23): p. 3456-61., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17687149, http://jco.ascopubs.org/content/25/23/3456.full.pdf
842. Alberts, S. R., Sargent, D. J., Nair, S., Mahoney, M. R., Mooney, M., Thibodeau, S. N., et.al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial, JAMA, 2012. 307(13): p. 1383-93., http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3442260/pdf/nihms402124.pdf
843. Taieb, J., Tabernero, J., Mini, E., Subtil, F., Folprecht, G., Van Laethem, J. L., et.al. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial, Lancet Oncol, 2014. 15(8): p. 862-73., http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70227-X/abstract
844. Allegra, C. J., Yothers, G., O'Connell, M. J., Sharif, S., Petrelli, N. J., Lopa, S. H., et.al. Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial, J Clin Oncol, 2013. 31(3): p. 359-64., http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3732014/pdf/zlj359.pdf
845. de Gramont, A., Van Cutsem, E., Schmoll, H. J., Tabernero, J., Clarke, S., Moore, M. J., et.al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial, Lancet Oncol, 2012. 13(12): p. 1225-33., http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70509-0/abstract
846. Kerr, R. S., Love, S., Segelov, E., Johnstone, E., Falcon, B., Hewett, P., et.al. Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial, Lancet Oncol, 2016. 17(11): p. 1543-1557.
847. Amlani, A., Kumar, A., Ruan, J. Y., Cheung, W. Y., Compliance with adjuvant capecitabine in patients with stage II and III colon cancer: comparison of administrative versus medical record data, Cancer Med, 2016. 5(8): p. 1776-82., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4884630/pdf/CAM4-5-1776.pdf
848. Grothey, A, Sobrero, AF, Shields, AF, Yoshino, T, Paul, J, Taieb, J, et.al. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer., N Engl J Med, 2018. 378 (13)(13): p. 1177-1188., https://pubmed.ncbi.nlm.nih.gov/29590544/
849. André, T, Vernerey, D, Mineur, L, Bennouna, J, Desrame, J, Faroux, R, et.al. Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial., J Clin Oncol, 2018. 36 (15)(15): p. 1469-1477., https://pubmed.ncbi.nlm.nih.gov/29620995/
850. Sobrero, A, Lonardi, S, Rosati, G, Di Bartolomeo, M, Ronzoni, M, Pella, N, et.al. FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial., J Clin Oncol, 2018. 36 (15)(15): p. 1478-1485., https://pubmed.ncbi.nlm.nih.gov/29620994/
851. Iveson, TJ, Kerr, RS, Saunders, MP, Cassidy, J, Hollander, NH, Tabernero, J, et.al. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial., Lancet Oncol, 2018. 19 (4)(4): p. 562-578., https://pubmed.ncbi.nlm.nih.gov/29611518/
852. Shi, Qian, Sobrero, Alberto F., Shields, Anthony Frank, Yoshino, Takayuki, Paul, James, Taieb, Julien, et.al. Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration.Wolters Kluwer, Journal of Clinical Oncology 35(18_suppl): p. LBA1 - LBA1., https://doi.org/10.1200/JCO.2017.35.18_suppl.LBA1
853. Grothey, A., Sobrero, A. F., Shields, A. F., Yoshino, T., Paul, J., Taieb, J., et.al. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer, N Engl J Med, 2018. 378(13): p. 1177-1188.
854. André, T, Meyerhardt, J, Iveson, T, Sobrero, A, Yoshino, T, Souglakos, I, et.al. Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials., Lancet Oncol, 2020. 21 (12)(12): p. 1620-1629., https://pubmed.ncbi.nlm.nih.gov/33271092/
855. Andre, T., Vernerey, D., Mineur, L., Bennouna, J., Desrame, J., Faroux, R., et.al. Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial, J Clin Oncol, 2018. 36(15): p. 1469-1477.
856. Sobrero, A., Lonardi, S., Rosati, G., Di Bartolomeo, M., Ronzoni, M., Pella, N., et.al. FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial, J Clin Oncol, 2018. 36(15): p. 1478-1485.
857. Iveson, T. J., Kerr, R. S., Saunders, M. P., Cassidy, J., Hollander, N. H., Tabernero, J., et.al. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial, Lancet Oncol, 2018. 19(4): p. 562-578.
858. Sobrero, A., Grothey, A., Iveson, T., Labianca, R., Yoshino, T., Taieb, J., et.al. The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?, Ann Oncol, 2018. 29(5): p. 1099-1107.
859. Hwang, In Gyu, Lee, Ji Sung, Lee, Sang-Cheol, Baek, Sun Kyung, Kim, Jong Gwang, Kim, Tae Won, Association between timing and duration of adjuvant chemotherapy and survival for colorectal cancer in korea, 2011-2014: A nationwide study based on the database of quality assessment and the health insurance, Journal of Clinical Oncology, 2017. 35(15_suppl): p. 3605-3605., http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.3605
860. Karoui, M, Gallois, C, Piessen, G, Legoux, JL, Barbier, E, De Chaisemartin, C, et.al. Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high-risk Stage II and III colon cancers? Three years' follow-up results of the PRODIGE 22 phase II randomized multicentre trial., Colorectal Dis, 2021. 23 (6)(6): p. 1357-1369., https://pubmed.ncbi.nlm.nih.gov/33580623/
861. Morton, D, Seymour, M, Magill, L, Handley, K, Glasbey, J, Glimelius, B, et.al. Preoperative Chemotherapy for Operable Colon Cancer: Mature Results of an International Randomized Controlled Trial., J Clin Oncol, 2023. 41 (8)(8): p. 1541-1552., https://pubmed.ncbi.nlm.nih.gov/36657089/
862. Kamel, MK, Al-Qudah, G, Shchatsko, A, Keane, CA, Serpa, E, Nituica, C, et.al. Robotic Approach is Associated With a Lower Conversion Rate Compared to Laparoscopic Approach for Patients Undergoing Colectomy for T4b Colon Cancer. An Analysis of the National Cancer Database., Surg Innov, 2023. 30 (2)(2): p. 193-200., https://pubmed.ncbi.nlm.nih.gov/36069752/
863. Chalabi, M, Verschoor, YL, Tan, PB, Balduzzi, S, Van Lent, AU, Grootscholten, C, et.al. Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer., N Engl J Med, 2024. 390 (21)(21): p. 1949-1958., https://pubmed.ncbi.nlm.nih.gov/38838311/
864. Zhou, L, Yang, XQ, Zhao, GY, Wang, FJ, Liu, X, Meta-analysis of neoadjuvant immunotherapy for non-metastatic colorectal cancer., Front Immunol, 2023. 14 (): p. 1044353., https://pubmed.ncbi.nlm.nih.gov/36776899/
865. Wittekind C, TNM Supplement: A Commentary on Uniform Use, 2019.
866. D'Souza, N, Lord, A, Shaw, A, Patel, A, Balyasnikova, S, Tudyka, V, et.al. The sigmoid take-off: An anatomical imaging definition of the rectum validated on specimen analysis., Eur J Surg Oncol, 2020. 46 (9)(9): p. 1668-1672., https://pubmed.ncbi.nlm.nih.gov/32061459/
867. Borstlap, WA, Coeymans, TJ, Tanis, PJ, Marijnen, CA, Cunningham, C, Bemelman, WA, et.al. Meta-analysis of oncological outcomes after local excision of pT1-2 rectal cancer requiring adjuvant (chemo)radiotherapy or completion surgery., Br J Surg, 2016. 103 (9)(9): p. 1105-16., https://pubmed.ncbi.nlm.nih.gov/27302385/
868. van Oostendorp, SE, Belgers, HJ, Bootsma, BT, Hol, JC, Belt, EJTH, Bleeker, W, et.al. Locoregional recurrences after transanal total mesorectal excision of rectal cancer during implementation., Br J Surg, 2020. 107 (9)(9): p. 1211-1220., https://pubmed.ncbi.nlm.nih.gov/32246472/
869. Verseveld, M., de Graaf, E. J., Verhoef, C., van Meerten, E., Punt, C. J., de Hingh, I. H., et.al. Chemoradiation therapy for rectal cancer in the distal rectum followed by organ-sparing transanal endoscopic microsurgery (CARTS study), Br J Surg, 2015. 102(7): p. 853-60., http://onlinelibrary.wiley.com/doi/10.1002/bjs.9809/abstract
870. Stijns, RCH, de Graaf, EJR, Punt, CJA, Nagtegaal, ID, Nuyttens, JJME, van Meerten, E, et.al. Long-term Oncological and Functional Outcomes of Chemoradiotherapy Followed by Organ-Sparing Transanal Endoscopic Microsurgery for Distal Rectal Cancer: The CARTS Study., JAMA Surg, 2019. 154 (1)(1): p. 47-54., https://pubmed.ncbi.nlm.nih.gov/30304338/
871. Bach, SP, Gilbert, A, Brock, K, Korsgen, S, Geh, I, Hill, J, et.al. Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open-label feasibility study., Lancet Gastroenterol Hepatol, 2021. 6 (2)(2): p. 92-105., https://pubmed.ncbi.nlm.nih.gov/33308452/
872. Taylor, FG, Quirke, P, Heald, RJ, Moran, B, Blomqvist, L, Swift, I, et.al. Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study., Ann Surg, 2011. 253 (4)(4): p. 711-9., https://pubmed.ncbi.nlm.nih.gov/21475011/
873. Ruppert, R, Junginger, T, Kube, R, Strassburg, J, Lewin, A, Baral, J, et.al. Risk-Adapted Neoadjuvant Chemoradiotherapy in Rectal Cancer: Final Report of the OCUM Study., J Clin Oncol, 2023. 41 (24)(24): p. 4025-4034., https://pubmed.ncbi.nlm.nih.gov/37335957/
874. Schrag, D, Shi, Q, Weiser, MR, Gollub, MJ, Saltz, LB, Musher, BL, et.al. Preoperative Treatment of Locally Advanced Rectal Cancer., N Engl J Med, 2023. 389 (4)(4): p. 322-334., https://pubmed.ncbi.nlm.nih.gov/37272534/
875. Basch, E, Dueck, AC, Mitchell, SA, Mamon, H, Weiser, M, Saltz, L, et.al. Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048)., J Clin Oncol, 2023. 41 (21)(21): p. 3724-3734., https://pubmed.ncbi.nlm.nih.gov/37270691/
876. Mei, WJ, Wang, XZ, Li, YF, Sun, YM, Yang, CK, Lin, JZ, et.al. Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Initial Results of a Phase III Trial., Ann Surg, 2023. 277 (4)(4): p. 557-564., https://pubmed.ncbi.nlm.nih.gov/36538627/
877. Ding, PR, Application of Molecular Profiling in Colorectal Cancer Surgery., Clin Colon Rectal Surg, 2023. 36 (6)(6): p. 367-368., https://pubmed.ncbi.nlm.nih.gov/37795467/
878. Rullier, E, Rouanet, P, Tuech, JJ, Valverde, A, Lelong, B, Rivoire, M, et.al. Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trial., Lancet, 2017. 390 (10093)(10093): p. 469-479., https://pubmed.ncbi.nlm.nih.gov/28601342/
879. Rullier, E, Vendrely, V, Asselineau, J, Rouanet, P, Tuech, JJ, Valverde, A, et.al. Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trial., Lancet Gastroenterol Hepatol, 2020. 5 (5)(5): p. 465-474., https://pubmed.ncbi.nlm.nih.gov/32043980/
880. Serra-Aracil, X, Pericay, C, Badia-Closa, J, Golda, T, Biondo, S, Hernández, P, et.al. Short-term outcomes of chemoradiotherapy and local excision versus total mesorectal excision in T2-T3ab,N0,M0 rectal cancer: a multicentre randomised, controlled, phase III trial (the TAU-TEM study)., Ann Oncol, 2023. 34 (1)(1): p. 78-90., https://pubmed.ncbi.nlm.nih.gov/36220461/
881. Lynch, P, Ryan, OK, Donnelly, M, Ryan, ÉJ, Davey, MG, Reynolds, IS, et.al. Comparing neoadjuvant therapy followed by local excision to total mesorectal excision in the treatment of early stage rectal cancer: a systematic review and meta-analysis of randomised clinical trials., Int J Colorectal Dis, 2023. 38 (1)(1): p. 263., https://pubmed.ncbi.nlm.nih.gov/37924372/
882. Habr-Gama, A., Perez, R. O., Nadalin, W., Sabbaga, J., Ribeiro, U., Jr., Silva e Sousa, A. H., Jr., et.al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results, Ann Surg, 2004. 240(4): p. 711-7; discussion 717-8., http://www.ncbi.nlm.nih.gov/pubmed/15383798
883. Renehan, AG, Malcomson, L, Emsley, R, Gollins, S, Maw, A, Myint, AS, et.al. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis., Lancet Oncol, 2016. 17 (2)(2): p. 174-183., https://pubmed.ncbi.nlm.nih.gov/26705854/
884. van der Valk, MJM, Hilling, DE, Bastiaannet, E, Meershoek-Klein Kranenbarg, E, Beets, GL, Figueiredo, NL, et.al. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study., Lancet, 2018. 391 (10139)(10139): p. 2537-2545., https://pubmed.ncbi.nlm.nih.gov/29976470/
885. Fernandez, LM, São Julião, GP, Figueiredo, NL, Beets, GL, van der Valk, MJM, Bahadoer, RR, et.al. Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait Database: a retrospective, international, multicentre registry study., Lancet Oncol, 2021. 22 (1)(1): p. 43-50., https://pubmed.ncbi.nlm.nih.gov/33316218/
886. Temmink, SJD, Peeters, KCMJ, Bahadoer, RR, Kranenbarg, EM, Roodvoets, AGH, Melenhorst, J, et.al. Watch and wait after neoadjuvant treatment in rectal cancer: comparison of outcomes in patients with and without a complete response at first reassessment in the International Watch & Wait Database (IWWD)., Br J Surg, 2023. 110 (6)(6): p. 676-684., https://pubmed.ncbi.nlm.nih.gov/36972213/
887. Fernandez, LM, São Julião, GP, Renehan, AG, Beets, GL, Papoila, AL, Vailati, BB, et.al. The Risk of Distant Metastases in Patients With Clinical Complete Response Managed by Watch and Wait After Neoadjuvant Therapy for Rectal Cancer: The Influence of Local Regrowth in the International Watch and Wait Database., Dis Colon Rectum, 2023. 66 (1)(1): p. 41-49., https://pubmed.ncbi.nlm.nih.gov/36515514/
888. Dossa, F, Chesney, TR, Acuna, SA, Baxter, NN, A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis., Lancet Gastroenterol Hepatol, 2017. 2 (7)(7): p. 501-513., https://pubmed.ncbi.nlm.nih.gov/28479372/
889. Dattani, M, Heald, RJ, Goussous, G, Broadhurst, J, São Julião, GP, Habr-Gama, A, et.al. Oncological and Survival Outcomes in Watch and Wait Patients With a Clinical Complete Response After Neoadjuvant Chemoradiotherapy for Rectal Cancer: A Systematic Review and Pooled Analysis., Ann Surg, 2018. 268 (6)(6): p. 955-967., https://pubmed.ncbi.nlm.nih.gov/29746338/
890. Zhang, X, Ding, R, Li, J, Wu, T, Shen, Z, Li, S, et.al. Efficacy and safety of the "watch-and-wait" approach for rectal cancer with clinical complete response after neoadjuvant chemoradiotherapy: a meta-analysis., Surg Endosc, 2022. 36 (4)(4): p. 2233-2244., https://pubmed.ncbi.nlm.nih.gov/34981233/
891. Hupkens, BJP, Martens, MH, Stoot, JH, Berbee, M, Melenhorst, J, Beets-Tan, RG, et.al. Quality of Life in Rectal Cancer Patients After Chemoradiation: Watch-and-Wait Policy Versus Standard Resection - A Matched-Controlled Study., Dis Colon Rectum, 2017. 60 (10)(10): p. 1032-1040., https://pubmed.ncbi.nlm.nih.gov/28891846/
892. Custers, PA, van der Sande, ME, Grotenhuis, BA, Peters, FP, van Kuijk, SMJ, Beets, GL, et.al. Long-term Quality of Life and Functional Outcome of Patients With Rectal Cancer Following a Watch-and-Wait Approach., JAMA Surg, 2023. 158 (5)(5): p. e230146., https://pubmed.ncbi.nlm.nih.gov/36988922/
893. Appelt, AL, Pløen, J, Harling, H, Jensen, FS, Jensen, LH, Jørgensen, JC, et.al. High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study., Lancet Oncol, 2015. 16 (8)(8): p. 919-27., https://pubmed.ncbi.nlm.nih.gov/26156652/
894. Gerard, JP, Barbet, N, Schiappa, R, Magné, N, Martel, I, Mineur, L, et.al. Neoadjuvant chemoradiotherapy with radiation dose escalation with contact x-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2-cT3 rectal adenocarcinoma (OPERA): a phase 3, randomised controlled trial., Lancet Gastroenterol Hepatol, 2023. 8 (4)(4): p. 356-367., https://pubmed.ncbi.nlm.nih.gov/36801007/
895. Garcia-Aguilar, J, Patil, S, Gollub, MJ, Kim, JK, Yuval, JB, Thompson, HM, et.al. Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy., J Clin Oncol, 2022. 40 (23)(23): p. 2546-2556., https://pubmed.ncbi.nlm.nih.gov/35483010/
896. Verheij, FS, Omer, DM, Williams, H, Lin, ST, Qin, LX, Buckley, JT, et.al. Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial., J Clin Oncol, 2024. 42 (5)(5): p. 500-506., https://pubmed.ncbi.nlm.nih.gov/37883738/
897. Bahadoer, RR, Dijkstra, EA, van Etten, B, Marijnen, CAM, Putter, H, Kranenbarg, EM, et.al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial., Lancet Oncol, 2021. 22 (1)(1): p. 29-42., https://pubmed.ncbi.nlm.nih.gov/33301740/
898. Dijkstra, EA, Nilsson, PJ, Hospers, GAP, Bahadoer, RR, Meershoek-Klein Kranenbarg, E, Roodvoets, AGH, et.al. Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery: A 5-Year Follow-up of the RAPIDO Trial., Ann Surg, 2023. 278 (4)(4): p. e766-e772., https://pubmed.ncbi.nlm.nih.gov/36661037/
899. Conroy, T, Bosset, JF, Etienne, PL, Rio, E, François, É, Mesgouez-Nebout, N, et.al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial., Lancet Oncol, 2021. 22 (5)(5): p. 702-715., https://pubmed.ncbi.nlm.nih.gov/33862000/
900. Xiong, K, Bao, T, Cao, Y, Hu, W, Deng, J, Chen, J, et.al. Efficacy and safety of total neoadjuvant therapy in locally advanced rectal cancer: a meta-analysis., Int J Colorectal Dis, 2023. 38 (1)(1): p. 89., https://pubmed.ncbi.nlm.nih.gov/37004572/
901. Jin, J, Tang, Y, Hu, C, Jiang, LM, Jiang, J, Li, N, et.al. Multicenter, Randomized, Phase III Trial of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR)., J Clin Oncol, 2022. 40 (15)(15): p. 1681-1692., https://pubmed.ncbi.nlm.nih.gov/35263150/
902. Ciseł, B, Pietrzak, L, Michalski, W, Wyrwicz, L, Rutkowski, A, Kosakowska, E, et.al. Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study., Ann Oncol, 2019. 30 (8)(8): p. 1298-1303., https://pubmed.ncbi.nlm.nih.gov/31192355/
903. Conroy, T, Castan, F, Etienne, PL, Rio, E, Mesgouez-Nebout, N, Evesque, L, et.al. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial., Ann Oncol, 2024. 35 (10)(10): p. 873-881., https://pubmed.ncbi.nlm.nih.gov/38986769/
904. Peeters, K. C., Marijnen, C. A., Nagtegaal, I. D., Kranenbarg, E. K., Putter, H., Wiggers, T., et.al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma, Ann Surg, 2007. 246(5): p. 693-701., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17968156
905. Cedermark, B, Dahlberg, M, Glimelius, B, Påhlman, L, Rutqvist, LE, Wilking, N, Improved survival with preoperative radiotherapy in resectable rectal cancer., N Engl J Med, 1997. 336 (14)(14): p. 980-7., https://pubmed.ncbi.nlm.nih.gov/9091798/
906. Peeters, K. C., Marijnen, C. A., Nagtegaal, I. D., Kranenbarg, E. K., Putter, H., Wiggers, T., et.al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma, Ann Surg, 2007. 246(5): p. 693-701.
907. Sauer, R., Becker, H., Hohenberger, W., Rodel, C., Wittekind, C., Fietkau, R., et.al. Preoperative versus postoperative chemoradiotherapy for rectal cancer, N Engl J Med, 2004. 351(17): p. 1731-40., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15496622, http://www.nejm.org/doi/pdf/10.1056/NEJMoa040694
908. Schrag, D, Shi, Q, Weiser, MR, Gollub, MJ, Saltz, LB, Musher, BL, et.al. Preoperative Treatment of Locally Advanced Rectal Cancer., N Engl J Med, 2023. 389 (4)(4): p. 322-334., https://pubmed.ncbi.nlm.nih.gov/37272534/
909. Ngan, SY, Burmeister, B, Fisher, RJ, Solomon, M, Goldstein, D, Joseph, D, et.al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04., J Clin Oncol, 2012. 30 (31)(31): p. 3827-33., https://pubmed.ncbi.nlm.nih.gov/23008301/
910. Bujko, K., Nowacki, M. P., Nasierowska-Guttmejer, A., Michalski, W., Bebenek, M., Pudelko, M., et.al. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy, Radiother Oncol, 2004. 72(1): p. 15-24., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15236870, http://www.thegreenjournal.com/article/S0167-8140(04)00004-0/abstract
911. Bujko, K., Nowacki, M. P., Nasierowska-Guttmejer, A., Michalski, W., Bebenek, M., Kryj, M., Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer, Br J Surg, 2006. 93(10): p. 1215-23., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16983741, http://onlinelibrary.wiley.com/doi/10.1002/bjs.5506/abstract
912. Pietrzak, L, Bujko, K, Nowacki, MP, Kepka, L, Oledzki, J, Rutkowski, A, et.al. Quality of life, anorectal and sexual functions after preoperative radiotherapy for rectal cancer: report of a randomised trial., Radiother Oncol, 2007. 84 (3)(3): p. 217-25., https://pubmed.ncbi.nlm.nih.gov/17692977/
913. McLachlan, S. A., Fisher, R. J., Zalcberg, J., Solomon, M., Burmeister, B., Goldstein, D., et.al. The impact on health-related quality of life in the first 12 months: A randomised comparison of preoperative short-course radiation versus long-course chemoradiation for T3 rectal cancer (Trans-Tasman Radiation Oncology Group Trial 01.04), Eur J Cancer, 2016. 55: p. 15-26., http://www.ejcancer.com/article/S0959-8049(15)01017-5/fulltext
914. Pettersson, D., Cedermark, B., Holm, T., Radu, C., Pahlman, L., Glimelius, B., et.al. Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer, Br J Surg, 2010. 97(4): p. 580-7., http://onlinelibrary.wiley.com/doi/10.1002/bjs.6914/abstract
915. Erlandsson, J, Holm, T, Pettersson, D, Berglund, Å, Cedermark, B, Radu, C, et.al. Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial., Lancet Oncol, 2017. 18 (3)(3): p. 336-346., https://pubmed.ncbi.nlm.nih.gov/28190762/
916. Allegra, CJ, Yothers, G, O'Connell, MJ, Beart, RW, Wozniak, TF, Pitot, HC, et.al. Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial., J Natl Cancer Inst, 2015. 107 (11)(11):, https://pubmed.ncbi.nlm.nih.gov/26374429/
917. Fiorica, F, Cartei, F, Licata, A, Enea, M, Ursino, S, Colosimo, C, et.al. Can chemotherapy concomitantly delivered with radiotherapy improve survival of patients with resectable rectal cancer? A meta-analysis of literature data., Cancer Treat Rev, 2010. 36 (7)(7): p. 539-49., https://pubmed.ncbi.nlm.nih.gov/20334979/
918. Hofheinz, RD, Wenz, F, Post, S, Matzdorff, A, Laechelt, S, Hartmann, JT, et.al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial., Lancet Oncol, 2012. 13 (6)(6): p. 579-88., https://pubmed.ncbi.nlm.nih.gov/22503032/
919. O'Connell, MJ, Colangelo, LH, Beart, RW, Petrelli, NJ, Allegra, CJ, Sharif, S, et.al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04., J Clin Oncol, 2014. 32 (18)(18): p. 1927-34., https://pubmed.ncbi.nlm.nih.gov/24799484/
920. Ceelen, WP, Van Nieuwenhove, Y, Fierens, K, Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer., Cochrane Database Syst Rev, 2009. (1)(1): p. CD006041., https://pubmed.ncbi.nlm.nih.gov/19160264/
921. Gerard, J. P., Conroy, T., Bonnetain, F., Bouche, O., Chapet, O., Closon-Dejardin, M. T., et.al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203, J Clin Oncol, 2006. 24(28): p. 4620-5.
922. Bosset, J. F., Calais, G., Mineur, L., Maingon, P., Stojanovic-Rundic, S., Bensadoun, R. J., et.al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study, Lancet Oncol, 2014. 15(2): p. 184-90.
923. Ceelen, W. P., Van Nieuwenhove, Y., Fierens, K., Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer, Cochrane Database Syst Rev, 2009. p. Cd006041.
924. Fiorica, F., Cartei, F., Licata, A., Enea, M., Ursino, S., Colosimo, C., et.al. Can chemotherapy concomitantly delivered with radiotherapy improve survival of patients with resectable rectal cancer? A meta-analysis of literature data, Cancer Treat Rev, 2010. 36(7): p. 539-49.
925. Hofheinz, R. D., Wenz, F., Post, S., Matzdorff, A., Laechelt, S., Hartmann, J. T., et.al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial, Lancet Oncol, 2012. 13(6): p. 579-88.
926. Allegra, C. J., Yothers, G., O'Connell, M. J., Beart, R. W., Wozniak, T. F., Pitot, H. C., et.al. Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial, J Natl Cancer Inst, 2015. 107(11):
927. Gerard, J. P., Azria, D., Gourgou-Bourgade, S., Martel-Lafay, I., Hennequin, C., Etienne, P. L., et.al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer, J Clin Oncol, 2012. 30(36): p. 4558-65.
928. Aschele, C, Cionini, L, Lonardi, S, Pinto, C, Cordio, S, Rosati, G, et.al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial., J Clin Oncol, 2011. 29 (20)(20): p. 2773-80., https://pubmed.ncbi.nlm.nih.gov/21606427/
929. Rödel, C, Graeven, U, Fietkau, R, Hohenberger, W, Hothorn, T, Arnold, D, et.al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial., Lancet Oncol, 2015. 16 (8)(8): p. 979-89., https://pubmed.ncbi.nlm.nih.gov/26189067/
930. Schmoll, HJ, Stein, A, Van Cutsem, E, Price, T, Hofheinz, RD, Nordlinger, B, et.al. Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD., J Clin Oncol, 2021. 39 (1)(1): p. 17-29., https://pubmed.ncbi.nlm.nih.gov/33001764/
931. Des Guetz, G, Landre, T, Bollet, MA, Mathonnet, M, Quéro, L, Is There a Benefit of Oxaliplatin in Combination with Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer? An Updated Meta-Analysis., Cancers (Basel), 2021. 13 (23)(23):, https://pubmed.ncbi.nlm.nih.gov/34885147/
932. Hofheinz, RD, Arnold, D, Fokas, E, Kaufmann, M, Hothorn, T, Folprecht, G, et.al. Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: a post hoc analysis of the CAO/ARO/AIO-04 phase III trial., Ann Oncol, 2018. 29 (8)(8): p. 1793-1799., https://pubmed.ncbi.nlm.nih.gov/29873684/
933. Fontana, Elisa, Zichi, Clizia, Smyth, Elizabeth Catherine, Mauer, Murielle E., Roedel, Claus, Fokas, Emmanouil, et.al. Neoadjuvant chemoradiation (CRT) for locally advanced rectal cancer (LARC) with or without oxaliplatin (OX): Individual patient data (IPD) meta-analysis of three randomized controlled trials (RCTs) with subgroup analyses of age cohorts.Wolters Kluwer, Journal of Clinical Oncology 38(15_suppl): p. 4074 - 4074., https://doi.org/10.1200/JCO.2020.38.15_suppl.4074
934. Fokas, E, Allgäuer, M, Polat, B, Klautke, G, Grabenbauer, GG, Fietkau, R, et.al. Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12., J Clin Oncol, 2019. 37 (34)(34): p. 3212-3222., https://pubmed.ncbi.nlm.nih.gov/31150315/
935. Fokas, E, Schlenska-Lange, A, Polat, B, Klautke, G, Grabenbauer, GG, Fietkau, R, et.al. Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial., JAMA Oncol, 2022. 8 (1)(1): p. e215445., https://pubmed.ncbi.nlm.nih.gov/34792531/
936. Cercek, Andrea, Sinopoli, Jenna Cohen, Shia, Jinru, Weiss, Jill A., Temple, Lindsay, Smith, Jesse Joshua, et.al. Durable complete responses to PD-1 blockade alone in mismatch repair deficient locally advanced rectal cancer.Wolters Kluwer, Journal of Clinical Oncology, 2024. 42(17_suppl): p. LBA3512 - LBA3512., https://doi.org/10.1200/JCO.2024.42.17_suppl.LBA3512
937. Bosset, JF, Calais, G, Mineur, L, Maingon, P, Stojanovic-Rundic, S, Bensadoun, RJ, et.al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study., Lancet Oncol, 2014. 15 (2)(2): p. 184-90., https://pubmed.ncbi.nlm.nih.gov/24440473/
938. Sainato, A., Cernusco Luna Nunzia, V., Valentini, V., De Paoli, A., Maurizi, E. R., Lupattelli, M., et.al. No benefit of adjuvant Fluorouracil Leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): Long term results of a randomized trial (I-CNR-RT), Radiother Oncol, 2014. 113(2): p. 223-9.
939. Glynne-Jones, R., Counsell, N., Quirke, P., Mortensen, N., Maraveyas, A., Meadows, H. M., et.al. Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control, Ann Oncol, 2014. 25(7): p. 1356-62., https://academic.oup.com/annonc/article/25/7/1356/2801207
940. Breugom, A. J., van Gijn, W., Muller, E. W., Berglund, A., van den Broek, C. B., Fokstuen, T., et.al. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial, Ann Oncol, 2015. 26(4): p. 696-701., https://academic.oup.com/annonc/article/26/4/696/203767
941. Glynne-Jones, R, Counsell, N, Quirke, P, Mortensen, N, Maraveyas, A, Meadows, HM, et.al. Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control., Ann Oncol, 2014. 25 (7)(7): p. 1356-1362., https://pubmed.ncbi.nlm.nih.gov/24718885/
942. Breugom, AJ, Swets, M, Bosset, JF, Collette, L, Sainato, A, Cionini, L, et.al. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data., Lancet Oncol, 2015. 16 (2)(2): p. 200-7., https://pubmed.ncbi.nlm.nih.gov/25589192/
943. Hong, YS, Kim, SY, Lee, JS, Nam, BH, Kim, KP, Kim, JE, et.al. Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial., J Clin Oncol, 2019. 37 (33)(33): p. 3111-3123., https://pubmed.ncbi.nlm.nih.gov/31593484/
944. van Gijn, W., Marijnen, C. A., Nagtegaal, I. D., Kranenbarg, E. M., Putter, H., Wiggers, T., et.al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial, Lancet Oncol, 2011. 12(6): p. 575-82.
945. Petersen, SH, Harling, H, Kirkeby, LT, Wille-Jørgensen, P, Mocellin, S, Postoperative adjuvant chemotherapy in rectal cancer operated for cure., Cochrane Database Syst Rev, 2012. 2012 (3)(3): p. CD004078., https://pubmed.ncbi.nlm.nih.gov/22419291/
946. Meulendijks, D., Henricks, L. M., Sonke, G. S., Deenen, M. J., Froehlich, T. K., Amstutz, U., et.al. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data, Lancet Oncol, 2015. 16(16): p. 1639-50.
947. Wörmann, B, Bokemeyer, C, Burmeister, T, Köhne, CH, Schwab, M, Arnold, D, et.al. Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper., Oncol Res Treat, 2020. 43 (11)(11): p. 628-636., https://pubmed.ncbi.nlm.nih.gov/33099551/
948. Hulshof, EC, Deenen, MJ, Nijenhuis, M, Soree, B, de Boer-Veger, NJ, Buunk, AM, et.al. Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction between UGT1A1 and irinotecan., Eur J Hum Genet, 2023. 31 (9)(9): p. 982-987., https://pubmed.ncbi.nlm.nih.gov/36443464/
949. Rote Hand Brief 21.12.21, 2021.
950. Ruers, T, Van Coevorden, F, Punt, CJ, Pierie, JE, Borel-Rinkes, I, Ledermann, JA, et.al. Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial., J Natl Cancer Inst, 2017. 109 (9)(9):, https://pubmed.ncbi.nlm.nih.gov/28376151/
951. Meijerink, MR, Puijk, RS, van Tilborg, AAJM, Henningsen, KH, Fernandez, LG, Neyt, M, et.al. Radiofrequency and Microwave Ablation Compared to Systemic Chemotherapy and to Partial Hepatectomy in the Treatment of Colorectal Liver Metastases: A Systematic Review and Meta-Analysis., Cardiovasc Intervent Radiol, 2018. 41 (8)(8): p. 1189-1204., https://pubmed.ncbi.nlm.nih.gov/29666906/
952. Wasan, HS, Gibbs, P, Sharma, NK, Taieb, J, Heinemann, V, Ricke, J, et.al. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials., Lancet Oncol, 2017. 18 (9)(9): p. 1159-1171., https://pubmed.ncbi.nlm.nih.gov/28781171/
953. González-Flores, E, Zambudio, N, Pardo-Moreno, P, Gonzalez-Astorga, B, de la Rúa, JR, Triviño-Ibáñez, EM, et.al. Recommendations for the management of yttrium-90 radioembolization in the treatment of patients with colorectal cancer liver metastases: a multidisciplinary review., Clin Transl Oncol, 2024. 26 (4)(4): p. 851-863., https://pubmed.ncbi.nlm.nih.gov/37747636/
954. McDermott, RL, Dunne, EM, Zhao, Y, Bergman, A, Liu, MC, Schellenberg, D, et.al. Stereotactic Ablative Radiation Therapy for Colorectal Liver Metastases., Clin Colorectal Cancer, 2023. 22 (1)(1): p. 120-128., https://pubmed.ncbi.nlm.nih.gov/36526537/
955. Swierz, MJ, Storman, D, Mitus, JW, Hetnal, M, Kukielka, A, Szlauer-Stefanska, A, et.al. Transarterial (chemo)embolisation versus systemic chemotherapy for colorectal cancer liver metastases., Cochrane Database Syst Rev, 2024. 8 (8)(8): p. CD012757., https://pubmed.ncbi.nlm.nih.gov/39119869/
956. Mocellin, S, Pasquali, S, Nitti, D, Fluoropyrimidine-HAI (hepatic arterial infusion) versus systemic chemotherapy (SCT) for unresectable liver metastases from colorectal cancer., Cochrane Database Syst Rev, 2009. (3)(3): p. CD007823., https://pubmed.ncbi.nlm.nih.gov/19588444/
957. Schmitt, J, Klinkhammer-Schalke, M, Bierbaum, V, Gerken, M, Bobeth, C, Rößler, M, et.al. Initial Cancer Treatment in Certified Versus Non-Certified Hospitals., Dtsch Arztebl Int, 2023. 120 (39)(39): p. 647-654., https://pubmed.ncbi.nlm.nih.gov/37583089/
958. Morris, VK, Kennedy, EB, Baxter, NN, Benson, AB, Cercek, A, Cho, M, et.al. Treatment of Metastatic Colorectal Cancer: ASCO Guideline., J Clin Oncol, 2023. 41 (3)(3): p. 678-700., https://pubmed.ncbi.nlm.nih.gov/36252154/
959. van der Lei, S, Puijk, RS, Dijkstra, M, Schulz, HH, Vos, DJW, De Vries, JJJ, et.al. Thermal ablation versus surgical resection of small-size colorectal liver metastases (COLLISION): an international, randomised, controlled, phase 3 non-inferiority trial., Lancet Oncol, 2025. 26 (2)(2): p. 187-199., https://pubmed.ncbi.nlm.nih.gov/39848272/
960. Nordlinger, B, Sorbye, H, Glimelius, B, Poston, GJ, Schlag, PM, Rougier, P, et.al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial., Lancet Oncol, 2013. 14 (12)(12): p. 1208-15., https://pubmed.ncbi.nlm.nih.gov/24120480/
961. Nordlinger, B., Sorbye, H., Glimelius, B., Poston, G. J., Schlag, P. M., Rougier, P., et.al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial, Lancet, 2008. 371(9617): p. 1007-16., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18358928, http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(08)60455-9.pdf
962. Nigri, G, Petrucciani, N, Ferla, F, La Torre, M, Aurello, P, Ramacciato, G, Neoadjuvant chemotherapy for resectable colorectal liver metastases: what is the evidence? Results of a systematic review of comparative studies., Surgeon, 2015. 13 (2)(2): p. 83-90., https://pubmed.ncbi.nlm.nih.gov/25257725/
963. Mitry, E., Fields, A. L., Bleiberg, H., Labianca, R., Portier, G., Tu, D., et.al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials, J Clin Oncol, 2008. 26(30): p. 4906-11., https://www.ncbi.nlm.nih.gov/pubmed/18794541
964. Ciliberto, D., Role of systemic chemothreapy in the management of rsected or resectable colorectal liver metastases: A systematic review and meta-analysis of randomized controlled trials, Oncology Reports, 2012. 27: p. 1849 - 1856.
965. Zhu, Gui-Qi, Systematic Review with network Meta-Analysis, Medicine (Baltimore), 2015. 94:
966. André, T, Shiu, KK, Kim, TW, Jensen, BV, Jensen, LH, Punt, CJA, et.al. Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study., Ann Oncol, 2025. 36 (3)(3): p. 277-284., https://pubmed.ncbi.nlm.nih.gov/39631622/
967. Diaz, LA, Shiu, KK, Kim, TW, Jensen, BV, Jensen, LH, Punt, C, et.al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study., Lancet Oncol, 2022. 23 (5)(5): p. 659-670., https://pubmed.ncbi.nlm.nih.gov/35427471/
968. Andre, T, Elez, E, Van Cutsem, E, Jensen, LH, Bennouna, J, Mendez, G, et.al. Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer., N Engl J Med, 2024. 391 (21)(21): p. 2014-2026., https://pubmed.ncbi.nlm.nih.gov/39602630/
969. Ciliberto, D, Staropoli, N, Caglioti, F, Chiellino, S, Ierardi, A, Ingargiola, R, et.al. The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis., Crit Rev Oncol Hematol, 2018. 125 (): p. 69-77., https://pubmed.ncbi.nlm.nih.gov/29650279/
970. Baraniskin, A, Buchberger, B, Pox, C, Graeven, U, Holch, JW, Schmiegel, W, et.al. Efficacy of bevacizumab in first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis., Eur J Cancer, 2019. 106 (): p. 37-44., https://pubmed.ncbi.nlm.nih.gov/30476731/
971. Tang, W, Ren, L, Liu, T, Ye, Q, Wei, Y, He, G, et.al. Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for , J Clin Oncol, 2020. 38 (27)(27): p. 3175-3184., https://pubmed.ncbi.nlm.nih.gov/32749938/
972. Kabbinavar, F. F., Schulz, J., McCleod, M., Patel, T., Hamm, J. T., Hecht, J. R., et.al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial, J Clin Oncol, 2005. 23(16): p. 3697-705., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15738537, http://jco.ascopubs.org/content/23/16/3697.full.pdf
973. Pessino, A, Artale, S, Sciallero, S, Guglielmi, A, Fornarini, G, Andreotti, IC, et.al. First-line single-agent cetuximab in patients with advanced colorectal cancer., Ann Oncol, 2008. 19 (4)(4): p. 711-6., https://pubmed.ncbi.nlm.nih.gov/18073221/
974. Overman, MJ, Lonardi, S, Wong, KYM, Lenz, HJ, Gelsomino, F, Aglietta, M, et.al. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer., J Clin Oncol, 2018. 36 (8)(8): p. 773-779., https://pubmed.ncbi.nlm.nih.gov/29355075/
975. Hegewisch-Becker, S, Graeven, U, Lerchenmüller, CA, Killing, B, Depenbusch, R, Steffens, CC, et.al. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial., Lancet Oncol, 2015. 16 (13)(13): p. 1355-69., https://pubmed.ncbi.nlm.nih.gov/26361971/
976. Simkens, LH, van Tinteren, H, May, A, ten Tije, AJ, Creemers, GJ, Loosveld, OJ, et.al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group., Lancet, 2015. 385 (9980)(9980): p. 1843-52., https://pubmed.ncbi.nlm.nih.gov/25862517/
977. Modest, DP, Karthaus, M, Fruehauf, S, Graeven, U, Müller, L, König, AO, et.al. Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in , J Clin Oncol, 2022. 40 (1)(1): p. 72-82., https://pubmed.ncbi.nlm.nih.gov/34533973/
978. Pietrantonio, F, Morano, F, Corallo, S, Miceli, R, Lonardi, S, Raimondi, A, et.al. Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial., JAMA Oncol, 2019. 5 (9)(9): p. 1268-1275., https://pubmed.ncbi.nlm.nih.gov/31268481/
979. Pereira, AA, Rego, JF, Munhoz, RR, Hoff, PM, Sasse, AD, Riechelmann, RP, The impact of complete chemotherapy stop on the overall survival of patients with advanced colorectal cancer in first-line setting: A meta-analysis of randomized trials., Acta Oncol, 2015. 54 (10)(10): p. 1737-46., https://pubmed.ncbi.nlm.nih.gov/25984931/
980. Labianca, R, Sobrero, A, Isa, L, Cortesi, E, Barni, S, Nicolella, D, et.al. Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial., Ann Oncol, 2011. 22 (5)(5): p. 1236-1242., https://pubmed.ncbi.nlm.nih.gov/21078826/
981. Bennouna, J, Sastre, J, Arnold, D, Österlund, P, Greil, R, Van Cutsem, E, et.al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial., Lancet Oncol, 2013. 14 (1)(1): p. 29-37., https://pubmed.ncbi.nlm.nih.gov/23168366/
982. Kubicka, S, Greil, R, André, T, Bennouna, J, Sastre, J, Van Cutsem, E, et.al. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings., Ann Oncol, 2013. 24 (9)(9): p. 2342-9., https://pubmed.ncbi.nlm.nih.gov/23852309/
983. Van Cutsem, E, Tabernero, J, Lakomy, R, Prenen, H, Prausová, J, Macarulla, T, et.al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen., J Clin Oncol, 2012. 30 (28)(28): p. 3499-506., https://pubmed.ncbi.nlm.nih.gov/22949147/
984. Tabernero, J, Yoshino, T, Cohn, AL, Obermannova, R, Bodoky, G, Garcia-Carbonero, R, et.al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study., Lancet Oncol, 2015. 16 (5)(5): p. 499-508., https://pubmed.ncbi.nlm.nih.gov/25877855/
985. Mayer, R. J., Van Cutsem, E., Falcone, A., Yoshino, T., Garcia-Carbonero, R., Mizunuma, N., et.al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer, N Engl J Med, 2015. 372(20): p. 1909-19.
986. Yoshino, T., Mizunuma, N., Yamazaki, K., Nishina, T., Komatsu, Y., Baba, H., et.al. TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial, Lancet Oncol, 2012. 13(10): p. 993-1001.
987. Prager, GW, Taieb, J, Fakih, M, Ciardiello, F, Van Cutsem, E, Elez, E, et.al. Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer., N Engl J Med, 2023. 388 (18)(18): p. 1657-1667., https://pubmed.ncbi.nlm.nih.gov/37133585/
988. Drilon, A, Laetsch, TW, Kummar, S, DuBois, SG, Lassen, UN, Demetri, GD, et.al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children., N Engl J Med, 2018. 378 (8)(8): p. 731-739., https://pubmed.ncbi.nlm.nih.gov/29466156/
989. Demetri, GD, De Braud, F, Drilon, A, Siena, S, Patel, MR, Cho, BC, et.al. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors., Clin Cancer Res, 2022. 28 (7)(7): p. 1302-1312., https://pubmed.ncbi.nlm.nih.gov/35144967/
990. Hemminki, K., Li, X., Dong, C., Second primary cancers after sporadic and familial colorectal cancer, Cancer Epidemiol Biomarkers Prev, 2001. 10(7): p. 793-8., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11440965, http://cebp.aacrjournals.org/content/10/7/793.full.pdf
991. Secco, G. B., Fardelli, R., Gianquinto, D., Bonfante, P., Baldi, E., Campora, E., Factors influencing incidence and extension of metachronous liver metastases of colorectal adenocarcinoma. A multivariate analysis, Hepatogastroenterology, 1997. 44(16): p. 1057-62., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9261599
992. Pietra, N., Sarli, L., Thenasseril, B. J., Costi, R., Sansebastiano, G., Peracchia, A., Risk factors of local recurrence of colorectal cancer: a multivariate study, Hepatogastroenterology, 1998. 45(23): p. 1573-8., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9840107
993. Fuccio, L, Rex, D, Ponchon, T, Frazzoni, L, Dinis-Ribeiro, M, Bhandari, P, et.al. New and Recurrent Colorectal Cancers After Resection: a Systematic Review and Meta-analysis of Endoscopic Surveillance Studies., Gastroenterology, 2019. 156 (5)(5): p. 1309-1323.e3., https://pubmed.ncbi.nlm.nih.gov/30553914/
994. Scholmerich, J., [Sense and nonsense in after-care of colorectal carcinoma], Med Klin (Munich), 1996. 91(6): p. 420-7., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8767320
995. Jeffery, M, Hickey, BE, Hider, PN, Follow-up strategies for patients treated for non-metastatic colorectal cancer., Cochrane Database Syst Rev, 2019. 9 (9)(9): p. CD002200., https://pubmed.ncbi.nlm.nih.gov/31483854/
996. Kennedy, E, Zwaal, C, Asmis, T, Cho, C, Galica, J, Ginty, A, et.al. An Evidence-Based Guideline for Surveillance of Patients after Curative Treatment for Colon and Rectal Cancer., Curr Oncol, 2022. 29 (2)(2): p. 724-740., https://pubmed.ncbi.nlm.nih.gov/35200561/
997. Jeffery, G. M., Hickey, B. E., Hider, P., Follow-up strategies for patients treated for non-metastatic colorectal cancer, Cochrane Database Syst Rev, 2002. p. CD002200., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11869629, http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002200/abstract
998. Renehan, A. G., Egger, M., Saunders, M. P., O'Dwyer, S. T., Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials, Bmj, 2002. 324(7341): p. 813., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11934773, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC100789/pdf/813.pdf
999. Makela, J. T., Laitinen, S. O., Kairaluoma, M. I., Five-year follow-up after radical surgery for colorectal cancer. Results of a prospective randomized trial, Arch Surg, 1995. 130(10): p. 1062-7., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7575117, http://archsurg.jamanetwork.com/article.aspx?articleid=596341
1000. Ohlsson, B., Breland, U., Ekberg, H., Graffner, H., Tranberg, K. G., Follow-up after curative surgery for colorectal carcinoma. Randomized comparison with no follow-up, Dis Colon Rectum, 1995. 38(6): p. 619-26., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7774474
1001. Kjeldsen, B. J., Kronborg, O., Fenger, C., Jorgensen, O. D., A prospective randomized study of follow-up after radical surgery for colorectal cancer, Br J Surg, 1997. 84(5): p. 666-9., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9171758, http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2168.1997.02733.x/abstract
1002. Pietra, N., Sarli, L., Costi, R., Ouchemi, C., Grattarola, M., Peracchia, A., Role of follow-up in management of local recurrences of colorectal cancer: a prospective, randomized study, Dis Colon Rectum, 1998. 41(9): p. 1127-33., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9749496
1003. Schoemaker, D., Black, R., Giles, L., Toouli, J., Yearly colonoscopy, liver CT, and chest radiography do not influence 5-year survival of colorectal cancer patients, Gastroenterology, 1998. 114(1): p. 7-14., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9428212
1004. Secco, G. B., Fardelli, R., Gianquinto, D., Bonfante, P., Baldi, E., Ravera, G., et.al. Efficacy and cost of risk-adapted follow-up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial, Eur J Surg Oncol, 2002. 28(4): p. 418-23., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12099653, http://www.ejso.com/article/S0748-7983(01)91250-8/abstract
1005. Bruinvels, D. J., Stiggelbout, A. M., Kievit, J., van Houwelingen, H. C., Habbema, J. D., van de Velde, C. J., Follow-up of patients with colorectal cancer. A meta-analysis, Ann Surg, 1994. 219(2): p. 174-82., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8129488, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1243119/pdf/annsurg00060-0076.pdf
1006. Rosen, M., Chan, L., Beart, R. W., Jr., Vukasin, P., Anthone, G., Follow-up of colorectal cancer: a meta-analysis, Dis Colon Rectum, 1998. 41(9): p. 1116-26., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9749495
1007. Kievit, J., Colorectal cancer follow-up: a reassessment of empirical evidence on effectiveness, Eur J Surg Oncol, 2000. 26(4): p. 322-8., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10873350, http://www.ejso.com/article/S0748-7983(99)90893-4/abstract
1008. Kievit, J., Follow-up of patients with colorectal cancer: numbers needed to test and treat, Eur J Cancer, 2002. 38(7): p. 986-99., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11978524, http://www.ejcancer.com/article/S0959-8049(02)00061-8/abstract
1009. Benson, A. B., 3rd, Desch, C. E., Flynn, P. J., Krause, C., Loprinzi, C. L., Minsky, B. D., et.al. 2000 update of American Society of Clinical Oncology colorectal cancer surveillance guidelines, J Clin Oncol, 2000. 18(20): p. 3586-8., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11032600, http://jco.ascopubs.org/content/18/20/3586.full.pdf
1010. Desch, C. E., Benson, A. B., 3rd, Smith, T. J., Flynn, P. J., Krause, C., Loprinzi, C. L., et.al. Recommended colorectal cancer surveillance guidelines by the American Society of Clinical Oncology, J Clin Oncol, 1999. 17(4): p. 1312., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10561194, http://jco.ascopubs.org/content/17/4/1312.full.pdf
1011. Duffy, M. J., van Dalen, A., Haglund, C., Hansson, L., Klapdor, R., Lamerz, R., et.al. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines, Eur J Cancer, 2003. 39(6): p. 718-27., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12651195, http://www.ejcancer.com/article/S0959-8049(02)00811-0/abstract
1012. Macdonald, J. S., Carcinoembryonic antigen screening: pros and cons, Semin Oncol, 1999. 26(5): p. 556-60., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10528904
1013. Pietra, N., Sarli, L., Costi, R., Ouchemi, C., Grattarola, M., Peracchia, A., Role of follow-up in management of local recurrences of colorectal cancer: a prospective, randomized study, Dis Colon Rectum, 1998. 41(9): p. 1127-33., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9749496
1014. Wille-Jørgensen, P, Syk, I, Smedh, K, Laurberg, S, Nielsen, DT, Petersen, SH, et.al. Effect of More vs Less Frequent Follow-up Testing on Overall and Colorectal Cancer-Specific Mortality in Patients With Stage II or III Colorectal Cancer: The COLOFOL Randomized Clinical Trial., JAMA, 2018. 319 (20)(20): p. 2095-2103., https://pubmed.ncbi.nlm.nih.gov/29800179/
1015. Duffy, M. J., van Dalen, A., Haglund, C., Hansson, L., Klapdor, R., Lamerz, R., et.al. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines, Eur J Cancer, 2003. 39(6): p. 718-27., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12651195, http://www.ejcancer.com/article/S0959-8049(02)00811-0/abstract
1016. Pita-Fernández, S, Alhayek-Aí, M, González-Martín, C, López-Calviño, B, Seoane-Pillado, T, Pértega-Díaz, S, Intensive follow-up strategies improve outcomes in nonmetastatic colorectal cancer patients after curative surgery: a systematic review and meta-analysis., Ann Oncol, 2015. 26 (4)(4): p. 644-656., https://pubmed.ncbi.nlm.nih.gov/25411419/
1017. Shinkins, B, Nicholson, BD, James, T, Pathiraja, I, Pugh, S, Perera, R, et.al. What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow-up? A systematic review and secondary analysis of a randomised controlled trial., Health Technol Assess, 2017. 21 (22)(22): p. 1-60., https://pubmed.ncbi.nlm.nih.gov/28617240/
1018. Jeffery, G. M., Hickey, B. E., Hider, P., Follow-up strategies for patients treated for non-metastatic colorectal cancer, Cochrane Database Syst Rev, 2002. p. CD002200., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11869629, http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002200/abstract
1019. Berman, J. M., Cheung, R. J., Weinberg, D. S., Surveillance after colorectal cancer resection, Lancet, 2000. 355(9201): p. 395-9., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10665570, http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(99)06552-6/abstract
1020. Makela, J. T., Laitinen, S. O., Kairaluoma, M. I., Five-year follow-up after radical surgery for colorectal cancer. Results of a prospective randomized trial, Arch Surg, 1995. 130(10): p. 1062-7., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7575117, http://archsurg.jamanetwork.com/article.aspx?articleid=596341
1021. Hunerbein, M., Totkas, S., Moesta, K. T., Ulmer, C., Handke, T., Schlag, P. M., The role of transrectal ultrasound-guided biopsy in the postoperative follow-up of patients with rectal cancer, Surgery, 2001. 129(2): p. 164-9., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11174709, http://www.surgjournal.com/article/S0039-6060(01)16661-4/abstract
1022. Jeffery, M., Hickey, B. E., Hider, P. N., Follow-up strategies for patients treated for non-metastatic colorectal cancer, Cochrane Database Syst Rev, 2007. p. CD002200., http://www.ncbi.nlm.nih.gov/pubmed/17253476
1023. Sugarbaker, P. H., Gianola, F. J., Dwyer, A., Neuman, N. R., A simplified plan for follow-up of patients with colon and rectal cancer supported by prospective studies of laboratory and radiologic test results, Surgery, 1987. 102(1): p. 79-87., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=3589978
1024. Schoemaker, D., Black, R., Giles, L., Toouli, J., Yearly colonoscopy, liver CT, and chest radiography do not influence 5-year survival of colorectal cancer patients, Gastroenterology, 1998. 114(1): p. 7-14., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9428212
1025. Desch, C. E., Benson, A. B., 3rd, Somerfield, M. R., Flynn, P. J., Krause, C., Loprinzi, C. L., et.al. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline, J Clin Oncol, 2005. 23(33): p. 8512-9., http://www.ncbi.nlm.nih.gov/pubmed/16260687
1026. Chau, I., Allen, M. J., Cunningham, D., Norman, A. R., Brown, G., Ford, H. E., et.al. The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer, J Clin Oncol, 2004. 22(8): p. 1420-9., http://www.ncbi.nlm.nih.gov/pubmed/15007086
1027. Rex, D. K., Kahi, C. J., Levin, B., Smith, R. A., Bond, J. H., Brooks, D., et.al. Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and the US Multi-Society Task Force on Colorectal Cancer, Gastroenterology, 2006. 130(6): p. 1865-71., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16697749, http://www.gastrojournal.org/article/S0016-5085(06)00562-2/pdf
1028. Bouvier, A. M., Latournerie, M., Jooste, V., Lepage, C., Cottet, V., Faivre, J., The lifelong risk of metachronous colorectal cancer justifies long-term colonoscopic follow-up, Eur J Cancer, 2008. 44(4): p. 522-7., http://www.ncbi.nlm.nih.gov/pubmed/18255278
1029. Renehan, A. G., Egger, M., Saunders, M. P., O'Dwyer, S. T., Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials, Bmj, 2002. 324(7341): p. 813., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11934773, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC100789/pdf/813.pdf
1030. Rulyak, S. J., Lieberman, D. A., Wagner, E. H., Mandelson, M. T., Outcome of follow-up colon examination among a population-based cohort of colorectal cancer patients, Clin Gastroenterol Hepatol, 2007. 5(4): p. 470-6; quiz 407., http://www.ncbi.nlm.nih.gov/pubmed/17270502
1031. Wang, T., Cui, Y., Huang, W. S., Deng, Y. H., Gong, W., Li, C. J., et.al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study, Gastrointest Endosc, 2009. 69(3 Pt 2): p. 609-15., http://www.ncbi.nlm.nih.gov/pubmed/19136105
1032. Wang, T., Cui, Y., Huang, W. S., Deng, Y. H., Gong, W., Li, C. J., et.al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study, Gastrointest Endosc, 2009. 69(3 Pt 2): p. 609-15., http://www.ncbi.nlm.nih.gov/pubmed/19136105
1033. Rulyak, S. J., Lieberman, D. A., Wagner, E. H., Mandelson, M. T., Outcome of follow-up colon examination among a population-based cohort of colorectal cancer patients, Clin Gastroenterol Hepatol, 2007. 5(4): p. 470-6; quiz 407., http://www.ncbi.nlm.nih.gov/pubmed/17270502
1034. Rex, D. K., Kahi, C. J., Levin, B., Smith, R. A., Bond, J. H., Brooks, D., et.al. Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and the US Multi-Society Task Force on Colorectal Cancer, Gastroenterology, 2006. 130(6): p. 1865-71., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16697749, http://www.gastrojournal.org/article/S0016-5085(06)00562-2/pdf
1035. Cali, R. L., Pitsch, R. M., Thorson, A. G., Watson, P., Tapia, P., Blatchford, G. J., et.al. Cumulative incidence of metachronous colorectal cancer, Dis Colon Rectum, 1993. 36(4): p. 388-93., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8458267
1036. Merkel, S., Meyer, T., Gohl, J., Hohenberger, W., Late locoregional recurrence in rectal carcinoma, Eur J Surg Oncol, 2002. 28(7): p. 716-22., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12431468, http://www.ejso.com/article/S0748-7983(02)91305-3/abstract
1037. Ohlsson, B., Breland, U., Ekberg, H., Graffner, H., Tranberg, K. G., Follow-up after curative surgery for colorectal carcinoma. Randomized comparison with no follow-up, Dis Colon Rectum, 1995. 38(6): p. 619-26., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7774474
1038. Kjeldsen, B. J., Kronborg, O., Fenger, C., Jorgensen, O. D., A prospective randomized study of follow-up after radical surgery for colorectal cancer, Br J Surg, 1997. 84(5): p. 666-9., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9171758, http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2168.1997.02733.x/abstract
1039. Secco, G. B., Fardelli, R., Gianquinto, D., Bonfante, P., Baldi, E., Ravera, G., et.al. Efficacy and cost of risk-adapted follow-up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial, Eur J Surg Oncol, 2002. 28(4): p. 418-23., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12099653, http://www.ejso.com/article/S0748-7983(01)91250-8/abstract
1040. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), Psychoonkologische Diagnostik, Beratung und Behandlung von erwachsenen Krebspatient*innen, Langversion 2.1, AWMF-Registernummer: 032-051OL, 2023., https://www.leitlinienprogramm-onkologie.de/leitlinien/psychoonkologie/
1041. Keller, M., Sommerfeldt, S., Fischer, C., Knight, L., Riesbeck, M., Lowe, B., et.al. Recognition of distress and psychiatric morbidity in cancer patients: a multi-method approach, Ann Oncol, 2004. 15(8): p. 1243-9., https://www.ncbi.nlm.nih.gov/pubmed/15277265
1042. Sharpe, M., Strong, V., Allen, K., Rush, R., Postma, K., Tulloh, A., et.al. Major depression in outpatients attending a regional cancer centre: screening and unmet treatment needs, Br J Cancer, 2004. 90(2): p. 314-20., http://www.ncbi.nlm.nih.gov/pubmed/14735170
1043. Singer, S., Das-Munshi, J., Brahler, E., Prevalence of mental health conditions in cancer patients in acute care--a meta-analysis, Ann Oncol, 2010. 21(5): p. 925-30., http://www.ncbi.nlm.nih.gov/pubmed/19887467
1044. Jansen, L., Herrmann, A., Stegmaier, C., Singer, S., Brenner, H., Arndt, V., Health-related quality of life during the 10 years after diagnosis of colorectal cancer: a population-based study, J Clin Oncol, 2011. 29(24): p. 3263-9., http://www.ncbi.nlm.nih.gov/pubmed/21768465
1045. Lynch, B. M., Steginga, S. K., Hawkes, A. L., Pakenham, K. I., Dunn, J., Describing and predicting psychological distress after colorectal cancer, Cancer, 2008. 112(6): p. 1363-70., http://www.ncbi.nlm.nih.gov/pubmed/18318044
1046. Andreu, Y, Martinez, P, Soto-Rubio, A, Fernández, S, Bosch, C, Cervantes, A, Colorectal cancer survival: prevalence of psychosocial distress and unmet supportive care needs., Support Care Cancer, 2022. 30 (2)(2): p. 1483-1491., https://pubmed.ncbi.nlm.nih.gov/34529142/
1047. Miovic, M., Block, S., Psychiatric disorders in advanced cancer, Cancer, 2007. 110(8): p. 1665-76., http://www.ncbi.nlm.nih.gov/pubmed/17847017
1048. Ramsey, S. D., Andersen, M. R., Etzioni, R., Moinpour, C., Peacock, S., Potosky, A., et.al. Quality of life in survivors of colorectal carcinoma, Cancer, 2000. 88(6): p. 1294-303., http://www.ncbi.nlm.nih.gov/pubmed/10717609
1049. Zettl, S, Hartlapp, J., Sexualstörungen durch Krankheit und Therapie, 1997. p. S. 59.
1050. Fallowfield, L., Ratcliffe, D., Jenkins, V., Saul, J., Psychiatric morbidity and its recognition by doctors in patients with cancer, Br J Cancer, 2001. 84(8): p. 1011-5., http://www.ncbi.nlm.nih.gov/pubmed/11308246
1051. Sollner, W., DeVries, A., Steixner, E., Lukas, P., Sprinzl, G., Rumpold, G., et.al. How successful are oncologists in identifying patient distress, perceived social support, and need for psychosocial counselling?, Br J Cancer, 2001. 84(2): p. 179-85., http://www.ncbi.nlm.nih.gov/pubmed/11161373
1052. Van Gossum, A., Munoz-Navas, M., Fernandez-Urien, I., Carretero, C., Gay, G., Delvaux, M., et.al. Capsule endoscopy versus colonoscopy for the detection of polyps and cancer, N Engl J Med, 2009. 361(3): p. 264-70., http://www.ncbi.nlm.nih.gov/pubmed/19605831
1053. Bradshaw, N., Holloway, S., Penman, I., Dunlop, M. G., Porteous, M. E., Colonoscopy surveillance of individuals at risk of familial colorectal cancer, Gut, 2003. 52(12): p. 1748-51., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14633955, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1773898/pdf/gut05201748.pdf
1054. Brenner, H., Hoffmeister, M., Haug, U., Family history and age at initiation of colorectal cancer screening, Am J Gastroenterol, 2008. 103(9): p. 2326-31., http://www.ncbi.nlm.nih.gov/pubmed/18702651
1055. Waldmann, A., Raspe, H., Katalinic, A., [Colon cancer risk in persons at familial or hereditary risk aged < 55 years], Z Gastroenterol, 2009. 47(10): p. 1052-8., http://www.ncbi.nlm.nih.gov/pubmed/19809955
1056. Levin, B, Lieberman, DA, McFarland, B, Smith, RA, Brooks, D, Andrews, KS, et.al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology., CA Cancer J Clin, 2008. 58 (3)(3): p. 130-60., https://pubmed.ncbi.nlm.nih.gov/18322143/
1057. Engel, C., Rahner, N., Schulmann, K., Holinski-Feder, E., Goecke, T. O., Schackert, H. K., et.al. Efficacy of annual colonoscopic surveillance in individuals with hereditary nonpolyposis colorectal cancer, Clin Gastroenterol Hepatol, 2010. 8(2): p. 174-82., http://www.ncbi.nlm.nih.gov/pubmed/19835992
1058. Dove-Edwin, I., Sasieni, P., Adams, J., Thomas, H. J., Prevention of colorectal cancer by colonoscopic surveillance in individuals with a family history of colorectal cancer: 16 year, prospective, follow-up study, BMJ, 2005. 331(7524): p. 1047., http://www.ncbi.nlm.nih.gov/pubmed/16243849
1059. Vasen, H. F., Mecklin, J. P., Khan, P. M., Lynch, H. T., The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC), Dis Colon Rectum, 1991. 34(5): p. 424-5., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2022152
1060. Muscaritoli, M, Arends, J, Bachmann, P, Baracos, V, Barthelemy, N, Bertz, H, et.al. ESPEN practical guideline: Clinical Nutrition in cancer., Clin Nutr, 2021. 40 (5)(5): p. 2898-2913., https://pubmed.ncbi.nlm.nih.gov/33946039/
1061. Martin, L, Senesse, P, Gioulbasanis, I, Antoun, S, Bozzetti, F, Deans, C, et.al. Diagnostic criteria for the classification of cancer-associated weight loss., J Clin Oncol, 2015. 33 (1)(1): p. 90-9., https://pubmed.ncbi.nlm.nih.gov/25422490/
1062. Martin, L, Birdsell, L, Macdonald, N, Reiman, T, Clandinin, MT, McCargar, LJ, et.al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index., J Clin Oncol, 2013. 31 (12)(12): p. 1539-47., https://pubmed.ncbi.nlm.nih.gov/23530101/
1063. Pan, H, Cai, S, Ji, J, Jiang, Z, Liang, H, Lin, F, et.al. The impact of nutritional status, nutritional risk, and nutritional treatment on clinical outcome of 2248 hospitalized cancer patients: a multi-center, prospective cohort study in Chinese teaching hospitals., Nutr Cancer, 2013. 65 (1)(1): p. 62-70., https://pubmed.ncbi.nlm.nih.gov/23368914/
1064. Isenring, E, Elia, M, Which screening method is appropriate for older cancer patients at risk for malnutrition?, Nutrition, 2015. 31 (4)(4): p. 594-7., https://pubmed.ncbi.nlm.nih.gov/25770324/
1065. Meijers, JM, Tan, F, Schols, JM, Halfens, RJ, Nutritional care; do process and structure indicators influence malnutrition prevalence over time?, Clin Nutr, 2014. 33 (3)(3): p. 459-65., https://pubmed.ncbi.nlm.nih.gov/23890720/
1066. Geiker, NR, Hørup Larsen, SM, Stender, S, Astrup, A, Poor performance of mandatory nutritional screening of in-hospital patients., Clin Nutr, 2012. 31 (6)(6): p. 862-7., https://pubmed.ncbi.nlm.nih.gov/22531501/
1067. Del Fabbro, E, Hui, D, Dalal, S, Dev, R, Nooruddin, ZI, Bruera, E, Clinical outcomes and contributors to weight loss in a cancer cachexia clinic., J Palliat Med, 2011. 14 (9)(9): p. 1004-8., https://pubmed.ncbi.nlm.nih.gov/21793729/
1068. Gagnon, B, Murphy, J, Eades, M, Lemoignan, J, Jelowicki, M, Carney, S, et.al. A prospective evaluation of an interdisciplinary nutrition-rehabilitation program for patients with advanced cancer., Curr Oncol, 2013. 20 (6)(6): p. 310-8., https://pubmed.ncbi.nlm.nih.gov/24311946/
1069. Bozzetti, F, Nutritional support in patients with oesophageal cancer., Support Care Cancer, 2010. 18 Suppl 2 (): p. S41-50., https://pubmed.ncbi.nlm.nih.gov/19551411/
1070. Skipworth, RJ, Stewart, GD, Dejong, CH, Preston, T, Fearon, KC, Pathophysiology of cancer cachexia: much more than host-tumour interaction?, Clin Nutr, 2007. 26 (6)(6): p. 667-76., https://pubmed.ncbi.nlm.nih.gov/17507116/
1071. Fearon, K, Strasser, F, Anker, SD, Bosaeus, I, Bruera, E, Fainsinger, RL, et.al. Definition and classification of cancer cachexia: an international consensus., Lancet Oncol, 2011. 12 (5)(5): p. 489-95., https://pubmed.ncbi.nlm.nih.gov/21296615/
1072. Muscaritoli, M, Anker, SD, Argilés, J, Aversa, Z, Bauer, JM, Biolo, G, et.al. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) "cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics"., Clin Nutr, 2010. 29 (2)(2): p. 154-9., https://pubmed.ncbi.nlm.nih.gov/20060626/
1073. Eaton, CB, McBride, PE, Gans, KA, Underbakke, GL, Teaching nutrition skills to primary care practitioners., J Nutr, 2003. 133 (2)(2): p. 563S-6S., https://pubmed.ncbi.nlm.nih.gov/12566503/
1074. Brown, T, Findlay, M, von Dincklage, J, Davidson, W, Hill, J, Isenring, E, et.al. Using a wiki platform to promote guidelines internationally and maintain their currency: evidence-based guidelines for the nutritional management of adult patients with head and neck cancer., J Hum Nutr Diet, 2013. 26 (2)(2): p. 182-90., https://pubmed.ncbi.nlm.nih.gov/23336961/
1075. Clutter Snyder, D, Sloane, R, Haines, PS, Miller, P, Clipp, EC, Morey, MC, et.al. The Diet Quality Index-Revised: a tool to promote and evaluate dietary change among older cancer survivors enrolled in a home-based intervention trial., J Am Diet Assoc, 2007. 107 (9)(9): p. 1519-29., https://pubmed.ncbi.nlm.nih.gov/17761229/
1076. Isenring, Elisabeth, Zabel, Rachel, Bannister, Melanie, Brown, Teresa, Findlay, Merran, Kiss, Nicole, et.al. Updated evidence-based practice guidelines for the nutritional management of patients receiving radiation therapy and/or chemotherapyJohn Wiley & Sons, Ltd, Nutrition & Dietetics, 2013. 70(4): p. 312 - 324., https://doi.org/10.1111/1747-0080.12013
1077. Baldwin, C, Spiro, A, Ahern, R, Emery, PW, Oral nutritional interventions in malnourished patients with cancer: a systematic review and meta-analysis., J Natl Cancer Inst, 2012. 104 (5)(5): p. 371-85., https://pubmed.ncbi.nlm.nih.gov/22345712/
1078. Bourdel-Marchasson, I, Blanc-Bisson, C, Doussau, A, Germain, C, Blanc, JF, Dauba, J, et.al. Nutritional advice in older patients at risk of malnutrition during treatment for chemotherapy: a two-year randomized controlled trial., PLoS One, 2014. 9 (9)(9): p. e108687., https://pubmed.ncbi.nlm.nih.gov/25265392/
1079. Ni, X, Jia, D, Chen, Y, Wang, L, Suo, J, Is the Enhanced Recovery After Surgery (ERAS) Program Effective and Safe in Laparoscopic Colorectal Cancer Surgery? A Meta-Analysis of Randomized Controlled Trials., J Gastrointest Surg, 2019. 23 (7)(7): p. 1502-1512., https://pubmed.ncbi.nlm.nih.gov/30859422/
1080. Greer, NL, Gunnar, WP, Dahm, P, Lee, AE, MacDonald, R, Shaukat, A, et.al. Enhanced Recovery Protocols for Adults Undergoing Colorectal Surgery: A Systematic Review and Meta-analysis., Dis Colon Rectum, 2018. 61 (9)(9): p. 1108-1118., https://pubmed.ncbi.nlm.nih.gov/30086061/
1081. Forsmo, HM, Erichsen, C, Rasdal, A, Tvinnereim, JM, Körner, H, Pfeffer, F, Randomized Controlled Trial of Extended Perioperative Counseling in Enhanced Recovery After Colorectal Surgery., Dis Colon Rectum, 2018. 61 (6)(6): p. 724-732., https://pubmed.ncbi.nlm.nih.gov/29664800/
1082. Rodríguez-Cañamero, S, Cobo-Cuenca, AI, Carmona-Torres, JM, Pozuelo-Carrascosa, DP, Santacruz-Salas, E, Rabanales-Sotos, JA, et.al. Impact of physical exercise in advanced-stage cancer patients: Systematic review and meta-analysis., Cancer Med, 2022. 11 (19)(19): p. 3714-3727., https://pubmed.ncbi.nlm.nih.gov/35411694/
1083. Zhang, Q, Gao, Y, Wang, W, Zhao, X, Yu, J, Huang, H, Effect of resistance exercise on physical fitness, quality of life, and fatigue in patients with cancer: a systematic review., Front Oncol, 2024. 14 (): p. 1393902., https://pubmed.ncbi.nlm.nih.gov/39099690/
1084. Braam, KI, van der Torre, P, Takken, T, Veening, MA, van Dulmen-den Broeder, E, Kaspers, GJ, Physical exercise training interventions for children and young adults during and after treatment for childhood cancer., Cochrane Database Syst Rev, 2016. 3 (3)(3): p. CD008796., https://pubmed.ncbi.nlm.nih.gov/27030386/
1085. Braam, KI, van der Torre, P, Takken, T, Veening, MA, van Dulmen-den Broeder, E, Kaspers, GJ, Physical exercise training interventions for children and young adults during and after treatment for childhood cancer., Cochrane Database Syst Rev, 2013. (4)(4): p. CD008796., https://pubmed.ncbi.nlm.nih.gov/23633361/
1086. Turner, RR, Steed, L, Quirk, H, Greasley, RU, Saxton, JM, Taylor, SJ, et.al. Interventions for promoting habitual exercise in people living with and beyond cancer., Cochrane Database Syst Rev, 2018. 9 (9)(9): p. CD010192., https://pubmed.ncbi.nlm.nih.gov/30229557/
1087. Bourke, L, Homer, KE, Thaha, MA, Steed, L, Rosario, DJ, Robb, KA, et.al. Interventions for promoting habitual exercise in people living with and beyond cancer., Cochrane Database Syst Rev, 2013. (9)(9): p. CD010192., https://pubmed.ncbi.nlm.nih.gov/24065550/
1088. Meyerhardt, J. A., Giovannucci, E. L., Holmes, M. D., Chan, A. T., Chan, J. A., Colditz, G. A., et.al. Physical activity and survival after colorectal cancer diagnosis, J Clin Oncol, 2006. 24(22): p. 3527-34., http://www.ncbi.nlm.nih.gov/pubmed/16822844
1089. Meyerhardt, J. A., Heseltine, D., Niedzwiecki, D., Hollis, D., Saltz, L. B., Mayer, R. J., et.al. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803, J Clin Oncol, 2006. 24(22): p. 3535-41., http://www.ncbi.nlm.nih.gov/pubmed/16822843
1090. Stene, GB, Helbostad, JL, Balstad, TR, Riphagen, II, Kaasa, S, Oldervoll, LM, Effect of physical exercise on muscle mass and strength in cancer patients during treatment--a systematic review., Crit Rev Oncol Hematol, 2013. 88 (3)(3): p. 573-93., https://pubmed.ncbi.nlm.nih.gov/23932804/
1091. Cheng, F, Li, N, Yang, J, Yang, J, Yang, W, Ran, J, et.al. The effect of resistance training on patients with secondary sarcopenia: a systematic review and meta-analysis., Sci Rep, 2024. 14 (1)(1): p. 28784., https://pubmed.ncbi.nlm.nih.gov/39567607/
1092. Nationales Zentrum für Tumorerkrankungen Heidelberg (NCT), Ein Ratgeber für mehr Sport im Leben – auch mit oder nach Krebs! SPORT, BEWEGUNG UND KREBS, 6. Auflage, 2020.
1093. Hübner, J, Muenstedt, K, Muecke, R, Micke, O, Stoll, C, Kleeberg, UR, et.al. Counseling cancer patients on complementary and alternative medicine. Background, theory, and implementation of nationwide counseling facilities., Strahlenther Onkol, 2013. 189 (8)(8): p. 613-7., https://pubmed.ncbi.nlm.nih.gov/23824107/
1094. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), S3-Leitlinie Komplementärmedizin in der Behandlung von onkologischen PatientInnen Langversion 1.1, AWMF-Registernummer: 032/055OL, 2021., https://www.leitlinienprogramm-onkologie.de/leitlinien/komplementaermedizin
1095. Hack, CC, Hüttner, NB, Fasching, PA, Beckmann, MW, Development and Validation of a Standardized Questionnaire and Standardized Diary for Use in Integrative Medicine Consultations in Gynecologic Oncology., Geburtshilfe Frauenheilkd, 2015. 75 (4)(4): p. 377-383., https://pubmed.ncbi.nlm.nih.gov/26028695/
1096. Horneber, M, Bueschel, G, Dennert, G, Less, D, Ritter, E, Zwahlen, M, How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis., Integr Cancer Ther, 2012. 11 (3)(3): p. 187-203., https://pubmed.ncbi.nlm.nih.gov/22019489/
1097. Huebner, J, Micke, O, Muecke, R, Buentzel, J, Prott, FJ, Kleeberg, U, et.al. User rate of complementary and alternative medicine (CAM) of patients visiting a counseling facility for CAM of a German comprehensive cancer center., Anticancer Res, 2014. 34 (2)(2): p. 943-8., https://pubmed.ncbi.nlm.nih.gov/24511037/
1098. Micke, O., Büntzel, J., Glatzel, M., Schönekäes, K., Micke, P., Bruns, F., et.al. Predictive factors for the use of complementary and alternative medicine (CAM) in radiation oncology, 2008. 1: p. 11., https://www.sciencedirect.com/science/article/pii/S1876382008000188
1099. Molassiotis, A, Fernández-Ortega, P, Pud, D, Ozden, G, Scott, JA, Panteli, V, et.al. Use of complementary and alternative medicine in cancer patients: a European survey., Ann Oncol, 2005. 16 (4)(4): p. 655-63., https://pubmed.ncbi.nlm.nih.gov/15699021/
1100. Lüking, E, Und welche Internetseite empfehlen Sie Ihren Patienten?, 2019. p. 23 - 23., https://www.aekno.de/aerzte/rheinisches-aerzteblatt/ausgabe/artikel/2019/03-2019/und-welche-internetseite-empfehlen-sie-ihren-patienten
1101. Sänger, S., Lang, B., Klemperer, D., Thomeczek, C., & Dierks, M.-L, Manual Patienteninformation – Empfehlungen zur Erstellung evidenzbasierter Patienteninformationen, äzq Schriftenreihe, 2006. 25:
1102. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), Palliativmedizin für Patienten mit einer nicht-heilbaren Krebserkrankung, Langversion 2.2, AWMF-Registernummer: 128/001O, 2020., https://www.leitlinienprogramm-onkologie.de/leitlinien/palliativmediz
1103. Haun, MW, Estel, S, Rücker, G, Friederich, HC, Villalobos, M, Thomas, M, et.al. Early palliative care for adults with advanced cancer., Cochrane Database Syst Rev, 2017. 6 (6)(6): p. CD011129., https://pubmed.ncbi.nlm.nih.gov/28603881/
1104. Adler, K, Schlieper, D, Kindgen-Milles, D, Meier, S, Schwartz, J, van Caster, P, et.al. [Integration of palliative care into intensive care : Systematic review]., Anaesthesist, 2017. 66 (9)(9): p. 660-666., https://pubmed.ncbi.nlm.nih.gov/28589374/
1105. Dalgaard, KM, Bergenholtz, H, Nielsen, ME, Timm, H, Early integration of palliative care in hospitals: A systematic review on methods, barriers, and outcome., Palliat Support Care, 2014. 12 (6)(6): p. 495-513., https://pubmed.ncbi.nlm.nih.gov/24621947/
1106. Davis, MP, Temel, JS, Balboni, T, Glare, P, A review of the trials which examine early integration of outpatient and home palliative care for patients with serious illnesses., Ann Palliat Med, 2015. 4 (3)(3): p. 99-121., https://pubmed.ncbi.nlm.nih.gov/26231807/
1107. Gaertner, J, Siemens, W, Meerpohl, JJ, Antes, G, Meffert, C, Xander, C, et.al. Effect of specialist palliative care services on quality of life in adults with advanced incurable illness in hospital, hospice, or community settings: systematic review and meta-analysis., BMJ, 2017. 357 (): p. j2925., https://pubmed.ncbi.nlm.nih.gov/28676557/
1108. Hui, D, Kim, YJ, Park, JC, Zhang, Y, Strasser, F, Cherny, N, et.al. Integration of oncology and palliative care: a systematic review., Oncologist, 2015. 20 (1)(1): p. 77-83., https://pubmed.ncbi.nlm.nih.gov/25480826/
1109. Hui, D, Meng, YC, Bruera, S, Geng, Y, Hutchins, R, Mori, M, et.al. Referral Criteria for Outpatient Palliative Cancer Care: A Systematic Review., Oncologist, 2016. 21 (7)(7): p. 895-901., https://pubmed.ncbi.nlm.nih.gov/27185614/
1110. Tassinari, D, Drudi, F, Monterubbianesi, MC, Stocchi, L, Ferioli, I, Marzaloni, A, et.al. Early Palliative Care in Advanced Oncologic and Non-Oncologic Chronic Diseases: A Systematic Review of Literature., Rev Recent Clin Trials, 2016. 11 (1)(1): p. 63-71., https://pubmed.ncbi.nlm.nih.gov/26464077/
1111. World Health Organisation (WHO), Cancer Control: Knowledge into Action: WHO Guide for Effective Programmes, 2017. Editor:, https://pubmed.ncbi.nlm.nih.gov/24716263/
1112. Radbruch, Lukas, SA, Payne, White paper on standards and norms for hospice and palliative care in Europe: Part 1, 2010/01/01. 17: p. 22 - 33.
1113. Stockler, MR, Tattersall, MH, Boyer, MJ, Clarke, SJ, Beale, PJ, Simes, RJ, Disarming the guarded prognosis: predicting survival in newly referred patients with incurable cancer., Br J Cancer, 2006. 94 (2)(2): p. 208-12., https://pubmed.ncbi.nlm.nih.gov/16404420/
1114. World Health Organisation (WHO)., Definition of Palliative Care, 2002., http://www.who.int/cancer/palliative/definition/en/
1115. Gaugler, JE, Hanna, N, Linder, J, Given, CW, Tolbert, V, Kataria, R, et.al. Cancer caregiving and subjective stress: a multi-site, multi-dimensional analysis., Psychooncology, 2005. 14 (9)(9): p. 771-85., https://pubmed.ncbi.nlm.nih.gov/15750995/
1116. Glajchen, M, The emerging role and needs of family caregivers in cancer care., J Support Oncol, 2004. 2 (2)(2): p. 145-55., https://pubmed.ncbi.nlm.nih.gov/15328817/
1117. Romito, F, Goldzweig, G, Cormio, C, Hagedoorn, M, Andersen, BL, Informal caregiving for cancer patients., Cancer, 2013. 119 Suppl 11 (0 11)(0 11): p. 2160-9., https://pubmed.ncbi.nlm.nih.gov/23695928/
1118. Trapp, SK, Woods, JD, Grove, A, Stern, M, Male coping processes as demonstrated in the context of a cancer-related social support group., Support Care Cancer, 2013. 21 (2)(2): p. 619-27., https://pubmed.ncbi.nlm.nih.gov/22903162/
1119. Meredith, C, Symonds, P, Webster, L, Lamont, D, Pyper, E, Gillis, CR, et.al. Information needs of cancer patients in west Scotland: cross sectional survey of patients' views., BMJ, 1996. 313 (7059)(7059): p. 724-6., https://pubmed.ncbi.nlm.nih.gov/8819442/
1120. Oldenmenger, WH, Sillevis Smitt, PA, van Dooren, S, Stoter, G, van der Rijt, CC, A systematic review on barriers hindering adequate cancer pain management and interventions to reduce them: a critical appraisal., Eur J Cancer, 2009. 45 (8)(8): p. 1370-80., https://pubmed.ncbi.nlm.nih.gov/19201599/
1121. McCusker M, Ceronsky L, Crone C, Epstein H, Greene B, Halvorson J, Kephart K, Mallen E, Nosan B, Rohr M, Rosenberg E, Ruff R, Schlecht K, Setterlund L, Health Care Guideline – Palliative Care for Adults, Institute for Clinical Systems Improvement (ICSI), 3d edition, 2013., https://www.icsi.org/guidelines__more/catalog_guidelines_and_more/catalog_guidelines/catalog_palliative_care_guidelines/palliative_care/
1122. Moss, AH, Lunney, JR, Culp, S, Auber, M, Kurian, S, Rogers, J, et.al. Prognostic significance of the "surprise" question in cancer patients., J Palliat Med, 2010. 13 (7)(7): p. 837-40., https://pubmed.ncbi.nlm.nih.gov/20636154/
1123. Ferrell, BR, Temel, JS, Temin, S, Alesi, ER, Balboni, TA, Basch, EM, et.al. Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update., J Clin Oncol, 2017. 35 (1)(1): p. 96-112., https://pubmed.ncbi.nlm.nih.gov/28034065/
1124. Bundesministerium der Justiz und für Verbraucherschutz, Sozialgesetzbuch Neuntes Buch - Rehabilitation und Teilhabe von Menschen mit Behinderungen - (Neuntes Buch Sozialgesetzbuch - SGB IX)., Zuletzt geändert durch Art. 6 Abs. 3 G v. 28.11.2018 l 2016., 2018.
1125. Deutsche Rentenversicherung (DRV), Indikationskatalog für Anschlussrehabilitation (AHB), 2017.
1126. Bundesarbeitsgemeinschaft für Rehabilitation (BAR), Rahmenempfehlungen zur ambulanten onkologischen Rehabilitation, 2004.
1127. Deutsche Rentenversicherung (DRV), Strukturqualität von Reha-Einrichtungen - Anforderungen der Deutschen Rentenversicherung, 2. überarbeitete und erweiterte Auflage, 2014.
1128. Deutsche Rentenversicherung (DRV), Anforderungsprofil für eine stationäre Einrichtung zur onkologischen Rehabilitation Erwachsener, 2018.
1129. Mishra, SI, Scherer, RW, Snyder, C, Geigle, PM, Berlanstein, DR, Topaloglu, O, Exercise interventions on health-related quality of life for people with cancer during active treatment., Cochrane Database Syst Rev, 2012. 2012 (8)(8): p. CD008465., https://pubmed.ncbi.nlm.nih.gov/22895974/
1130. Bourke, L, Homer, KE, Thaha, MA, Steed, L, Rosario, DJ, Robb, KA, et.al. Interventions to improve exercise behaviour in sedentary people living with and beyond cancer: a systematic review., Br J Cancer, 2014. 110 (4)(4): p. 831-41., https://pubmed.ncbi.nlm.nih.gov/24335923/
1131. Rock, CL, Doyle, C, Demark-Wahnefried, W, Meyerhardt, J, Courneya, KS, Schwartz, AL, et.al. Nutrition and physical activity guidelines for cancer survivors., CA Cancer J Clin, 2012. 62 (4)(4): p. 243-74., https://pubmed.ncbi.nlm.nih.gov/22539238/
1132. Mishra, SI, Scherer, RW, Geigle, PM, Berlanstein, DR, Topaloglu, O, Gotay, CC, et.al. Exercise interventions on health-related quality of life for cancer survivors., Cochrane Database Syst Rev, 2012. 2012 (8)(8): p. CD007566., https://pubmed.ncbi.nlm.nih.gov/22895961/
1133. Scott, DA, Mills, M, Black, A, Cantwell, M, Campbell, A, Cardwell, CR, et.al. Multidimensional rehabilitation programmes for adult cancer survivors., Cochrane Database Syst Rev, 2013. 2013 (3)(3): p. CD007730., https://pubmed.ncbi.nlm.nih.gov/23543556/
1134. de Boer, AG, Taskila, TK, Tamminga, SJ, Feuerstein, M, Frings-Dresen, MH, Verbeek, JH, Interventions to enhance return-to-work for cancer patients., Cochrane Database Syst Rev, 2015. 2015 (9)(9): p. CD007569., https://pubmed.ncbi.nlm.nih.gov/26405010/
1135. Croese, AD, Lonie, JM, Trollope, AF, Vangaveti, VN, Ho, YH, A meta-analysis of the prevalence of Low Anterior Resection Syndrome and systematic review of risk factors., Int J Surg, 2018. 56 (): p. 234-241., https://pubmed.ncbi.nlm.nih.gov/29936195/
1136. Emmertsen, KJ et al., Functional results after treatment for rectal cancer, Journal of Coloproctology, 2014. 34(01): p. 055 - 061., https://www.thieme-connect.de/products/ejournals/abstract/10.1016/j.jcol.2014.02.004
1137. Rosen, H, Sebesta, CG, Sebesta, C, Management of Low Anterior Resection Syndrome (LARS) Following Resection for Rectal Cancer., Cancers (Basel), 2023. 15 (3)(3):, https://pubmed.ncbi.nlm.nih.gov/36765736/
1138. Emmertsen, KJ, Laurberg, S, Low anterior resection syndrome score: development and validation of a symptom-based scoring system for bowel dysfunction after low anterior resection for rectal cancer., Ann Surg, 2012. 255 (5)(5): p. 922-8., https://pubmed.ncbi.nlm.nih.gov/22504191/
1139. Liu, W, Xia, HO, The Association Between Dietary Intake and Improvement of LARS Among Rectal Cancer Patients After Sphincter-Saving Surgery-A Descriptive Cohort Study., Front Surg, 2022. 9 (): p. 892452., https://pubmed.ncbi.nlm.nih.gov/35662817/
1140. Park, IJ, Lee, JH, Kye, BH, Oh, HK, Cho, YB, Kim, YT, et.al. Effects of PrObiotics on the Symptoms and Surgical ouTComes after Anterior REsection of Colon Cancer (POSTCARE): A Randomized, Double-Blind, Placebo-Controlled Trial., J Clin Med, 2020. 9 (7)(7):, https://pubmed.ncbi.nlm.nih.gov/32664289/
1141. Visser, WS, Te Riele, WW, Boerma, D, van Ramshorst, B, van Westreenen, HL, Pelvic floor rehabilitation to improve functional outcome after a low anterior resection: a systematic review., Ann Coloproctol, 2014. 30 (3)(3): p. 109-14., https://pubmed.ncbi.nlm.nih.gov/24999460/
1142. Pachler, J, Wille-Jørgensen, P, Quality of life after rectal resection for cancer, with or without permanent colostomy., Cochrane Database Syst Rev, 2012. 12 (12)(12): p. CD004323., https://pubmed.ncbi.nlm.nih.gov/23235607/
1143. Rao, SS, Valestin, J, Brown, CK, Zimmerman, B, Schulze, K, Long-term efficacy of biofeedback therapy for dyssynergic defecation: randomized controlled trial., Am J Gastroenterol, 2010. 105 (4)(4): p. 890-6., https://pubmed.ncbi.nlm.nih.gov/20179692/
1144. Norton, C, Cody, JD, Biofeedback and/or sphincter exercises for the treatment of faecal incontinence in adults., Cochrane Database Syst Rev, 2012. (7)(7): p. CD002111., https://pubmed.ncbi.nlm.nih.gov/22786479/
1145. Cazemier, M, Felt-Bersma, RJ, Mulder, CJ, Anal plugs and retrograde colonic irrigation are helpful in fecal incontinence or constipation., World J Gastroenterol, 2007. 13 (22)(22): p. 3101-5., https://pubmed.ncbi.nlm.nih.gov/17589927/
1146. Kuo, LJ, Lin, YC, Lai, CH, Lin, YK, Huang, YS, Hu, CC, et.al. Improvement of fecal incontinence and quality of life by electrical stimulation and biofeedback for patients with low rectal cancer after intersphincteric resection., Arch Phys Med Rehabil, 2015. 96 (8)(8): p. 1442-7., https://pubmed.ncbi.nlm.nih.gov/25838018/
1147. Trahms, L., Auflösung von Tabletten im Magen-Darm-Trakt wird sichtbar, PTBnews, 2005., https://www.ptb.de/cms/presseaktuelles/zeitschriften-magazine/ptb-news/ptb-news-ausgaben/archivederptb-news/news05-1/aufloesung-von-tabletten-im-magen-darm-trakt-wird-sichtbar.html
1148. Etzioni, D. A., El-Khoueiry, A. B., Beart, R. W., Jr., Rates and predictors of chemotherapy use for stage III colon cancer: a systematic review, Cancer, 2008. 113(12): p. 3279-89., http://www.ncbi.nlm.nih.gov/pubmed/18951522
1149. Grothey, A., Kellermann, L., Schmoll, H. J., [Deficits in management of patients with colorectal carcinoma in Germany. Results of multicenter documentation of therapy algorithms], Med Klin (Munich), 2002. 97(5): p. 270-7., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12078387
1150. von der Schulenburg, J. M., Prenzler, A., Schurer, W., Cancer management and reimbursement aspects in Germany: an overview demonstrated by the case of colorectal cancer, Eur J Health Econ, 2010. 10 Suppl 1: p. S21-6., http://www.ncbi.nlm.nih.gov/pubmed/20012133
1151. Adler, G., Seufferlein, T., [Hope and disappointment in cancer medicine], Z Arztl Fortbild Qualitatssich, 2007. 101(5): p. 287-92., http://www.ncbi.nlm.nih.gov/pubmed/17711253
1152. Harrison, J. D., Young, J. M., Price, M. A., Butow, P. N., Solomon, M. J., What are the unmet supportive care needs of people with cancer? A systematic review, Support Care Cancer, 2009. 17(8): p. 1117-28., https://www.ncbi.nlm.nih.gov/pubmed/19319577
1153. Lewis, R., Neal, R. D., Williams, N. H., France, B., Wilkinson, C., Hendry, M., et.al. Nurse-led vs. conventional physician-led follow-up for patients with cancer: systematic review, J Adv Nurs, 2009. 65(4): p. 706-23., http://www.ncbi.nlm.nih.gov/pubmed/19278415
1154. Howell, D. M., Sussman, J., Wiernikowski, J., Pyette, N., Bainbridge, D., O'Brien, M., et.al. A mixed-method evaluation of nurse-led community-based supportive cancer care, Support Care Cancer, 2008. 16(12): p. 1343-52., http://www.ncbi.nlm.nih.gov/pubmed/18335260
1155. Ouwens, M., Hulscher, M., Hermens, R., Faber, M., Marres, H., Wollersheim, H., et.al. Implementation of integrated care for patients with cancer: a systematic review of interventions and effects, Int J Qual Health Care, 2009. 21(2): p. 137-44., http://www.ncbi.nlm.nih.gov/pubmed/19147593
1156. Jahn, P., Renz, P., Stukenkemper, J., Book, K., Kuss, O., Jordan, K., et.al. Reduction of chemotherapy-induced anorexia, nausea, and emesis through a structured nursing intervention: a cluster-randomized multicenter trial, Support Care Cancer, 2009. 17(12): p. 1543-52., http://www.ncbi.nlm.nih.gov/pubmed/19629539
1157. Jahn, P., Kitzmantel, M., Renz, P., Kukk, E., Kuss, O., Thoke-Colberg, A., et.al. Improvement of pain related self management for oncologic patients through a trans institutional modular nursing intervention: protocol of a cluster randomized multicenter trial, Trials, 2010. 11: p. 29., http://www.ncbi.nlm.nih.gov/pubmed/20307262
1158. Chen, R. C., Mamon, H. J., Chen, Y. H., Gelman, R. S., Suh, W. W., Talcott, J. A., et.al. Patient-reported acute gastrointestinal symptoms during concurrent chemoradiation treatment for rectal cancer, Cancer, 2010. 116(8): p. 1879-86., http://www.ncbi.nlm.nih.gov/pubmed/20166212
1159. Booth, Christopher, Vardy, Janette, O'Callaghan, Christopher, Gill, Sharlene, Friedenreich, Christine, Wong, Rebecca, et.al. A randomized phase III trial of the impact of a structured exercise program on disease-free survival (DFS) in stage 3 or high-risk stage 2 colon cancer: Canadian Cancer Trials Group (CCTG) CO.21 (CHALLENGE)., 2025/06/10. 43:
1160. Tie, J, Cohen, JD, Lo, SN, Wang, Y, Li, L, Christie, M, et.al. Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies., Int J Cancer, 2021. 148 (4)(4): p. 1014-1026., https://pubmed.ncbi.nlm.nih.gov/32984952/
1161. Umar, A., Boland, C. R., Terdiman, J. P., Syngal, S., de la Chapelle, A., Ruschoff, J., et.al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability, J Natl Cancer Inst, 2004. 96(4): p. 261-8., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14970275, http://jnci.oxfordjournals.org/content/96/4/261.full.pdf